| X3063 |
12890 |
Activity of 13-week old females, total counts of fine movements and ambulatory activity [counts/unit time] |
Activity |
| X3352 |
12960 |
Activity of 13-week old males, total counts of fine movements and ambulatory activity [counts/unit time] |
Activity |
| X1093 |
15698 |
Activity (ambulations) at night, metabolic cage, chow diet, males [AUC] |
Activity |
| X2256 |
15699 |
Activity (ambulations) at night, metabolic cage, high fat diet, males [AUC] |
Activity |
| X830 |
17629 |
Activity (movement) at dark phase (night) _CD, males [AUC] |
Activity |
| X1516 |
17630 |
Activity (movement) at dark phase (night) _HFD, males [AUC] |
Activity |
| X2451 |
17631 |
Activity (rearing) at night _CD, males [AUC] |
Activity |
| X3938 |
17632 |
Activity (rearing) at night _HFD, males [AUC] |
Activity |
| X1892 |
17713 |
Activity (movement) during full day (24 hours), _CD, males [counts/hour] |
Activity |
| X908 |
17714 |
Activity (movement) during full day (24 hours), _HFD, males [counts/hour] |
Activity |
| X2130 |
17715 |
Activity (movement) during light phase (day), _CD, males [counts/hour] |
Activity |
| X2410 |
17716 |
Activity (movement) during light phase (day), _HFD, males [counts/hour] |
Activity |
| X1869 |
17717 |
Activity (movement) during dark phase (night), _CD, males [counts/hour] |
Activity |
| X1361 |
17718 |
Activity (movement) during dark phase (night), _HFD, males [counts/hour] |
Activity |
| X2500 |
17719 |
Activity (rearing) during full day (24 hours), _CD, males [counts/hour] |
Activity |
| X1574 |
17720 |
Activity (rearing) during full day (24 hours), _HFD, males [counts/hour] |
Activity |
| X4361 |
17721 |
Activity (rearing) during light phase (day), _CD, males [counts/hour] |
Activity |
| X2840 |
17722 |
Activity (rearing) during light phase (day), _HFD, males [counts/hour] |
Activity |
| X1281 |
17723 |
Activity (rearing) during dark phase (night), _CD, males [counts/hour] |
Activity |
| X1154 |
17724 |
Activity (rearing) during dark phase (night) _HFD, males [counts/hour] |
Activity |
| X1146 |
17733 |
Run distance untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [m] |
Activity |
| X2100 |
17734 |
Run distance untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [m] |
Activity |
| X712 |
17735 |
Run distance trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [m] |
Activity |
| X768 |
17736 |
Run distance trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [m] |
Activity |
| X2736 |
17737 |
Run distance improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [m] |
Activity |
| X1290 |
17738 |
Run distance improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [m] |
Activity |
| X1964 |
17761 |
Locomotor activity, light phase (day) running distance, activity wheel at 25 weeks of age_CD, males [km] |
Activity |
| X1927 |
17762 |
Locomotor activity, dark phase (night) running distance, activity wheel at 25 weeks of age_CD, males [km] |
Activity |
| X1972 |
17763 |
Locomotor activity, light phase (day) running distance, activity wheel at 25 weeks of age_HFD, males [km] |
Activity |
| X453 |
17764 |
Locomotor activity, 24 h running distance, activity wheel at 25 weeks of age_CD, males [km] |
Activity |
| X1056 |
17765 |
Locomotor activity, dark phase (night) running distance, activity wheel at 25 weeks of age_HFD, males [km] |
Activity |
| X299 |
17766 |
Locomotor activity, 24 h running distance, activity wheel at 25 weeks of age_HFD, males [km] |
Activity |
| X379 |
10285 |
Novel open fled behavior, habituation measured as the difference in locomotion between 0-5 min and 26-30 min periods for males and females [cm] |
Anxiety |
| X370 |
10331 |
Novel open fled behavior, habituation measured as the difference in locomotion between 0-5 min and 26-30 min periods for males [cm] |
Anxiety |
| X4573 |
10332 |
Novel open fled behavior, habituation measured as the difference in locomotion between 0-5 min and 26-30 min periods for females [cm] |
Anxiety |
| X376 |
10505 |
Open-field activity following saline injection [number of crossings during 3 min] |
Anxiety |
| X3851 |
10896 |
Anxiety assay, closed arm entries in an elevated plus maze test [n] |
Anxiety |
| X2491 |
10898 |
Anxiety assay, open arm entries in an elevated plus maze test [n] |
Anxiety |
| X1253 |
10904 |
Anxiety assay, locomotion in the light compartment relative to total in a light-dark test [%] |
Anxiety |
| X910 |
10905 |
Anxiety assay, time in the center of an elevated plus maze [sec] |
Anxiety |
| X2119 |
10906 |
Novel open field behavior, time in the field center [sec] |
Anxiety |
| X4147 |
10907 |
Anxiety assay, percentage of time in light compartment of a light-dark test [%] |
Anxiety |
| X1020 |
10908 |
Anxiety assay, percentage of time in open arms of an elevated plus maze [%] |
Anxiety |
| X5021 |
10909 |
Anxiety assay, arm entries (total) in an elevated plus maze [n] |
Anxiety |
| X4155 |
10910 |
Novel open field behavior, locomotion from 0-30 min [cm] |
Anxiety |
| X288 |
10911 |
Novel open field behavior, locomotion from 0-5 min [cm] |
Anxiety |
| X3096 |
10912 |
Novel open field behavior, locomotion from 10-15 min [cm] |
Anxiety |
| X4398 |
10913 |
Novel open field behavior, locomotion from 15-20 min [cm] |
Anxiety |
| X4526 |
10914 |
Novel open field behavior, locomotion from 20-25 min [cm] |
Anxiety |
| X4397 |
10915 |
Novel open field behavior, locomotion from 25-30 min [cm] |
Anxiety |
| X4332 |
10916 |
Novel open field behavior, locomotion from 5-10 min [cm] |
Anxiety |
| X3300 |
10917 |
Anxiety assay, transitions between light and dark compartments in light/dark test [n] |
Anxiety |
| X2750 |
10955 |
Anxiety assay (S5_PDT), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent distance traveled in light side using a light-dark box in 8-12 week-old males during 5 min session [%] |
Anxiety |
| X383 |
10957 |
Anxiety assay (S5_TLA) following restraint stress (15 min) and a saline injection (0.018 mL/g ip), distance traveled in light-dark box by 8-12 week-old males during a 5 min session [cm] |
Anxiety |
| X730 |
10960 |
Anxiety assay (S5_NT) following restraint stress (15 min) and a saline injection (0.018 mL/g ip), entries into light side of light-dark box by 8-12 week-old males during a 5 min session [n] |
Anxiety |
| X2449 |
10961 |
Anxiety assay (S5_NR) following restraint stress (15 min) and a saline injection (0.018 mL/g ip), rearing events in the light side using a light-dark box in 8-12 week-old males during a 5 min session [n] |
Anxiety |
| X187 |
10964 |
Anxiety assay (E5_PDT), after restraint stress (15 min) with ethanol treatment (1.8 g/kg i.p.), percent distance traveled in light side (cm) using a light-dark box in 8-12 week-old males during 5 min session |
Anxiety |
| X1081 |
10966 |
Anxiety assay (E5_TLA) following restraint stress (15 min) and ethanol injection (1.8 g/kg ip), locomotor activity in light-dark box by 8-12 week-old males during a 5 min session [cm] |
Anxiety |
| X2880 |
10969 |
Anxiety level following restraint stress (15 min) and ethanol treatment (1.8 g/kg i.p., E5 NT group) measured as the number of entries into light side of light-dark box in 8-12 week-old males (5 min session) |
Anxiety |
| X3717 |
10970 |
Anxiety assay following restraint stress (15 min) and ethanol injection (1.8 g/kg ip), rearing events in the light side using a light-dark box by 8-12 week-old males during a 5 min session [n] |
Anxiety |
| X982 |
10973 |
Anxiety assay following restraint stress (15 min) and saline injection (0.018 ml/g ip), percent distance in light side using a light-dark box by 8-12 week-old males during 10 min session [%] |
Anxiety |
| X493 |
10975 |
Anxiety assay (S10_TLA), restraint stress (15 min) and saline treated (0.018 ml/g ip), distance traveled in light-dark box, 8-12 week-old males during a 10 min session [cm] |
Anxiety |
| X428 |
10978 |
Anxiety assay (S10_NT), entries into light side of light-dark box after restraint stress (15 min) and saline control injection (0.018 ml/g ip) in 8-12 week-old males during a 10 min test [n] |
Anxiety |
| X2291 |
10979 |
Anxiety assay after restraint stress (15 min) and a saline injection (0.018 ml/g ip), rearing events in the light side using a light-dark box by 8-12 week-old males during a 10 min session [n] |
Anxiety |
| X398 |
10982 |
Anxiety assay (E10_PDT), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent distance traveled in light side (cm) using a light-dark box in 8-12 week-old males during 10 min session [%] |
Anxiety |
| X433 |
10984 |
Anxiety assay (E10_TLA), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), total distance traveled in light-dark box, using 8-12 week-old males during 10 min session [cm] |
Anxiety |
| X1793 |
10987 |
Anxiety assay (E10_NT), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), number of entries into light side of light-dark box, using 8-12 week-old males during a 10 min session [n] |
Anxiety |
| X4646 |
10988 |
Anxiety assay after restraint stress (15 min) and an ethanol injection (1.8 g/kg ip), rearing events in the light side using a light-dark box by 8-12 week-old males during a 10 min session [n] |
Anxiety |
| X3095 |
11012 |
Anxiety assay, time in open arm of elevated plus maze in young adult males and females [sec] |
Anxiety |
| X4739 |
11013 |
Anxiety assay, number of closed arm entries using elevated plus maze [n] |
Anxiety |
| X3186 |
11014 |
Locomotor activity, distance, open field behavior [cm] |
Anxiety |
| X4514 |
11015 |
Anxiety assay, open field behavior, duration in center of field [sec] |
Anxiety |
| X1074 |
11341 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males in the morphine test battery [n beam breaks] |
Anxiety |
| X3456 |
11342 |
Novel open field behavior, locomotion in the periphery from 15-30 min for males in the morphine test battery [n beam breaks] |
Anxiety |
| X2888 |
11343 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males in the morphine test battery [n beam breaks] |
Anxiety |
| X3007 |
11344 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males in the morphine test battery [n beam breaks] |
Anxiety |
| X1438 |
11345 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males in the morphine test battery [cm] |
Anxiety |
| X3241 |
11346 |
Novel open field behavior, locomotion locomotion in the periphery from 15-30 min for males in the morphine test battery [cm] |
Anxiety |
| X3465 |
11347 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males in the morphine test battery [cm] |
Anxiety |
| X2197 |
11348 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males in the morphine test battery [cm] |
Anxiety |
| X1070 |
11349 |
Novel open field behavior, vertical activity (rears) from 0-15 min for males [n beam breaks] |
Anxiety |
| X355 |
11350 |
Novel open field behavior, vertical activity (rears) from 15-30 min for males [n beam breaks] |
Anxiety |
| X256 |
11351 |
Novel open field behavior, vertical activity (rears) from 30-45 min for males [n beam breaks] |
Anxiety |
| X245 |
11352 |
Novel open field behavior, vertical activity (rears) from 45-60 min for males [n beam breaks] |
Anxiety |
| X2452 |
11353 |
Novel open field behavior, locomotion in the center from 0-60 min for males [n beam breaks] |
Anxiety |
| X2855 |
11354 |
Novel open field behavior, locomotion in the center from 0-60 min for males [cm] |
Anxiety |
| X219 |
11355 |
Novel open field behavior, vertical activity (rears) in the center from 0-60 min for males [n beam breaks] |
Anxiety |
| X2629 |
11363 |
Novel open field behavior, urinations for males [n/test period] |
Anxiety |
| X2383 |
11385 |
Anxiety assay, time in dark side of a light-dark box for males [sec] |
Anxiety |
| X3331 |
11387 |
Anxiety assay, locomotion in the light compartment of a light-dark box for males [cm] |
Anxiety |
| X2384 |
11388 |
Anxiety assay, time in light side of a light-dark box for males [sec] |
Anxiety |
| X1882 |
11389 |
Anxiety assay, percentage of locomotion in light side of a light-dark box for males [%] |
Anxiety |
| X2390 |
11390 |
Anxiety assay, percentage of time in light side of a light-dark box for males [%] |
Anxiety |
| X2043 |
11391 |
Anxiety assay, transitions between light and dark sides of a light-dark box for males [n] |
Anxiety |
| X1248 |
11404 |
Open field behavior, percentage of distance in the center for males [%] |
Anxiety |
| X1991 |
11405 |
Open field behavior, percentage of time in center for males [%] |
Anxiety |
| X4313 |
11406 |
Open field behavior, time in corners for males [min] |
Anxiety |
| X1791 |
11407 |
Open field behavior, locomotion from 0-5 min for males [cm] |
Anxiety |
| X2290 |
11408 |
Open field behavior, locomotion from 10-15 min for males [cm] |
Anxiety |
| X1740 |
11409 |
Open field behavior, locomotion from 15-20 min for males [cm] |
Anxiety |
| X4442 |
11410 |
Open field behavior, locomotion from 5-10 min for males [cm] |
Anxiety |
| X1160 |
11411 |
Open field activity, habituation ratio for males (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks] |
Anxiety |
| X2360 |
11412 |
Open field behavior, percentage time in perimeter minus time in corners for males [%] |
Anxiety |
| X3955 |
11413 |
Open field behavior, vertical activity (rears) from 0-20 min for males [n beam breaks] |
Anxiety |
| X3172 |
11414 |
Open field behavior, vertical activity (rears) from 0-5 min for males [n beam breaks] |
Anxiety |
| X2563 |
11415 |
Open field behavior, vertical activity (rears) 10-15 min for males [n beam breaks] |
Anxiety |
| X2202 |
11416 |
Open field behavior, vertical activity (rears) from 15-20 min for males [n beam breaks] |
Anxiety |
| X4181 |
11417 |
Open field behavior, vertical activity (rears) from 5-10 min for males [n beam breaks] |
Anxiety |
| X2683 |
11418 |
Open field behavior, locomotion for entire test period for males [cm] |
Anxiety |
| X1249 |
11419 |
Open field behavior, percentage of distance in the perimeter for males [%] |
Anxiety |
| X1990 |
11420 |
Open field behavior, percentage of time in perimeter for males [%] |
Anxiety |
| X1053 |
11434 |
Anxiety assay, entries in closed quadrants of a zero maze for males [n] |
Anxiety |
| X1031 |
11435 |
Anxiety assay, entries in open quadrants of a zero maze for males [n] |
Anxiety |
| X4508 |
11437 |
Anxiety assay, percentage of time in open quadrants of a zero maze for males [%] |
Anxiety |
| X4639 |
11438 |
Anxiety assay, time in closed quadrants of a zero maze for males [sec] |
Anxiety |
| X4640 |
11439 |
Anxiety assay, time in open quadrants of a zero maze for males [sec] |
Anxiety |
| X3859 |
11454 |
Anxiety assay, untreated baseline, entries into closed arms of a plus maze for males [n] |
Anxiety |
| X4966 |
11455 |
Anxiety assay, untreated baseline, entries into open arms of a plus maze for males [n] |
Anxiety |
| X2547 |
11456 |
Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for males [%] |
Anxiety |
| X4036 |
11457 |
Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for males [%] |
Anxiety |
| X3728 |
11458 |
Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for males [%] |
Anxiety |
| X3814 |
11459 |
Anxiety assay, untreated baseline, percentage of time in open arms of a plus maze for males [%] |
Anxiety |
| X3727 |
11466 |
Anxiety assay, time in closed arms of an elevated plus maze for males [sec] |
Anxiety |
| X3531 |
11467 |
Anxiety assay, time in middle of an elevated plus maze for males [sec] |
Anxiety |
| X3818 |
11468 |
Anxiety assay, time in open arms of a plus maze for males [sec] |
Anxiety |
| X2918 |
11500 |
Novel open field behavior, locomotion in the center from 0-60 min for males [n beam breaks] |
Anxiety |
| X3192 |
11501 |
Novel open field behavior, locomotion in the center from 0-60 min for males [cm] |
Anxiety |
| X1529 |
11502 |
Novel open field behavior, vertical activity (rears) from 0-60 min in the center for males [n beam breaks] |
Anxiety |
| X3290 |
11506 |
Novel open field behavior, locomotion in the center from 0-15 min for males [n beam breaks] |
Anxiety |
| X2641 |
11507 |
Novel open field behavior, locomotion in the center from 15-30 min for males [n beam breaks] |
Anxiety |
| X2314 |
11508 |
Novel open field behavior, locomotion in the center from 30-45 min for males [n beam breaks] |
Anxiety |
| X2676 |
11509 |
Novel open field behavior, locomotion in the center from 45-60 min for males [n beam breaks] |
Anxiety |
| X3144 |
11510 |
Novel open field behavior, locomotion in the center from 0-15 min for males [cm] |
Anxiety |
| X2916 |
11511 |
Novel open field behavior, locomotion in the center from 15-30 min for males [cm] |
Anxiety |
| X2698 |
11512 |
Novel open field behavior, locomotion in the center from 30-45 min for males [cm] |
Anxiety |
| X2943 |
11513 |
Novel open field behavior, locomotion in the center from 45-60 min for males [cm] |
Anxiety |
| X1605 |
11514 |
Novel open field behavior, vertical activity (rears) from 0-15 min in the center for males [n beam breaks] |
Anxiety |
| X1378 |
11515 |
Novel open field behavior, vertical activity (rears) from 15-30 min in the center for males [n beam breaks] |
Anxiety |
| X2337 |
11516 |
Novel open field behavior, vertical activity (rears) from 30-45 min in the center for males [n beam breaks] |
Anxiety |
| X3329 |
11517 |
Novel open field behavior, vertical activity (rears) from 45-60 min in the center for males [n beam breaks] |
Anxiety |
| X4019 |
11518 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X2605 |
11519 |
Novel open field behavior, locomotion in the periphery from 15-30 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X2506 |
11520 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X3341 |
11521 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X3857 |
11522 |
Novel open field behavior, locomotion from 0-15 min in the periphery for males in the cocaine test battery [cm] |
Anxiety |
| X2422 |
11523 |
Novel open field behavior, locomotion from 15-30 min in the periphery for males in the cocaine test battery [cm] |
Anxiety |
| X3246 |
11524 |
Novel open field behavior, locomotion from 30-45 min in the periphery for males in the cocaine test battery [cm] |
Anxiety |
| X3917 |
11525 |
Novel open field behavior, locomotion from 45-60 min in the periphery for males in the cocaine test battery [cm] |
Anxiety |
| X1019 |
11526 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for males [n beam breaks] |
Anxiety |
| X1729 |
11527 |
Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for males [n beam breaks] |
Anxiety |
| X1423 |
11528 |
Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for males [n beam breaks] |
Anxiety |
| X2162 |
11529 |
Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for males [n beam breaks] |
Anxiety |
| X1151 |
11530 |
Novel open field behavior, percentage of locomotion in the periphery for males [%] |
Anxiety |
| X3311 |
11531 |
Novel open field behavior, locomotion in the periphery from 0-60 min for males [n beam breaks] |
Anxiety |
| X2857 |
11532 |
Novel open field behavior, locomotion in the periphery from 0-60 min for males [cm] |
Anxiety |
| X1161 |
11533 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for males [n beam breaks] |
Anxiety |
| X2481 |
11553 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X2386 |
11554 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for males in the cocaine test battery [cm] |
Anxiety |
| X1134 |
11555 |
Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X1836 |
11598 |
Novel open field behavior, locomotion in the periphery from 0-15 min for females in the morphine test battery [n beam breaks] |
Anxiety |
| X984 |
11599 |
Novel open field behavior, locomotion in the periphery from 15-30 min for females in the morphine test battery [n beam breaks] |
Anxiety |
| X682 |
11600 |
Novel open field behavior, locomotion in the periphery from 30-45 min for females in the morphine test battery [n beam breaks] |
Anxiety |
| X320 |
11601 |
Novel open field behavior, locomotion in the periphery from 45-60 min for females in the morphine test battery [n beam breaks] |
Anxiety |
| X1266 |
11602 |
Novel open field behavior, locomotion in the periphery from 0-15 min for females in the morphine test battery [cm] |
Anxiety |
| X529 |
11603 |
Novel open field behavior, locomotion in the periphery from 15-30 min for females in the morphine test battery [cm] |
Anxiety |
| X470 |
11604 |
Novel open field behavior, locomotion in the periphery from 30-45 min for females in the morphine test battery [cm] |
Anxiety |
| X235 |
11605 |
Novel open field behavior, locomotion in the periphery from 45-60 min for females in the morphine test battery [cm] |
Anxiety |
| X262 |
11606 |
Novel open field behavior, vertical activity (rears) from 0-15 for females [n beam breaks] |
Anxiety |
| X316 |
11607 |
Novel open field behavior, vertical activity (rears) from 15-30 min for females [n beam breaks] |
Anxiety |
| X377 |
11608 |
Novel open field behavior, vertical activity (rears) from 30-45 min for females [n beam breaks] |
Anxiety |
| X277 |
11609 |
Novel open field behavior, vertical activity (rears) from 45-60 min for females [n beam breaks] |
Anxiety |
| X890 |
11610 |
Novel open field behavior, locomotion in the center from 0-60 min for females [n beam breaks] |
Anxiety |
| X451 |
11611 |
Novel open field behavior, locomotion in the center from 0-60 min for females [cm] |
Anxiety |
| X1873 |
10204 |
TRBV4+ T cell levels among CD8+ T cells in spleen [%] |
Immune |
| X271 |
11612 |
Novel open field behavior, vertical activity (rears) in the center from 0-60 min for females [n beam breaks] |
Anxiety |
| X995 |
11620 |
Novel open field behavior, urinations for females [n/test period] |
Anxiety |
| X3155 |
11642 |
Anxiety assay, time in dark side of a light-dark box for females [sec] |
Anxiety |
| X4333 |
11644 |
Anxiety assay, locomotion in the light compartment of a light-dark box for females [cm] |
Anxiety |
| X3156 |
11645 |
Anxiety assay, time in light side of a light-dark box for females [sec] |
Anxiety |
| X2514 |
11646 |
Anxiety assay, percentage of locomotion in light side of a light-dark box for females [%] |
Anxiety |
| X3308 |
11647 |
Anxiety assay, percentage of time in the light side of a light-dark box for females [%] |
Anxiety |
| X1978 |
11648 |
Anxiety assay, transitions between light and dark sides of a light-dark box for females [n] |
Anxiety |
| X4691 |
11661 |
Open field behavior, percentage of distance in the center for females [%] |
Anxiety |
| X4570 |
11662 |
Open field behavior, percentage of time in center for females [%] |
Anxiety |
| X4768 |
11663 |
Open field behavior, time in corners for females [min] |
Anxiety |
| X2978 |
11664 |
Open field behavior, locomotion from 0-5 min for females [cm] |
Anxiety |
| X1324 |
11665 |
Open field behavior, locomotion from 10-15 min for females [cm] |
Anxiety |
| X703 |
11666 |
Open field behavior, locomotion from 15-20 min for females [cm] |
Anxiety |
| X2129 |
11667 |
Open field behavior locomotion from 5-10 min for females [cm] |
Anxiety |
| X2795 |
11668 |
Open field activity, habituation ratio for females (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks] |
Anxiety |
| X4622 |
11669 |
Open field behavior, percentage time in perimeter minus time in corners for females [%] |
Anxiety |
| X2745 |
11670 |
Open field behavior, vertical activity (rears) from 0-20 min for females [n beam breaks] |
Anxiety |
| X2254 |
11671 |
Open field behavior, vertical activity (rears) from 0-5 min for females [n beam breaks] |
Anxiety |
| X3729 |
11672 |
Open field behavior, vertical activity (rears) from 10-15 min for females [n beam breaks] |
Anxiety |
| X2554 |
11673 |
Open field behavior, vertical activity (rears) from 15-20 min for females [n beam breaks] |
Anxiety |
| X1471 |
11674 |
Open field behavior, vertical activity (rears) from 5-10 min for females [n beam breaks] |
Anxiety |
| X2139 |
11675 |
Open field behavior, locomotion for entire test period for females [cm] |
Anxiety |
| X4692 |
11676 |
Open field behavior, percentage distance in the perimeter for females [%] |
Anxiety |
| X4569 |
11677 |
Open field behavior, percentage of time in perimeter for females [%] |
Anxiety |
| X2859 |
11691 |
Anxiety assay, entries in closed quadrants of a zero maze for females [n] |
Anxiety |
| X2836 |
11692 |
Anxiety assay, entries into open quadrants of a zero maze for females [n] |
Anxiety |
| X1800 |
11694 |
Anxiety assay, percentage time in open quadrants of a zero maze for females [%] |
Anxiety |
| X1753 |
11695 |
Anxiety assay, time in closed quadrants of a zero maze for females [sec] |
Anxiety |
| X1754 |
11696 |
Anxiety assay, time in open quadrants of a zero maze for females [sec] |
Anxiety |
| X2487 |
11711 |
Anxiety assay, untreated baseline, entries into closed arms of a plus maze for females [n] |
Anxiety |
| X2441 |
11712 |
Anxiety assay, untreated baseline, entries into open arms of a plus maze for females [n] |
Anxiety |
| X1779 |
11713 |
Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for females [%] |
Anxiety |
| X3102 |
11714 |
Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for females [%] |
Anxiety |
| X726 |
11715 |
Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for females [%] |
Anxiety |
| X2321 |
11716 |
Anxiety assay, untreated baseline, percentage of time in open arms of a plus maze for females [%] |
Anxiety |
| X727 |
11723 |
Anxiety assay, time in closed arms of an elevated plus maze for females [sec] |
Anxiety |
| X1905 |
11724 |
Anxiety assay, time in middle of an elevated plus maze for females [sec] |
Anxiety |
| X1221 |
11725 |
Anxiety assay, time in open arms of an elevated plus maze for females [sec] |
Anxiety |
| X2168 |
11757 |
Novel open field behavior, locomotion in the center from 0-60 min for females [n beam breaks] |
Anxiety |
| X1686 |
11758 |
Novel open field behavior, locomotion in the center from 0-60 min for females [cm] |
Anxiety |
| X471 |
11759 |
Novel open field behavior, vertical activity (rears) from 0-60 min in the center for females [n beam breaks] |
Anxiety |
| X797 |
11763 |
Novel open field behavior, locomotion in the center from 0-15 min for females [n beam breaks] |
Anxiety |
| X2267 |
11764 |
Novel open field behavior, locomotion in the center from 15-30 min for females [n beam breaks] |
Anxiety |
| X2939 |
11765 |
Novel open field behavior, locomotion in the center from 30-45 min for females [n beam breaks] |
Anxiety |
| X2756 |
11766 |
Novel open field behavior, locomotion in the center from 45-60 min for females [n beam breaks] |
Anxiety |
| X1310 |
11767 |
Novel open field behavior, locomotion in the center from 0-15 min for females [cm] |
Anxiety |
| X1343 |
11768 |
Novel open field behavior, locomotion in the center from 15-30 min for females [cm] |
Anxiety |
| X2590 |
11769 |
Novel open field behavior, locomotion in the center from 30-45 min for females [cm] |
Anxiety |
| X2803 |
11770 |
Novel open field behavior, locomotion in the center from 45-60 min for females [cm] |
Anxiety |
| X944 |
11771 |
Novel open field behavior, vertical activity (rears) from 0-15 min in the center for females [n beam breaks] |
Anxiety |
| X371 |
11772 |
Novel open field behavior, vertical activity (rears) from15-30 min in the center for females [n beam breaks] |
Anxiety |
| X620 |
11773 |
Novel open field behavior, vertical activity (rears) from 30-45 min in the center for females [n beam breaks] |
Anxiety |
| X1777 |
11774 |
Novel open field behavior, vertical activity (rears) from 45-60 min in the center for females [n beam breaks] |
Anxiety |
| X1733 |
11775 |
Novel open field behavior, locomotion in the periphery from 0-15 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3307 |
11776 |
Novel open field behavior, locomotion in the periphery from 15-30 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3512 |
12542 |
Iron level of plasma of 120-day-old females fed 3 ppm Fe diet [ug/dL] |
Hematology |
| X2541 |
11777 |
Novel open field behavior, locomotion in the periphery from 30-45 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3430 |
11778 |
Novel open field behavior, locomotion in the periphery from 45-60 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3037 |
11780 |
Novel open field behavior, locomotion from 15-30 min in the periphery for females in the cocaine test battery [cm] |
Anxiety |
| X3072 |
11781 |
Novel open field behavior, locomotion from 30-45 min in the periphery for females in the cocaine test battery [cm] |
Anxiety |
| X3893 |
11782 |
Novel open field behavior, locomotion from 45-60 min in the periphery for females in the cocaine test battery [cm] |
Anxiety |
| X472 |
11783 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for females [n beam breaks] |
Anxiety |
| X401 |
11784 |
Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for females [n beam breaks] |
Anxiety |
| X385 |
11785 |
Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for females [n beam breaks] |
Anxiety |
| X276 |
11786 |
Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for females [n beam breaks] |
Anxiety |
| X3377 |
11787 |
Novel open field behavior, percentage of locomotion in the periphery for females [%] |
Anxiety |
| X3304 |
11788 |
Novel open field behavior, locomotion in the periphery from 0-60 min for females [n beam breaks] |
Anxiety |
| X3183 |
11789 |
Novel open field behavior, locomotion in the periphery from 0-60 min for females [cm] |
Anxiety |
| X253 |
11790 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for females [n beam breaks] |
Anxiety |
| X1569 |
11810 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X1391 |
11811 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for females in the cocaine test battery [cm] |
Anxiety |
| X168 |
11812 |
Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3460 |
11855 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the morphine test battery [n beam breaks] |
Anxiety |
| X2182 |
11856 |
Novel open field behavior, locomotion in the periphery from 15-30 min for males and females in the morphine test battery [n beam breaks] |
Anxiety |
| X1050 |
11857 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the morphine test battery [n beam breaks] |
Anxiety |
| X467 |
11858 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the morphine test battery [n beam breaks] |
Anxiety |
| X2944 |
11859 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the morphine test battery [cm] |
Anxiety |
| X1385 |
11860 |
Novel open field behavior, locomotion locomotion in the periphery from 15-30 for males and females in the morphine test battery [cm] |
Anxiety |
| X1468 |
15570 |
Kramer RM, Lamkin T, and colleagues TAFI15 |
Immune |
| X673 |
11861 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the morphine test battery [cm] |
Anxiety |
| X325 |
11862 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the morphine test battery [cm] |
Anxiety |
| X326 |
11863 |
Novel open field behavior,vertical activity (rears) from 0-15 min for males and females [n beam breaks] |
Anxiety |
| X238 |
11864 |
Novel open field behavior, vertical activity (rears) from 15-30 min for males and females [n beam breaks] |
Anxiety |
| X191 |
11865 |
Novel open field behavior, vertical activity (rears) from min 30-45 for males and females [n beam breaks] |
Anxiety |
| X177 |
11866 |
Novel open field behavior, vertical activity (rears) from 45-60 min for males and females [n beam breaks] |
Anxiety |
| X1413 |
11867 |
Novel open field behavior, locomotion in the center from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X799 |
11868 |
Novel open field behavior, locomotion in the center from 0-60 min for males and females [cm] |
Anxiety |
| X186 |
11869 |
Novel open field behavior, vertical activity (rears) in the center from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X2669 |
11877 |
Novel open field behavior, urinations for males and females [n/test period] |
Anxiety |
| X3871 |
11899 |
Anxiety assay, time in dark side of a light-dark box for males and females [sec] |
Anxiety |
| X4308 |
11901 |
Anxiety assay, locomotion in the light compartment of a light-dark box for males and females [cm] |
Anxiety |
| X3872 |
11902 |
Anxiety assay, time in light side of a light-dark box for males and females [sec] |
Anxiety |
| X1899 |
11903 |
Anxiety assay, percentage of locomotion in light side of a light-dark box for males and females [%] |
Anxiety |
| X3931 |
11904 |
Anxiety assay, percentage time in light side of a light-dark box for males and females [%] |
Anxiety |
| X1948 |
11905 |
Anxiety assay, transitions between light and dark sides of a light-dark box for males and females [n] |
Anxiety |
| X2597 |
11918 |
Open field behavior, percentage of distance in the center for males and females [%] |
Anxiety |
| X2014 |
11919 |
Open field behavior, percentage of time in center for males and females [%] |
Anxiety |
| X3648 |
11920 |
Open field behavior, time in corners for males and females [min] |
Anxiety |
| X3571 |
11921 |
Open field behavior, locomotion from 0-5 min for males and females [cm] |
Anxiety |
| X2990 |
11922 |
Open field behavior, locomotion from 10-15 min for males and females [cm] |
Anxiety |
| X1752 |
11923 |
Open field behavior, locomotion from 15-20 min for males and females [cm] |
Anxiety |
| X4190 |
11924 |
Open field behavior, locomotion from 5-10 min for males and females [cm] |
Anxiety |
| X2700 |
11925 |
Open field activity, habituation ratio for males and females (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks] |
Anxiety |
| X3461 |
11926 |
Open field behavior, percentage of time in perimeter minus time in corners for males and females [%] |
Anxiety |
| X2549 |
11927 |
Open field behavior, vertical activity (rears) from 0-20 min for males and females [n beam breaks] |
Anxiety |
| X2322 |
10205 |
TRBV4+ T cell levels among CD8+ T cells in peripheral blood [%] |
Immune |
| X2667 |
11928 |
Open field behavior, vertical activity (rears) from 0-5 min for males and females [n beam breaks] |
Anxiety |
| X3336 |
11929 |
Open field behavior, vertical activity (rears) from 10-15 min for males and females [n beam breaks] |
Anxiety |
| X2405 |
11930 |
Open field behavior, vertical activity (rears) from 15-20 min for males and females [n beam breaks] |
Anxiety |
| X2934 |
11931 |
Open field behavior, vertical activity (rears) from 5-10 min for males and females [n beam breaks] |
Anxiety |
| X2819 |
11932 |
Open field behavior, locomotion for entire test period for males and females [cm] |
Anxiety |
| X2596 |
11933 |
Open field behavior, percentage of distance in the perimeter for males and females [%] |
Anxiety |
| X2015 |
11934 |
Open field behavior, percentage of time in perimeter for males and females [%] |
Anxiety |
| X1372 |
11948 |
Anxiety assay, entries in closed quadrants of a zero maze for males and females [n] |
Anxiety |
| X1382 |
11949 |
Anxiety assay, entries into open quadrants of a zero maze for males and females [n] |
Anxiety |
| X2143 |
11950 |
Anxiety assay, latency to enter an open quadrant of a zero maze for males and females [sec] |
Anxiety |
| X3759 |
11951 |
Anxiety assay, percentage time in open quadrants of a zero maze for males and females [%] |
Anxiety |
| X2723 |
11952 |
Anxiety assay, time in closed quadrants of a zero maze for males and females [sec] |
Anxiety |
| X2724 |
11953 |
Anxiety assay, time in open quadrants of a zero maze for males and females [sec] |
Anxiety |
| X1444 |
11968 |
Anxiety assay, untreated baseline, entries into closed arms of a plus maze for males and females [n] |
Anxiety |
| X3159 |
11969 |
Anxiety assay, untreated baseline, entries into open arms of a plus maze for males and females [n] |
Anxiety |
| X3204 |
11970 |
Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for males and females [%] |
Anxiety |
| X3276 |
11971 |
Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for males and females [%] |
Anxiety |
| X1947 |
11972 |
Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for males and females [%] |
Anxiety |
| X1657 |
11973 |
Anxiety assay, untreated baseline, percentage of time in open arms of plus maze for males and females [%] |
Anxiety |
| X1946 |
11980 |
Anxiety assay, time in closed arms of an elevated plus maze for males and females [sec] |
Anxiety |
| X1721 |
11981 |
Anxiety assay, time in middle of an elevated plus maze for males and females [sec] |
Anxiety |
| X1292 |
11982 |
Anxiety assay, time in open arms of an elevated plus maze for males and females [sec] |
Anxiety |
| X2090 |
12014 |
Novel open field behavior, locomotion in the center from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X2447 |
12015 |
Novel open field behavior, locomotion in the center from 0-60 min for males and females [cm] |
Anxiety |
| X2000 |
12016 |
Novel open field behavior, vertical activity (rears) from 0-60 min in the center for males and females [n beam breaks] |
Anxiety |
| X1508 |
12020 |
Novel open field behavior, locomotion in the center from 0-15 min for males and females [n beam breaks] |
Anxiety |
| X3265 |
12543 |
Transferrin saturation of 120-day-old males fed 3 ppm iron diet [%] |
Hematology |
| X3021 |
12021 |
Novel open field behavior, locomotion in the center from 15-30 min for males and females [n beam breaks] |
Anxiety |
| X1849 |
12022 |
Novel open field behavior, locomotion in the center from 30-45 min for males and females [n beam breaks] |
Anxiety |
| X2181 |
12023 |
Novel open field behavior, locomotion in the center from 45-60 min for males and females [n beam breaks] |
Anxiety |
| X1785 |
12024 |
Novel open field behavior, locomotion in the center from 0-15 min for males and females [cm] |
Anxiety |
| X2811 |
12025 |
Novel open field behavior, locomotion in the center from 15-30 min for males and females [cm] |
Anxiety |
| X2666 |
12026 |
Novel open field behavior, locomotion in the center from 30-45 min for males and females [cm] |
Anxiety |
| X2110 |
12027 |
Novel open field behavior, locomotion in the center from 45-60 min for males and females [cm] |
Anxiety |
| X2132 |
12028 |
Novel open field behavior, vertical activity (rears) from 0-15 min in the center for males and females [n beam breaks] |
Anxiety |
| X1607 |
12029 |
Novel open field behavior, vertical activity (rears) from 15-30 min in the center for males and females [n beam breaks] |
Anxiety |
| X2206 |
12030 |
Novel open field behavior, vertical activity (rears) from 30-45 min in the center for males and females [n beam breaks] |
Anxiety |
| X2488 |
12031 |
Novel open field behavior, vertical activity (rears) from 45-60 min in the center for males and females [n beam breaks] |
Anxiety |
| X2822 |
12032 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X2553 |
12033 |
Novel open field behavior, locomotion in the periphery from 15-30 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X2635 |
12034 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3452 |
12035 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X2933 |
12036 |
Novel open field behavior, locomotion from 0-15 min in the periphery for males and females in the cocaine test battery [cm] |
Anxiety |
| X2363 |
12037 |
Novel open field behavior, locomotion from 15-30 min in the periphery for males and females in the cocaine test battery [cm] |
Anxiety |
| X3247 |
12038 |
Novel open field behavior, locomotion from 30-45 min in the periphery for males and females in the cocaine test battery [cm] |
Anxiety |
| X3644 |
12039 |
Novel open field behavior, locomotion from 45-60 min in the periphery for males and females in the cocaine test battery [cm] |
Anxiety |
| X1133 |
12040 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for males and females [n beam breaks] |
Anxiety |
| X762 |
12041 |
Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for males and females [n beam breaks] |
Anxiety |
| X548 |
12042 |
Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for males and females [n beam breaks] |
Anxiety |
| X518 |
12043 |
Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for males and females [n beam breaks] |
Anxiety |
| X926 |
12044 |
Novel open field behavior, percentage of locomotion in the periphery for males and females [%] |
Anxiety |
| X3318 |
12045 |
Novel open field behavior, locomotion in the periphery from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X3236 |
12046 |
Novel open field behavior, locomotion in the periphery from 0-60 min for males and females [cm] |
Anxiety |
| X397 |
12047 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X2146 |
12067 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X2208 |
12068 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for males and females in the cocaine test battery [cm] |
Anxiety |
| X439 |
12069 |
Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X4445 |
12335 |
Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X3472 |
12336 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time] |
Anxiety |
| X4789 |
12337 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percentage of time] |
Anxiety |
| X4176 |
12338 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] |
Anxiety |
| X669 |
12339 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X592 |
12340 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X391 |
12341 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X1490 |
12342 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] |
Anxiety |
| X3543 |
12343 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X2609 |
12344 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] |
Anxiety |
| X1132 |
12345 |
Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X4087 |
12762 |
Anxiety (center-distance ratio) in open-field (OFA) in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% of WT] |
Anxiety |
| X4207 |
12346 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time] |
Anxiety |
| X4299 |
12347 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time] |
Anxiety |
| X3672 |
12348 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time] |
Anxiety |
| X1212 |
12349 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X1956 |
12350 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X651 |
12351 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X3226 |
12352 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] |
Anxiety |
| X3891 |
12353 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] |
Anxiety |
| X3099 |
12354 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X656 |
12355 |
Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X3953 |
12356 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] |
Anxiety |
| X4191 |
12357 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time] |
Anxiety |
| X4381 |
12358 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] |
Anxiety |
| X632 |
12359 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] |
Anxiety |
| X1831 |
12360 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X545 |
12361 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X1441 |
12362 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X3478 |
12363 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] |
Anxiety |
| X1965 |
12364 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec] |
Anxiety |
| X2440 |
12365 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X2847 |
12366 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females during first 5 min [% time] |
Anxiety |
| X2365 |
12367 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percent time] |
Anxiety |
| X3961 |
12368 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females during whole 10 min test [% time] |
Anxiety |
| X1119 |
12369 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X348 |
12370 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X454 |
12371 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X5024 |
12372 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] |
Anxiety |
| X725 |
12373 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X3178 |
12374 |
Anxiety assay, ethanol treated (1.8 g/kg ip) (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] |
Anxiety |
| X3208 |
12375 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X4889 |
12376 |
Anxiety assay, ethanol treated (1.8 g/kg i.p.) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [% time] |
Anxiety |
| X4352 |
12377 |
Anxiety assay, ethanol treated (1.8 g/kg i.p.) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [% time] |
Anxiety |
| X4687 |
12378 |
Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [% time] |
Anxiety |
| X3001 |
12379 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X1270 |
12380 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X1592 |
12381 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X5091 |
12382 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] |
Anxiety |
| X5077 |
12383 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] |
Anxiety |
| X5092 |
12384 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X4030 |
12385 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X2535 |
12386 |
Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] |
Anxiety |
| X4420 |
12387 |
Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [% time] |
Anxiety |
| X4454 |
12388 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] |
Anxiety |
| X2258 |
12389 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] |
Anxiety |
| X784 |
12390 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X925 |
12391 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X5064 |
12392 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X4738 |
12394 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min (BXD102 winterized from 21.008 +-19.93 to 3.0 and BX |
Anxiety |
| X2418 |
12395 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X2380 |
12396 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time] |
Anxiety |
| X4121 |
13442 |
OFA, boli produced in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only |
Anxiety |
| X2259 |
12397 |
Anxiety assay, saline treated (0.18 ml/kg ip, NOS group), time in open quadrants only during last 5 min of test using an elevated zero maze for 60- to 120-day-old females [%] |
Anxiety |
| X3490 |
12398 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] |
Anxiety |
| X3375 |
12399 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X686 |
12400 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X889 |
12401 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X3822 |
12402 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] |
Anxiety |
| X3137 |
12403 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X4520 |
12404 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] |
Anxiety |
| X5006 |
12405 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X3693 |
12406 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time] |
Anxiety |
| X3228 |
12407 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time] |
Anxiety |
| X2416 |
12408 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time] |
Anxiety |
| X209 |
12409 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X1796 |
12410 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X462 |
12411 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X3197 |
12412 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] |
Anxiety |
| X4787 |
17546 |
number of jumps observed from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X3355 |
12413 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] |
Anxiety |
| X2688 |
12414 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X5029 |
12415 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X4849 |
12416 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] |
Anxiety |
| X4256 |
12417 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time] |
Anxiety |
| X3903 |
12418 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] |
Anxiety |
| X457 |
12419 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] |
Anxiety |
| X332 |
12420 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X228 |
12421 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X2490 |
12422 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X2645 |
12423 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] |
Anxiety |
| X2689 |
12424 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec] |
Anxiety |
| X5000 |
12425 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X1243 |
12426 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [% time] |
Anxiety |
| X3898 |
12427 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [% time] |
Anxiety |
| X2702 |
12428 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] |
Anxiety |
| X4276 |
15962 |
Tuberculosis, bacterial load in lung [CFU] |
Immune |
| X3153 |
12429 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X234 |
12430 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X591 |
12431 |
Anxiety assay, restraint stress (15 min) followed by ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X5081 |
12432 |
Anxiety assay, restraint stress (15 min) followed by ethanol (1.8 g/kg ip)(RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks/sec] |
Anxiety |
| X4809 |
12433 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X4765 |
12434 |
Anxiety assay, restraint stress [15 min] + ethanol treated [1.8 g/kg ip] (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females over 10 min [beam breaks/sec] |
Anxiety |
| X4918 |
12435 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X2557 |
12436 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [% time] |
Anxiety |
| X3059 |
12437 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [% time] |
Anxiety |
| X2680 |
12438 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [% time] |
Anxiety |
| X3056 |
12439 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X691 |
12440 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X959 |
12441 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X1485 |
12442 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks/sec] |
Anxiety |
| X4658 |
12443 |
Anxiety assay, restraint stress [15 min] + ethanol treated [1.8 g/kg i.p.] (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min (data for BXD77 (4.463 +/- |
Anxiety |
| X1928 |
17547 |
number of fecal boli observed from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X5083 |
12444 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X4800 |
12445 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X2373 |
12446 |
Anxiety assay, restraint stress [15 min] and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [% time] |
Anxiety |
| X4287 |
12447 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [% time] |
Anxiety |
| X4466 |
12448 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [% time] |
Anxiety |
| X1462 |
12449 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] |
Anxiety |
| X162 |
12450 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X329 |
12451 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X5080 |
12452 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X4021 |
12453 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] |
Anxiety |
| X3712 |
12454 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min (data for BXD11 (16.419 +/-15. |
Anxiety |
| X5075 |
12455 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X2673 |
12456 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time] |
Anxiety |
| X4706 |
12457 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percentage of time] |
Anxiety |
| X4612 |
12458 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] |
Anxiety |
| X2636 |
12546 |
Transferrin saturation of 120-day-old females fed 270 ppm iron diet [%] |
Hematology |
| X1871 |
12459 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X507 |
12460 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X638 |
12461 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X3385 |
12462 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] |
Anxiety |
| X3017 |
12463 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X3417 |
12464 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] |
Anxiety |
| X4464 |
12465 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X4068 |
12466 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time] |
Anxiety |
| X3306 |
12467 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time] |
Anxiety |
| X3214 |
12468 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time] |
Anxiety |
| X1666 |
12469 |
Anxiety assay, restraint stress (15 min) + saline treated (0.018 ml/kg ip) for RSS group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X2983 |
12470 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X1654 |
12471 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X3299 |
12472 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] |
Anxiety |
| X3667 |
12473 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] |
Anxiety |
| X4544 |
12474 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X5061 |
12475 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X4169 |
12476 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] |
Anxiety |
| X3737 |
12477 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time] |
Anxiety |
| X3941 |
12478 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] |
Anxiety |
| X539 |
12479 |
Anxiety assay, restraint stress (15 min) + saline treated (0.018 ml/kg ip) in the RSS group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam break |
Anxiety |
| X496 |
12480 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X281 |
12481 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X3541 |
12482 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X4129 |
12483 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] |
Anxiety |
| X2999 |
12484 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec] |
Anxiety |
| X1326 |
12631 |
Anxiety assay (E5_PTR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p), percent time spent (sec) without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min session |
Anxiety |
| X306 |
12632 |
Anxiety assay (E5_PTS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 5 min session [%] |
Anxiety |
| X1327 |
12633 |
Anxiety assay (E5_TR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min session [n sec]. |
Anxiety |
| X307 |
12634 |
Anxiety assay (E5_TS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 5 min [sec] |
Anxiety |
| X3716 |
12635 |
Anxiety assay (E5_NR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), number of rears in the light side using a light-dark box in 8-12 week-old males during 5 min session [n beam breaks]. |
Anxiety |
| X381 |
12636 |
Anxiety assay (E10_PTS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 10 min session [%] |
Anxiety |
| X380 |
12637 |
Anxiety assay (E10_TS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 10 min [n sec] |
Anxiety |
| X1580 |
12638 |
Anxiety assay (E10_TR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 10 min session [n sec] |
Anxiety |
| X1581 |
12639 |
Anxiety assay (E10_PTR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent time spent (sec) without locomotion in the light side of light-dark box in 8-12 week-old males during 10 min sess |
Anxiety |
| X1719 |
12640 |
Anxiety assay (S5_PTR), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent time spent (sec) without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min sessi |
Anxiety |
| X888 |
12641 |
Anxiety assay (S5_PTS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 5 min session [n %]. |
Anxiety |
| X1720 |
12642 |
Anxiety assay (S5_TR), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min session [n sec]. |
Anxiety |
| X887 |
12643 |
Anxiety assay (S5_TS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 5 min [n sec]. |
Anxiety |
| X3027 |
12644 |
Anxiety assay (S10_PTR), percent time spent without locomotion in the light side of light-dark box after restraint stress (15 min) and saline control injection (0.018 ml/g ip) in 8-12 week-old males during 1 |
Anxiety |
| X1768 |
12645 |
Anxiety assay (S10_PTS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 10 min session [n %]. |
Anxiety |
| X3028 |
12646 |
Anxiety assay (S10_TR), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 10 min session [n sec] |
Anxiety |
| X1766 |
12647 |
Anxiety assay (S10_TS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 10 min [n sec]. |
Anxiety |
| X2053 |
12760 |
Anxiety measured as center-distance:total distance ratio in the open-field (OFA) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [ratio] |
Anxiety |
| X1908 |
12761 |
Anxiety measured as center-distance to total distance ratio in open-field (OFA) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 mutant cases only [ratio] |
Anxiety |
| X2805 |
12544 |
Iron binding capacity in plasma of 120-day-old males fed 3 ppm iron diet [ug/dL] |
Hematology |
| X2828 |
13443 |
anxiety assay, number of fecal boli produced in an open field activity (OFA) test in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only |
Anxiety |
| X4485 |
13444 |
OFA, boli produced in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, [% WT only] |
Anxiety |
| X4460 |
13460 |
Rearing in open field test by 8-week-old F1 hybrids generated by crossing male BXDs with female C57BL/6J-R6/2 Huntington carriers [n beam breaks] |
Anxiety |
| X4911 |
13533 |
OFA, boli produced in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTEd R6/2 cases only |
Anxiety |
| X4340 |
13536 |
Anxiety measured as center-distance to total distance ratio in open-field (OFA) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED R6/2 mutant cases only [ratio] |
Anxiety |
| X1765 |
17528 |
locomotion, total distance traveled from 0 to 20 min for males at 11 weeks of age [cm] |
Anxiety |
| X2964 |
17529 |
thigmotaxis, distance traveled at the periphery (relative to total distance) from 0 to 20 min for males at 11 weeks of age [percent] |
Anxiety |
| X2534 |
17530 |
thigmotaxis, time spent at the periphery (relative to total time) from 0 to 20 min for males at 11 weeks of age [percent] |
Anxiety |
| X2864 |
17531 |
number of leans observed from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X2906 |
17532 |
number of rears observed from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X3642 |
17533 |
grooming frequency from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X1421 |
17534 |
grooming duration observed from 0 to 20 min for males at 11 weeks of age [sec] |
Anxiety |
| X4097 |
17535 |
grooming bout (grooming duration divided by grooming frequency) observed from 0 to 20 min for males at 11 weeks of age [sec] |
Anxiety |
| X4354 |
17536 |
number of jumps observed from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X2355 |
17537 |
number of fecal boli observed from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X2642 |
17538 |
locomotion, total distance traveled from 0 to 20 min for females at 11 weeks of age [cm] |
Anxiety |
| X2482 |
17539 |
thigmotaxis, distance traveled at the periphery (relative to total distance) from 0 to 20 min for females at 11 weeks of age [percent] |
Anxiety |
| X1514 |
17540 |
thigmotaxis, time spent at the periphery (relative to total time) from 0 to 20 min for females at 11 weeks of age [percent] |
Anxiety |
| X3052 |
17541 |
number of leans observed from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X4409 |
17542 |
number of rears observed from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X2310 |
17543 |
grooming frequency from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X4103 |
17544 |
grooming duration observed from 0 to 20 min for females at 11 weeks of age [sec] |
Anxiety |
| X4700 |
17545 |
grooming bout (grooming duration divided by grooming frequency) observed from 0 to 20 min for females at 11 weeks of age [sec] |
Anxiety |
| X964 |
12932 |
Hemoglobin of 14-week old males [g/dl] |
Hematology |
| X2638 |
10008 |
Phencyclidine response (7.5 mg/kg ip), locomotor response, difference in activity (PCP minus saline) between 1 hr test periods [cm] |
Drug response |
| X2940 |
10009 |
Phencyclidine response (7.5 mg/kg ip), locomotor activity from 0-60 min after PCP injection [cm] |
Drug response |
| X1192 |
10011 |
Amphetamine response (5 mg/kg ip), locomotor response, difference in activity (amphetamine minus saline) between 1 hr test periods [cm] |
Drug response |
| X1289 |
10012 |
Amphetamine response (5 mg/kg ip), locomotor activity from 0-60 min after injection [cm] |
Drug response |
| X955 |
10016 |
Morphine response (variable doses, ip), induced hypothermia [slope of drug-response curve] |
Drug response |
| X4936 |
10017 |
Morphine response (variable doses ip), analgesia, slope of the drug response curve [slope] |
Drug response |
| X1075 |
10018 |
Morphine response (variable doses ip), Straub tail test response, slope of the dose response curve [slope] |
Drug response |
| X835 |
10021 |
Saline control response (vehicle ip), open field activity after injection (unpublished data from Belknap and Crabbe, 1992) [units] |
Drug response |
| X3874 |
10025 |
Nitrous oxide response, withdrawal severity measured by handling-induced convulsion (HIC) area under the curve [units] |
Drug response |
| X3380 |
10026 |
Nitrous oxide response, withdrawal severity measured by handling-induced convulsion (HIC), corrected peak level [units] |
Drug response |
| X2993 |
10027 |
Nitrous oxide response, withdrawal severity measured by handling-induced convulsion (HIC), difference between treated and baseline untreated [units] |
Drug response |
| X2577 |
10028 |
Ethanol response, withdrawal severity measured as the difference in handling-induced convulsion (HIC) scores from a saline control group (unpublished supplementary data) [units] |
Drug response |
| X3523 |
10029 |
Morphine response (16 mg/kg), analgesia relative to maximum possible effect [%] |
Drug response |
| X2450 |
10040 |
Ethanol response, blood ethanol concentration (BEC) at recovery of righting reflex (retro-orbital sinus sample) [mg/ml] |
Drug response |
| X4522 |
10041 |
Ethanol response (2.5 g/kg ip), duration of loss of righting reflex [minutes] |
Drug response |
| X713 |
10042 |
Ethanol response (2.5 g/kg ip), ataxia, screen test sensitivity measured as the latency to fall, saline response minus ethanol response [seconds] |
Drug response |
| X4085 |
10046 |
Quinpirole dopaminergic D2 and D3 receptor response (1 mg/kg ip), hypothermia 60 min after injection on day 1 measured as change from baseline temperature [degrees C] |
Drug response |
| X1183 |
10047 |
Quinpirole dopaminergic D2 and D3 receptor response (1 mg/kg ip), hypothermia tolerance, day 2 compared to day 1 [degrees C] |
Drug response |
| X857 |
10048 |
Quinpirole dopaminergic D2 and D3 receptor response (1 mg/kg ip), hypothermia tolerance, day 3 compared to day 1 [degrees C] |
Drug response |
| X3101 |
10050 |
Quinpirole dopaminergic D2 and D3 receptor response (0.01 mg/kg ip), locomotion change relative to baseline [cm] |
Drug response |
| X2287 |
10051 |
Quinpirole dopaminergic D2 and D3 receptor response (0.03 mg/kg ip), locomotion change relative to baseline [cm] |
Drug response |
| X3932 |
10052 |
Quinpirole dopaminergic D2 and D3 receptor response (0.03 mg/kg ip), vertical activity (rears) change relative to baseline [n beam breaks] |
Drug response |
| X2257 |
10053 |
Quinpirole dopaminergic D2 and D3 receptor response (0.01 mg/kg ip), vertical activity (rears) change relative to baseline [n beam breaks] |
Drug response |
| X3313 |
10055 |
Ethanol withdrawal handling induced convulsions (HIC), 2-12 hours after 4 g/kg 20% v/v ethanol injection (ip), area under curve [HIC AUC] |
Drug response |
| X3738 |
10063 |
Ethanol response, withdrawal-associated handling-induced convulsions (HIC) after a 72 hr exposure to ethanol vapor (with Pyrazole injections to inhibit EtOH metabolism) (0=no effect, 1=facial grimace during |
Drug response |
| X1855 |
10064 |
Ethanol response, area under the 25-hr curve for withdrawal following 72 hr exposure to air. Pyrazole injections were given daily to inhibit EtOH metabolism. Handling-induced convulsions (HIC) were scored ho |
Drug response |
| X1763 |
10065 |
Ethanol response (1.5 g/kg ip loading dose and 68.1 mg/kg pyrazole), chronic withdrawal, handling-induced convulsion score (HIC) corrected for response to pyrazole alone (difference between strain mean value |
Drug response |
| X4960 |
10066 |
Ethanol response (1.5 g/kg), blood ethanol concentration (BEC) normalization data set (BEC was stabilized to ~1.5 mg EtOH/ml blood using daily pyrazole injections) [mg/ml] |
Drug response |
| X3608 |
10067 |
Ethanol response (2 g/kg ip), hypothermia at 30 and 60 min after injection [degrees C] |
Drug response |
| X3615 |
10068 |
Ethanol response (3 g/kg ip), hypothermia at 30 and 60 min after injection [degrees C] |
Drug response |
| X4623 |
10069 |
Ethanol response (4 g/kg ip), hypothermia at 30 and 60 min after injection [degrees C] |
Drug response |
| X2661 |
10070 |
Ethanol response (2 g/kg ip), hypothermia after injection [degrees C] |
Drug response |
| X3040 |
10071 |
Ethanol response (3 g/kg ip), hypothermia after injection [degrees C] |
Drug response |
| X3535 |
10072 |
Ethanol response (4 g/kg ip), hypothermia after injection [degrees C] |
Drug response |
| X4833 |
10073 |
Ethanol response (10% v/v in water), acceptance of ethanol under thirst motivation in a single-bottle (no choice) test following 24 hr water deprivation, total 24 hr ethanol intake relative to previous water |
Drug response |
| X2839 |
10074 |
Ethanol response (10% v/v in water), acceptance of ethanol under thirst motivation in a single-bottle (no choice) test following 24 hr water deprivation, total 24 hr ethanol intake in 20-24 week-old males [g |
Drug response |
| X1922 |
10075 |
Saline response (saline injection ip), open field activity in 20-24 week-old males (control for ethanol trait 10077) [beam crossings] |
Drug response |
| X1452 |
10076 |
Ethanol response (2.5 g/kg ip), distance run in the grid test, 10-12 min after injection in 20-24 week-old males [n beam crossings] |
Drug response |
| X4728 |
10077 |
Ethanol response (1.33 g/kg ip), open field activity in 20-24 week-old males tested under dim light, 10-13 min after injection of saline (day 1) and ethanol (day 2), difference in number of beam crossings re |
Drug response |
| X3596 |
10082 |
Ethanol response (4 g/kg ip), hypothermia tolerance (positive scores) or sensitization (negative scores), day 3 minus day 1, in young adult females (50 to 123 days) [degrees C] |
Drug response |
| X5044 |
10083 |
Ethanol response (3 g/kg ip), hypothermia tolerance (positive scores) or sensitization (negative scores), day 3 minus day 1, in young adult females (50 to 123 days) [degrees C] |
Drug response |
| X3301 |
10084 |
Ethanol response (2 g/kg), hypothermia tolerance (positive scores) or sensitization (negative scores), day 3 minus day 1, in young adult females (50 to 123 days) [degrees C] |
Drug response |
| X2154 |
10085 |
Ethanol response (4 g/kg ip), hypothermia in young adult females (50 to 123 days) relative to baseline rectal body temperature (positive scores = hypothermia) [degrees C] |
Drug response |
| X4908 |
10086 |
Ethanol response (3 g/kg ip), hypothermia in young adult females (50 to 123 days) relative to baseline rectal body temperature (positive scores = hypothermia) [degrees C] |
Drug response |
| X2850 |
10087 |
Ethanol response (2 g/kg ip), hypothermia in young adult females (50 to 123 days) relative to baseline rectal body temperature (positive scores = hypothermia) [degrees C] |
Drug response |
| X4721 |
10088 |
Ethanol response (2 g/kg ip), acute difference in locomotion between experimental ethanol-condidtioned and saline control group of males [activity counts/min] |
Drug response |
| X2276 |
10089 |
Ethanol response (2 g/kg ip), locomotor tolerance or sensitization in males, difference between activity after fourth ethanol trial and first trial [cm] |
Drug response |
| X2922 |
10090 |
Ethanol response (2 g/kg ip), conditioned place preference (CPP) for the ethanol-paired grid compartment in males in the experimental group over a 30 min trial test [% time] |
Drug response |
| X5039 |
10091 |
Saline control response (vehicle ip) of ethanol-treated (2 mg/kg ip) males, locomotion 1-5 min after saline injection, trial 4 (experimental group, prior ethanol exposure) [activity counts per min] |
Drug response |
| X2708 |
10092 |
Ethanol response (2 g/kg ip), locomotion from 1-5 min after injection, conditioning trial 1 in males [activity counts per min] |
Drug response |
| X3622 |
10094 |
Locomotion from 1-5 min after a single saline i.p. injection for the control group of males [activity/min] |
Drug response |
| X4684 |
10095 |
Saline control response (vehicle, ip), locomotion of control group from 1-5 min after injection on trial 1 [activity/min] |
Drug response |
| X4868 |
10096 |
Locomotion from 1-5 min after a saline injection for the control group of males on trial 4 [activity/min] |
Drug response |
| X4052 |
10097 |
Ethanol response (2 g/kg ip), conditioned place preference (CPP) for the ethanol-paired grid compartment in experimental group males [s/min] |
Drug response |
| X5088 |
10098 |
Ethanol response (2 g/kg ip), conditioned place preference (CPP) for the ethanol-paired hole floor in experimental group males [s/min] |
Drug response |
| X3238 |
10100 |
Locomotion from 1-5 min after a single saline ip injection of saline vehicle for the experimental group on trial 1 [activity counts per min] |
Drug response |
| X2595 |
10102 |
Ethanol response (2 g/kg ip), locomotion from 1-5 min after injection, conditioning trial 4 in males [activity counts per min] |
Drug response |
| X2333 |
10104 |
Ethanol response (2 g/kg ip), locomotor tolerance or sensitization in males, difference between experimental group (two prior exposures to ethanol) and saline control group on fourth conditioning day [activi |
Drug response |
| X2497 |
10105 |
Saline control response (0.9% ip), activity habituation in males [4th saline injection trial activity minus first saline activity trial activity] |
Drug response |
| X4368 |
10809 |
Iron binding capacity (total iron-binding capacity, TIBC, transferrin level) of males and females [ug/dL] |
Hematology |
| X2561 |
10120 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 0 to 5 min after injection [cm] |
Drug response |
| X2942 |
10121 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 5 to 10 min after injection [cm] |
Drug response |
| X1306 |
10122 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 10 to 15 min after injection [cm] |
Drug response |
| X1708 |
10123 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 15 to 20 min after injection [cm] |
Drug response |
| X1479 |
10124 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 5 to 20 min after injection [cm] |
Drug response |
| X4210 |
10125 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 0 to 5 min after injection [cm] |
Drug response |
| X2550 |
10126 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 5 to 10 min after injection [cm] |
Drug response |
| X2253 |
10127 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 10 to 15 min after injection [cm] |
Drug response |
| X1234 |
10128 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 15-20 min after injection [cm] |
Drug response |
| X2140 |
10129 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 5 to 20 min after injection [cm] |
Drug response |
| X3480 |
10135 |
Ethanol acceptance (10% in tap water after 24 hr water deprivation), raw mean consumption of adult males (same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg body weight] |
Drug response |
| X589 |
10136 |
Ethanol acceptance (10% in tap water after 24 hr water deprivation) by young adult females (74-91 days, same data as in Rodriguez et al., 1994 with outliers removed and two strains added) [g/kg] |
Drug response |
| X4676 |
10137 |
Ethanol acceptance (10% in tap water after 24 hr water deprivation) by young adult males (53-67 days, residual values and same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg |
Drug response |
| X3979 |
10138 |
Ethanol acceptance (10% in tap water after 24 hr water deprivation) by young adult females (74-91 day, residuals and same data as in Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg] |
Drug response |
| X3206 |
10139 |
Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult males (53-67 days, same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg] |
Drug response |
| X1092 |
10140 |
Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult females (74-91 days, and same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg] |
Drug response |
| X4545 |
10141 |
Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult males (53-67 days, residuals and same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/ |
Drug response |
| X4744 |
10142 |
Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult females (74-91 days, residuals over a two week test period and same data as Rodriguez et al, 1994 with outliers remov |
Drug response |
| X3719 |
10817 |
Iron level in plasma of males [ug/dL] |
Hematology |
| X2599 |
10144 |
Ethanol response (escalating dose given ip), initial sensitivity measured as the ataxia onset threshold following first of five injections [mg/kg] |
Drug response |
| X4836 |
10145 |
Ethanol response (escalating dose given ip), maximal threshold to ethanol induced ataxia [mg/ml] |
Drug response |
| X3913 |
10146 |
Ethanol response (escalating dose given ip), tolerance, difference between ethanol induced ataxia (maximal threshold blood ethanol concentration BEC) minus onset threshold [mg/ml] |
Drug response |
| X3289 |
10147 |
Ethanol response (escalating dose given ip), tolerance measured as the fold-increase of blood ethanol concentration (BEC) to ethanol-induced ataxia [ratio of tolerance BEC over initial BEC ataxia] |
Drug response |
| X240 |
10169 |
Methamphetamine response (4 mg/kg ip), body temperature change 48 min after injection in 10-14 week males [degree C] |
Drug response |
| X3278 |
10171 |
Methamphetamine response (16 mg/kg ip), body temperature change 48 min after injection in 10-14 week males [degree C] |
Drug response |
| X3256 |
10172 |
Methamphetamine response (8 mg/kg ip), brain concentration in brain after injection in 10-14 week males [ug/gm] |
Drug response |
| X1250 |
10174 |
Methamphetamine response (4 mg/kg ip), brain concentration after injection in 10-14 week males [ug/gm] |
Drug response |
| X3135 |
10202 |
Cocaine response (variable dose, iv), dosage required to induce tonic seizure infused via tail vein [mg/kg] |
Drug response |
| X4645 |
10203 |
Cocaine response (variable dose iv via tail vein), dose required to induce clonic seizure [mg/kg] |
Drug response |
| X877 |
10286 |
Cocaine response (5 mg/kg ip), stereotypy, repeated movements measured as difference from saline control in males [n difference] |
Drug response |
| X3212 |
10287 |
Cocaine response (5 mg/kg ip), stereotypy, repeated movements measured as difference from saline control in females [n difference] |
Drug response |
| X1105 |
10288 |
Cocaine response (5 mg/kg ip), stereotypy, repeated movements measured as difference from saline control in males and females [n difference] |
Drug response |
| X1389 |
10289 |
Cocaine response (5 mg/kg ip), locomotion activity measured as difference from saline control in males [cm difference] |
Drug response |
| X2539 |
10290 |
Cocaine response (5 mg/kg ip), locomotion measured as difference from saline control in females [cm difference] |
Drug response |
| X2854 |
10291 |
Cocaine response (5 mg/kg ip), locomotion activity measured as difference from saline control in males and females [cm difference] |
Drug response |
| X3867 |
10292 |
Cocaine response (5 mg/kg ip), exploratory activity, nose pokes in holeboard measured as difference from saline control in males [n] |
Drug response |
| X4690 |
10293 |
Cocaine response (5 mg/kg ip), exploratory activity, nose pokes in holeboard measured as difference from saline control in females [n difference |
Drug response |
| X4668 |
10294 |
Cocaine response (5 mg/kg ip), exploratory activity, nose pokes in holeboard measured as difference from saline control in males and females [n difference] |
Drug response |
| X2040 |
10295 |
Cocaine response (15 mg/kg ip), cocaine stereotypy, number of movements as difference from saline control injection in males [n] |
Drug response |
| X2407 |
10316 |
Cocaine response (45 mg/k ip), open field locomotor activity, total distance relative to saline control in males [cm] |
Drug response |
| X5084 |
10296 |
Cocaine response (15 mg/kg ip), stereotypy evaluated as the number of movements (difference from saline control) in adult females [n] |
Drug response |
| X3296 |
10297 |
Cocaine response (15 mg/kg ip), stereotypy evaluated as the number of movements (difference from saline control) in adult males and females [n] |
Drug response |
| X4736 |
10298 |
Cocaine response (15 mg/kg ip), locomotion in an open field, total distance measured as difference from saline control in males [cm] |
Drug response |
| X1348 |
10299 |
Cocaine response (15 mg/kg ip), open field activity, total distance, difference from saline control in females [cm] |
Drug response |
| X3686 |
10300 |
Cocaine response (15 mg/k ip), open field locomotor activity, total distance relative to saline control in males and females [cm] |
Drug response |
| X4212 |
10301 |
Cocaine response (15 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males [n difference] |
Drug response |
| X1101 |
10302 |
Cocaine response (15 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult females [n difference] |
Drug response |
| X4480 |
10303 |
Cocaine response (15 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males and females [n difference] |
Drug response |
| X1279 |
10304 |
Cocaine response (30 mg/kg ip), stereotypy, number of movements relative to saline control injection for males [n] |
Drug response |
| X3753 |
10305 |
Cocaine response (30 mg/k ip) stereotypy, increase in numbers of movements relative to saline controls in females [n] |
Drug response |
| X2066 |
10306 |
Cocaine response (30 mg/kg ip), stereotypy, number of movements relative to saline control injection, male and female combined [n] |
Drug response |
| X1040 |
10307 |
Cocaine response (30 mg/k ip), open field locomotor activity, total distance relative to saline control in males [cm] |
Drug response |
| X2863 |
10308 |
Cocaine response (30 mg/k ip), open field locomotor activity, total distance relative to saline control in females [cm] |
Drug response |
| X2930 |
10309 |
Cocaine response (30 mg/k ip), open field locomotor activity, total distance relative to saline control in males and females [cm] |
Drug response |
| X1202 |
10310 |
Cocaine response (30 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males [n difference] |
Drug response |
| X4382 |
10311 |
Cocaine response (30 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult females [n difference] |
Drug response |
| X1034 |
10312 |
Cocaine response (30 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males and females [n difference] |
Drug response |
| X2225 |
10313 |
Cocaine response (45 mg/k ip) stereotypy, increase in numbers of movements relative to saline controls in males [n] |
Drug response |
| X3075 |
10314 |
Cocaine response (45 mg/kg ip) stereotypy, increase in numbers of movements relative to saline controls in females [n] |
Drug response |
| X1026 |
10315 |
Cocaine response (45 mg/k ip) stereotypy, increase in numbers of movements relative to saline controls in males and females [n] |
Drug response |
| X4673 |
12545 |
Plasma iron of 120-day-old males fed 3 ppm iron (Fe) diet [ug/dL] |
Hematology |
| X4093 |
10317 |
Cocaine response (45 mg/k ip), open field locomotor activity, total distance relative to saline control in females [cm] |
Drug response |
| X2503 |
10318 |
Cocaine response (45 mg/k ip), open field locomotor activity, total distance relative to saline control in males and females [cm] |
Drug response |
| X4963 |
10319 |
Cocaine response (45 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males [n difference] |
Drug response |
| X1982 |
10320 |
Cocaine response (45 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult females [n difference] |
Drug response |
| X4621 |
10321 |
Cocaine response (45 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males and females [n difference] |
Drug response |
| X2523 |
10322 |
Cocaine response (5 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] |
Drug response |
| X4017 |
10323 |
Cocaine response (15 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] |
Drug response |
| X3130 |
10324 |
Cocaine response (30 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] |
Drug response |
| X1745 |
10325 |
Cocaine response (45 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] |
Drug response |
| X5028 |
10326 |
Cocaine response (15 mg/kg ip), open field behavior, difference in time spent in the field center relative saline injection for females [sec] |
Drug response |
| X4112 |
10327 |
Cocaine response (30 mg/kg), open field behavior, center time (difference from saline) in males [sec] |
Drug response |
| X3532 |
10328 |
Cocaine response (30 mg/kg ip), open field behavior, center time difference from saline control in females [sec] |
Drug response |
| X3494 |
10329 |
Cocaine response (45 mg/k ip), open field center time relative to saline control in males [sec] |
Drug response |
| X2646 |
10330 |
Cocaine response (45 mg/k ip), open field center time relative to saline control in females [sec] |
Drug response |
| X528 |
10333 |
Cocaine response (5 mg/kg, ip), open field center time (difference from saline) in males [sec] |
Drug response |
| X5020 |
10334 |
Cocaine response (5 mg/kg), anxiety assay, center time in an open field test, difference from saline control in females [sec] |
Drug response |
| X4940 |
10335 |
Cocaine response (15 mg/kg ip), open field behavior, time in the field center (difference from saline control) in males [sec] |
Drug response |
| X3471 |
10347 |
Ethanol response (1.75 g/kg ip), initial sensitivity measured by blood ethanol concentration (BEC, retrobulbar bleed) at loss of balance using a dowel test (BEC time 0) [mg % ethanol] |
Drug response |
| X2604 |
10348 |
Ethanol response (1.75 g/kg ip then 2 g/kg ip), acute functional tolerance (AFT) measured as the difference in blood alcohol concentration (BEC, retrobulbar bleed) following the second recovery of balance an |
Drug response |
| X4838 |
10349 |
Ethanol response (1.75 mg/kg ip), time to ataxia measured as loss of balance using a dowel test (Loss corresponds to BEC time 0) [min] |
Drug response |
| X4927 |
10350 |
Ethanol response (1.75 mg/kg ip), duration of ataxia following the first ethanol injection using a dowel test (Regain Test 1 corresponds to BEC1) [min] |
Drug response |
| X4559 |
10351 |
Ethanol response (1.75 g/kg ip then 2 g/kg ip), duration of ataxia following the second ethanol injection using a dowel test (Regain Test 2 corresponds to BEC2) [min] |
Drug response |
| X1089 |
10352 |
cyclic AMP accumulation in cerebellum, basal level measured by liquid scintillation counting [% conversion [3H]ATP to [3H]cAMP] |
Drug response |
| X2717 |
10353 |
cyclic AMP accumulation in cerebellum, stimuated with forskolin (10 uM) measured by liquid scintillation counting [% conversion [3H]ATP to [3H]cAMP] |
Drug response |
| X3809 |
10354 |
cyclic AMP accumulation in cerebellum, stimulated with isoproterenol (1 um) measured by liquid scintillation counting [% conversion [3H]ATP to [3H]cAMP] |
Drug response |
| X3395 |
10454 |
Allopregnanolone response (10 mg/kg 3a-hydroxy-5a-pregnan-20-one, THP, in 20% 2-hydroxypropyl-beta-cyclodextrin ip), difference in locomotion between day 3 (first injection) and day 2 (vehicle |
Drug response |
| X3591 |
10455 |
Allopregnanolone response (17 mg/kg 3a-hydroxy-5a-pregnan-20-one in 20% 2-hydroxypropyl-beta-cyclodextrin ip), difference in locomotion between day 3 (first injection) and day 2 (vehicle basel |
Drug response |
| X2008 |
10469 |
Morphine response (0.3 to 0.7 mg/ml in water), consumption using two-bottle choice test [ml/test period] |
Drug response |
| X3788 |
10474 |
Ethanol response (3%, g/kg in tap water), consumption using a two-bottle choice test vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] |
Drug response |
| X2618 |
10475 |
Ethanol response (3%, g/kg in 0.2% saccharin and tap water), consumption using a two-bottle choice test vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] |
Drug response |
| X1678 |
10476 |
Ethanol response (10%, g/kg in tap water), consumption using a two-bottle choice test offered vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] |
Drug response |
| X1976 |
10477 |
Ethanol response (10%, g/kg in 0.2% saccharin and tap water), consumption using a two-bottle choice test offered vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] |
Drug response |
| X4484 |
10478 |
Ethanol response, withdrawal severity, handling-induced convulsion (HIC) score, corrected area under the HIC curve after voluntary ethanol consumption [HIC AUC] |
Drug response |
| X2304 |
10479 |
Ethanol response (10%, g/kg in tap water), preference using a two-bottle choice test offered vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [ratio] |
Drug response |
| X4511 |
10480 |
Water response, consumption using a two-bottle choice test offered vs. 10% ethanol [ml] |
Drug response |
| X4824 |
10481 |
Water response, consumption using a two-bottle choice test offered vs. 0.2% saccharin [ml] |
Drug response |
| X697 |
10482 |
Ethanol response (2 g/kg ip), acute locomotor activity response (horizontal distance), 1-5 min after injections, difference between day 2 saline control and day 11 ethanol injection (first and only ethanol i |
Drug response |
| X2076 |
10483 |
Ethanol response (2 g/kg ip), sensitization to ethanol, difference in locomotor activity between saline control group (CS) and ethanol treated group (CD) to final acute ethanol test on day 11 (deltaBG) [cm] |
Drug response |
| X4914 |
10484 |
Ethanol response (2 g/kg ip), sensitization to ethanol (CD group), difference in locomotor activity between fifth ethanol treatment (day 11) and first ethanol treatment (day 3), 1- 5 min after injections in |
Drug response |
| X551 |
10485 |
Ethanol response (2 g/kg ip), acute locomotor activity response (horizontal distance), 1-5 min after injection, difference between day 2 saline injection response and day 3 ethanol injection in young adult f |
Drug response |
| X1792 |
10488 |
Cocaine response (10 mg/kg ip), difference in locomotion using Accuscan activity monitor between day 3 (first cocaine treatment) and day 2 (saline ip baseline) [cm/15 min] |
Drug response |
| X1179 |
10489 |
Cocaine response (40 mg/kg ip), difference in locomotion using Accuscan activity monitor between day 3 (first cocaine treatment) and day 2 (saline ip baseline) [cm/15 min] |
Drug response |
| X4844 |
10490 |
Cocaine response (10 mg/kg ip), sensitization of locomotion following 5 daily injections, difference between day 11 (fifth treatment) and day 3 (first treatment) [cm/15 min] |
Drug response |
| X1645 |
10491 |
Cocaine response (40 mg/kg ip), sensitization of locomotion following 5 daily injections, difference between day 11 (fifth treatment) and day 3 (first treatment) [cm/15 min] |
Drug response |
| X3565 |
10492 |
Cocaine response (5 mg/kg ip), sensitization of locomotion following 5 daily injections, difference between day 11 (fifth treatment) and day 3 (first treatment) [cm/15 min] |
Drug response |
| X2919 |
10493 |
Cocaine response (5 mg/kg ip), difference in locomotion using Accuscan activity monitor between day 3 (first cocaine treatment) and day 2 (saline ip baseline) [cm/15 min] |
Drug response |
| X1304 |
10494 |
Ethanol response (2 g/kg ip), difference in locomotion using grid test (Accuscan activity monitor) following ethanol injection, day 3 (first treatment) minus day 2 (saline baseline) in the chronic ethanol gr |
Drug response |
| X2427 |
10495 |
Ethanol response (2 g/kg ip), difference in locomotion between day 11 (first and only ethanol treatment) and day 2 (saline baseline) in the chronic saline group [n beam breaks/10 min test] |
Drug response |
| X4535 |
10496 |
Ethanol response (2 g/kg ip), sensitization to ethanol measured as the difference in locomotion using grid test (Accuscan activity monitor) after repeated treatment, day 11 (fifth treatment) minus day 3 (fir |
Drug response |
| X4477 |
10497 |
Ethanol response (2 g/kg ip), acute ataxia, difference between day 3 (first ethanol treatment) and day 2 (saline baseline) in the chronic drug group [n grid test errors/10 min test] |
Drug response |
| X2109 |
10498 |
Ethanol response (2 g/kg ip), acute ataxia measured using using grid test (Accuscan activity monitor), difference between day 11 (first and only ethanol treatment) and day 2 (saline baseline) in the chronic |
Drug response |
| X4792 |
10499 |
Ethanol response (2 g/kg ip), intoxication and adaptation measured as difference in missteps using grid test (Accuscan activity monitor) after repeated treatment, day 11 (fifth treatment) minus day 3 (first |
Drug response |
| X3806 |
10500 |
Ethanol response (2 g/kg ip), difference in ataxia using grid test (Accuscan activity monitor) between acute ethanol on day 3 (first ethanol treatment) and day 2 (saline baseline) in the chronic ethanol grou |
Drug response |
| X3354 |
10589 |
Ethanol response (4.1 g/kg ip), high dose sensitivity, duration of loss of righting reflex [min] |
Drug response |
| X4657 |
10501 |
Ethanol response (2 g/kg ip), difference in ataxia using grid test (Accuscan activity monitor) between injection on day 11 (first and only ethanol treatment) and day 2 (saline baseline) in the chronic saline |
Drug response |
| X1617 |
10502 |
Ethanol response, change in ataxic effects of 2 g/kg (ip) after repeated treatment, difference between day 11 (fifth treatment) minus day 3 (first treatment) in the chronic drug (CD) group, 10 min test [grid |
Drug response |
| X3442 |
10563 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity 16-20 min after injection [activity counts/min] |
Drug response |
| X3992 |
10564 |
Control response (10 mg/kg oil vehicle), locomotor activity 16-20 min after injection [activity counts/min] |
Drug response |
| X4773 |
10565 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity 21-25 min after injection [activity counts/min] |
Drug response |
| X2023 |
10566 |
Control response (10 mg/kg oil vehicle), locomotor activity 21-25 min after injection [activity counts/min] |
Drug response |
| X4631 |
10567 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity 26-30 min after injection [activity counts/min] |
Drug response |
| X2954 |
10568 |
Control response (10 mg/kg oil vehicle), locomotor activity 26-30 min after injection [activity counts/min] |
Drug response |
| X1036 |
10569 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity from 0-15 min after injection [activity counts/min] |
Drug response |
| X3665 |
10570 |
Control response (10 mg/kg oil vehicle), locomotor activity from 0-15 min after injection [activity counts/min] |
Drug response |
| X4035 |
10571 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity from 15-30 min after injection [activity counts/min] |
Drug response |
| X3911 |
10572 |
Control response (10 mg/kg oil vehicle), locomotor activity from 15-30 min after injection [activity counts/min] |
Drug response |
| X3929 |
10578 |
Ethanol response (4 g/kg ip), handling-induced convulsion (HIC) score 7 hr after injection [score] |
Drug response |
| X870 |
10581 |
Ethanol response (10% in water po), acceptance, total consumption over 24 hr for females [g/kg] |
Drug response |
| X3093 |
10582 |
Ethanol response (10% in water po), acceptance, total consumption over 24 hr for males [g/kg] |
Drug response |
| X933 |
10583 |
Ethanol response (10% in water po), preference for alcohol for females [g/kg] |
Drug response |
| X2055 |
10584 |
Ethanol response (10% v/v in water), preference of females using 2-bottle choice [g/kg] |
Drug response |
| X4912 |
10585 |
Ethanol response (variable dose ip), hypnotic dose sensitivity (HDS), sleep time for females [min] |
Drug response |
| X1258 |
10586 |
Ethanol response (4.1 g/kg ip), high dose sensitivity, duration of loss of righting reflex of males [min] |
Drug response |
| X1386 |
10587 |
Ethanol response (10% v/v in water), acceptance of ethanol under thirst motivation in a single-bottle (no choice) test following 24 hr water deprivation, total 24 hr ethanol intake [g/kg] |
Drug response |
| X1683 |
10588 |
Ethanol response (10% in water po), preference and consumption of 10% ethanol vs. water over 15 days [g/kg] |
Drug response |
| X1236 |
10609 |
Cocaine response (32 mg/kg ip), locomotion from 0-60 min after injections in an activity chamber [n beam breaks] |
Drug response |
| X4269 |
10610 |
Cocaine response (32 mg/kg ip), sensitization of locomotor response [% initial response] |
Drug response |
| X2603 |
10611 |
Cocaine response (32 mg/kg ip, daily), stereotypical behavior frequency after consecutive daily injections on day 8 [units] |
Drug response |
| X2921 |
10614 |
Pentylenetetrazol (PTZ, a GABA antagonists) response, dosage level (threshold) required to induce seizure [mg/kg] |
Drug response |
| X4128 |
10790 |
Ethanol response (1.5 g/kg ip), locomotion during 0 to 5 min interval (updated data PMID 9880575) [cm] |
Drug response |
| X1918 |
10791 |
Ethanol response (1.5 g/kg ip), locomotion during 5 to 10 min interval (updated data PMID 9880575) [cm] |
Drug response |
| X2174 |
10792 |
Ethanol response (1.5 g/kg ip), locomotion during 10 to 15 min interval (updated data PMID 9880575) [cm] |
Drug response |
| X1804 |
10793 |
Ethanol response (1.5 g/kg ip), locomotion during 15 to 20 min interval (updated data PMID 9880575) [cm] |
Drug response |
| X4402 |
10794 |
Ethanol response (1.5 g/kg ip), adaptation to ethanol defined as 15-20 min interval locomotion minus 0-5 min interval locomotion [cm] |
Drug response |
| X3287 |
11002 |
Ethanol response (3 g/kg ip), hypothermia (supplementary data to Brigman et al.) [deg C] |
Drug response |
| X832 |
11003 |
Ethanol response (3 g/kg ip), loss of righting reflex (LORR) sleep time (supplementary data to Brigman et al.) [min] |
Drug response |
| X724 |
11006 |
Ethanol response (1.75 g/kg ip), ataxia measured by rotarod performance, difference from saline baseline (supplementary data to Brigman et al.) |
Drug response |
| X3625 |
11303 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period immediately after injection for males [sec] |
Drug response |
| X3435 |
11304 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period starting 30 min after injection for males [sec] |
Drug response |
| X296 |
11312 |
Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X611 |
11313 |
Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2283 |
11314 |
Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2948 |
11315 |
Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4314 |
11316 |
Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2148 |
11317 |
Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X1659 |
11318 |
Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X224 |
11319 |
Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X99 |
11320 |
Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X102 |
11321 |
Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X172 |
11322 |
Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X188 |
11323 |
Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for males [cm] |
Drug response |
| X375 |
11324 |
Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for males |
Drug response |
| X1476 |
11325 |
Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for males [cm] |
Drug response |
| X1728 |
11326 |
Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for males [cm] |
Drug response |
| X3640 |
11327 |
Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injection in an activity chamber for males [cm] |
Drug response |
| X1526 |
11328 |
Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for males [cm] |
Drug response |
| X446 |
11329 |
Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for males [cm] |
Drug response |
| X117 |
11330 |
Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for males [cm] |
Drug response |
| X83 |
11331 |
Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for males [cm] |
Drug response |
| X87 |
11332 |
Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for males [cm] |
Drug response |
| X116 |
11333 |
Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for males [cm] |
Drug response |
| X4077 |
11334 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3987 |
11335 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for males [n fecal boli] |
Drug response |
| X985 |
11336 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for males [n/15 min test] |
Drug response |
| X138 |
11337 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min after injection (total open field activity over 3 hour test) for males [n beam breaks] |
Drug response |
| X114 |
11338 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males [cm] |
Drug response |
| X1864 |
11339 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for males (last 15 min of morphine test (165-180 min) minus first 15 min after naloxone) [ |
Drug response |
| X841 |
11340 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min after injection (total vertical activity over 3 hour test) for males [n beam breaks] |
Drug response |
| X1915 |
11356 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for males [n beam breaks] |
Drug response |
| X1613 |
11357 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for males [cm] |
Drug response |
| X2068 |
11358 |
Morphine response (50 mg/kg ip) and naloxone response (30 mg/kg ip), naloxone-induced withdrawal after morphine, vertical activity (rears) from 0-15 min for males [n beam breaks] |
Drug response |
| X3605 |
11359 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X4367 |
11360 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X1576 |
11361 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for males [ordinal scale, 0=control level, 3=max] |
Drug response |
| X4935 |
11362 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X904 |
11364 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2748 |
11365 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4111 |
11366 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3111 |
11367 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2332 |
11368 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 150-165 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X1900 |
11369 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X314 |
11370 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X139 |
11371 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X165 |
11372 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X341 |
11373 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4718 |
10820 |
Hematocrit (packed cell volume, erythrocyte volume fraction) in males and females [%] |
Hematology |
| X610 |
11374 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2771 |
11375 |
3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) response (10 mg/kg subcutaneous), locomotion on day 2 for males [cm/90 min test] |
Drug response |
| X3386 |
11378 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) 4 hrs after injection for males [explain the score] |
Drug response |
| X3752 |
11379 |
Ethanol response (4.0 g/kg ip), handling-induced convulsions (HIC) 6 hrs after injections for males (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion |
Drug response |
| X1502 |
11380 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) score 7 hrs after ethanol injection for males [units] |
Drug response |
| X1344 |
11382 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) after injection for males (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion during s |
Drug response |
| X523 |
11440 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for males [cm] |
Drug response |
| X1498 |
11441 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for males [cm] |
Drug response |
| X573 |
11442 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for males [cm] |
Drug response |
| X1098 |
11444 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for males [cm] |
Drug response |
| X1230 |
11446 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for males [cm] |
Drug response |
| X1676 |
11447 |
Saline control response (10 ml/kg ip) for cocaine, locomotion from 15-20 min after injection for males [cm] |
Drug response |
| X2844 |
11448 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for males [cm] |
Drug response |
| X1141 |
11449 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for males [cm] |
Drug response |
| X2049 |
11450 |
Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for males [cm] |
Drug response |
| X1218 |
11451 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for males [cm] |
Drug response |
| X1504 |
11452 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for males [cm] |
Drug response |
| X3225 |
11453 |
Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for males [mg/dl XX min after injection] |
Drug response |
| X3834 |
11460 |
Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for males and females [sec] |
Drug response |
| X2527 |
11461 |
Ethanol response (2.25 g/kg ip), duration on rotarod following injection for males [sec] |
Drug response |
| X4874 |
11462 |
Ethanol response (2.25 g/kg ip), motor coordination effects, tolerance assay, difference in time on rotarod between saline and ethanol for males [sec] |
Drug response |
| X4204 |
12934 |
Potassium of 14-week old males [mM] |
Hematology |
| X155 |
11463 |
Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for males [sec] |
Drug response |
| X3291 |
11469 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3975 |
11470 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4548 |
11471 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3468 |
11472 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3569 |
11473 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males [cm] |
Drug response |
| X4095 |
11474 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males [cm] |
Drug response |
| X4456 |
11475 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males [cm] |
Drug response |
| X2895 |
11476 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males [cm] |
Drug response |
| X1260 |
11477 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for males [n beam breaks] |
Drug response |
| X980 |
11478 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for males [n beam breaks] |
Drug response |
| X2394 |
11479 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for males [n beam breaks] |
Drug response |
| X2114 |
11480 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for males [n beam breaks] |
Drug response |
| X2457 |
11481 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2809 |
11482 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4486 |
11484 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3173 |
11485 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for males [cm] |
Drug response |
| X3483 |
11486 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for males [cm] |
Drug response |
| X3637 |
11487 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for males [cm] |
Drug response |
| X4009 |
11488 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for males [cm] |
Drug response |
| X1107 |
11489 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X1734 |
11490 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X1044 |
11491 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2051 |
11492 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3881 |
11495 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in drug-paired compartment on Day 5 for males [sec], |
Drug response |
| X2377 |
11496 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on Day 5 for males [sec] |
Drug response |
| X3847 |
11498 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for males [sec] |
Drug response |
| X3765 |
11499 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in percentage of time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for males [% cha |
Drug response |
| X3894 |
11503 |
Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3947 |
11504 |
Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for males [cm] |
Drug response |
| X1814 |
11505 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in open field from 0-60 min after first cocaine injection for males [n beam breaks] |
Drug response |
| X1987 |
11534 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males [n beam breaks] |
Drug response |
| X2134 |
11535 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males [cm] |
Drug response |
| X2117 |
11536 |
Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for males [n beam breaks/60 min] |
Drug response |
| X3747 |
11537 |
Cocaine response (2 x 10 mg/kg, ip), sensitization, locomotion after the second injection minus locomotion after the first injection for males [difference in cm/1 hr test, positive values indicate sensitizat |
Drug response |
| X3802 |
11538 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males [n beam breaks, positive values indicate sensitization] |
Drug response |
| X4366 |
11539 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males [cm, positive values indicate sensitization] |
Drug response |
| X996 |
11540 |
Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for males between first and second injections [difference in n/1 hr test, positive values indicate sensitization] |
Drug response |
| X3087 |
11541 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males [n beam breaks/15 min] |
Drug response |
| X4158 |
10822 |
Transferrin saturation of males [%] |
Hematology |
| X2299 |
11542 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males [n beam breaks/15 min] |
Drug response |
| X3347 |
11543 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males [n beam breaks/15 min] |
Drug response |
| X1954 |
11544 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males [n beam breaks/15 min] |
Drug response |
| X2586 |
11545 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males [cm] |
Drug response |
| X2388 |
11546 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males [cm] |
Drug response |
| X3800 |
11547 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males [cm] |
Drug response |
| X2551 |
11548 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males [cm] |
Drug response |
| X1200 |
11549 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for males [n beam breaks/15 min] |
Drug response |
| X2116 |
11550 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for males [n beam breaks/15 min] |
Drug response |
| X2526 |
11551 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for males [n beam breaks/15 min] |
Drug response |
| X3242 |
11552 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for males [n beam breaks/15 min] |
Drug response |
| X4628 |
11560 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period immediately after injection for females [sec] |
Drug response |
| X3948 |
11561 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period starting 30 min after injection for females [sec] |
Drug response |
| X631 |
11569 |
Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2504 |
11570 |
Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2411 |
11571 |
Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1286 |
11572 |
Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X940 |
11573 |
Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X257 |
11574 |
Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1054 |
11575 |
Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X260 |
11576 |
Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X161 |
11577 |
Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X182 |
11578 |
Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X291 |
11579 |
Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X535 |
11580 |
Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for females [cm] |
Drug response |
| X2187 |
11581 |
Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for females [cm] |
Drug response |
| X1138 |
11582 |
Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for females [cm] |
Drug response |
| X1401 |
11583 |
Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for females [cm] |
Drug response |
| X627 |
11584 |
Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injection in an activity chamber for females [cm] |
Drug response |
| X249 |
11585 |
Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for females [cm] |
Drug response |
| X480 |
11586 |
Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for females [cm] |
Drug response |
| X158 |
11587 |
Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for females [cm] |
Drug response |
| X115 |
11588 |
Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for females [cm] |
Drug response |
| X143 |
11589 |
Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for females [cm] |
Drug response |
| X244 |
11590 |
Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for females [cm] |
Drug response |
| X4951 |
11591 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X4187 |
11592 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for females [n fecal boli] |
Drug response |
| X4655 |
11593 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for females [n/15 min test] |
Drug response |
| X289 |
11594 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X246 |
11595 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [cm] |
Drug response |
| X896 |
11630 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X438 |
11596 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for females (last 15 min of morphine test (165-180 min) minus first 15 min after naloxone) |
Drug response |
| X2082 |
11597 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1739 |
11613 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for females [n beam breaks] |
Drug response |
| X1528 |
11614 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for females [cm] |
Drug response |
| X2782 |
11615 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), vertical activity (rears) from 0-15 min after naloxone injection for females [n beam breaks] |
Drug response |
| X4326 |
11616 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3576 |
11617 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3840 |
11618 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for females [ordinal scale, 0=control level, 3=max] |
Drug response |
| X2598 |
11619 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3221 |
11621 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2995 |
11622 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2448 |
11623 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1358 |
11624 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1916 |
11625 |
Morphine response (50 mg/kg ip), vertical activity (rears) 150-165 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1497 |
11626 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1491 |
11627 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X396 |
11628 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X476 |
11629 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2194 |
11631 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X4429 |
11635 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) 4 hrs after injection for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion |
Drug response |
| X4491 |
11636 |
Ethanol response (4.0 g/kg ip), handling-induced convulsions (HIC) 6 hrs after injections for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsio |
Drug response |
| X2773 |
11637 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) score 7 hrs after ethanol injection for females [units] |
Drug response |
| X3945 |
11639 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) after injection for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion during |
Drug response |
| X1374 |
11697 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for females [cm] |
Drug response |
| X368 |
11699 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for females [cm] |
Drug response |
| X1102 |
11701 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for females [cm] |
Drug response |
| X327 |
11703 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for females [cm] |
Drug response |
| X1407 |
11705 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for females [cm] |
Drug response |
| X1655 |
11706 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for females [cm] |
Drug response |
| X1813 |
11708 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for females [cm] |
Drug response |
| X285 |
11709 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for females [cm] |
Drug response |
| X2032 |
11717 |
Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for females [sec] |
Drug response |
| X1955 |
11718 |
Ethanol response (2.25 g/kg ip), duration on rotarod following injection for females [sec] |
Drug response |
| X2088 |
11719 |
Ethanol response (2.25 g/kg ip), motor coordination effects, tolerance assay, difference in time on rotarod between saline and ethanol for females [sec] |
Drug response |
| X3196 |
11720 |
Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for females [sec] |
Drug response |
| X780 |
11726 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for females [n beam breaks] |
Drug response |
| X729 |
11727 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2499 |
11728 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2378 |
11729 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for females [n beam breaks] |
Drug response |
| X506 |
11730 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for females [cm] |
Drug response |
| X986 |
11731 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for females [cm] |
Drug response |
| X2936 |
11732 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for females [cm] |
Drug response |
| X2316 |
11733 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for females [cm] |
Drug response |
| X324 |
11734 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for females [n beam breaks] |
Drug response |
| X605 |
11735 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for females [n beam breaks] |
Drug response |
| X613 |
11736 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for females [n beam breaks] |
Drug response |
| X643 |
11737 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for females [n beam breaks] |
Drug response |
| X609 |
11738 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1064 |
11739 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1704 |
11740 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 30-45 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X3180 |
11741 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X403 |
11742 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for females [cm] |
Drug response |
| X1165 |
11743 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for females [cm] |
Drug response |
| X1925 |
11744 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for females [cm] |
Drug response |
| X3211 |
11745 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for females [cm] |
Drug response |
| X1007 |
11746 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1223 |
11747 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X542 |
11748 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2191 |
11749 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X4399 |
11750 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for females [sec] |
Drug response |
| X483 |
11751 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for females [sec] |
Drug response |
| X4614 |
11752 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in drug-paired compartment on Day 5 for females [sec] |
Drug response |
| X3826 |
11753 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on Day 5 for females [sec] |
Drug response |
| X4490 |
11755 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for females [sec] |
Drug response |
| X3126 |
11756 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in percentage time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for females [% chan |
Drug response |
| X1142 |
11760 |
Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for females [n beam breaks] |
Drug response |
| X942 |
11761 |
Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for females [cm] |
Drug response |
| X361 |
11762 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in open field from 0-60 min after first cocaine injection for females [n beam breaks] |
Drug response |
| X1251 |
11791 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for females [n beam breaks] |
Drug response |
| X1436 |
11792 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for females [cm] |
Drug response |
| X259 |
11793 |
Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for females [n beam breaks/60 min] |
Drug response |
| X4729 |
11794 |
Cocaine response (2 x 10 mg/kg, ip), sensitization, locomotion after the second injection minus locomotion after the first injection for females [difference in cm/1 hr test, positive values indicate sensitiz |
Drug response |
| X1117 |
11795 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for females [n beam breaks, positive values indicate sensitization] |
Drug response |
| X1178 |
11796 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for females [cm, positive values indicate sensitization] |
Drug response |
| X785 |
11797 |
Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for females between first and second injections [difference in n/1 hr test, positive values indicate sensitization] |
Drug response |
| X1596 |
11798 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for females [n beam breaks/15 min] |
Drug response |
| X571 |
11799 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for females [n beam breaks/15 min] |
Drug response |
| X1261 |
11800 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for females [n beam breaks/15 min] |
Drug response |
| X1437 |
11801 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for females [n beam breaks/15 min] |
Drug response |
| X1085 |
11802 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for females [cm] |
Drug response |
| X645 |
11803 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for females [cm] |
Drug response |
| X1323 |
11804 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for females [cm] |
Drug response |
| X1775 |
11805 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for females [cm] |
Drug response |
| X226 |
11806 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for females [n beam breaks/15 min] |
Drug response |
| X435 |
11807 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for females [n beam breaks/15 min] |
Drug response |
| X386 |
11808 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for females [n beam breaks/15 min] |
Drug response |
| X400 |
11809 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for females [n beam breaks/15 min] |
Drug response |
| X2759 |
11817 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period immediately after injection for males and females [sec] |
Drug response |
| X1163 |
11818 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period starting 30 min after injection for males and females [sec] |
Drug response |
| X795 |
11821 |
Pain response, thermal nociception, Hargreaves' test for males and females |
Drug response |
| X2145 |
11822 |
Pain response, thermal nociception, hot plate test, average of two trials for males and females [sec] |
Drug response |
| X833 |
11823 |
Pain response, mechanical nociception, tail clip latency for males and females [sec] |
Drug response |
| X1412 |
11824 |
Pain response, thermal nociception, tail withdrawal latency for males and females [sec] |
Drug response |
| X189 |
11826 |
Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X447 |
11827 |
Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2099 |
11828 |
Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1511 |
11829 |
Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X505 |
11830 |
Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X243 |
11831 |
Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X845 |
11832 |
Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X169 |
11833 |
Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X101 |
11834 |
Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X100 |
11835 |
Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X134 |
11836 |
Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X163 |
11837 |
Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X342 |
11838 |
Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X1366 |
11839 |
Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X1522 |
11840 |
Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X410 |
11841 |
Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injections in an activity chamber for males and females [cm] |
Drug response |
| X231 |
11842 |
Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X267 |
11843 |
Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X108 |
11844 |
Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X84 |
11845 |
Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X91 |
11846 |
Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X112 |
11847 |
Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X3998 |
11848 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for males and females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X2412 |
10749 |
HDL cholesterol level following 16-week high-fat diet [mg/dL] |
Hematology |
| X3804 |
11849 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for males and females [n fecal boli] |
Drug response |
| X3666 |
11850 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for males and females [n/15 min test] |
Drug response |
| X132 |
11851 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X118 |
11852 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [cm] |
Drug response |
| X333 |
11853 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for males and females (last 15 min of morphine test (165-180 min) minus first 15 min after |
Drug response |
| X987 |
11854 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1184 |
11870 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for males and females [n beam breaks] |
Drug response |
| X916 |
11871 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for males and females [cm] |
Drug response |
| X3833 |
11872 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), vertical activity (rears) from 0-15 min after naloxone injection for males and females [n beam breaks] |
Drug response |
| X3198 |
11873 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for males and females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X2492 |
11874 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for males and females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3983 |
11875 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for males and females [ordinal scale, 0=control level, 3=max] |
Drug response |
| X2937 |
11876 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X1203 |
11878 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2004 |
11879 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2718 |
11880 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1394 |
11881 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1577 |
11882 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 150-165 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X650 |
11883 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X825 |
11884 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X142 |
11885 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X171 |
11886 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X382 |
11887 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X801 |
11888 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2371 |
11889 |
3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) response (10 mg/kg subcutaneous), locomotion on day 2 for males and females [cm/90 min test] |
Drug response |
| X4034 |
11892 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) 4 hrs after injection for males and females [ordinal scale] |
Drug response |
| X2348 |
11894 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) score 7 hrs after ethanol injection for males and females [ordinal scale] |
Drug response |
| X3368 |
11896 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) after injection for males and females [ordinal scale] |
Drug response |
| X4221 |
11954 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for males and females [cm] |
Drug response |
| X2931 |
11955 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for males and females [cm] |
Drug response |
| X4184 |
11956 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for males and females [cm] |
Drug response |
| X1143 |
11957 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 5-10 min after injection for males and females [cm] |
Drug response |
| X1492 |
11958 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for males and females [cm] |
Drug response |
| X683 |
11959 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 10-15 min for males and females [cm] |
Drug response |
| X796 |
11960 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for males and females [cm] |
Drug response |
| X602 |
11961 |
Saline control response (10 ml/kg ip), locomotion from 15-20 min after injection for males and females [cm] |
Drug response |
| X4154 |
11962 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for males and females [cm] |
Drug response |
| X2150 |
10750 |
HDL cholesterol levels following 16-week chow diet (control group) [mg/dL] |
Hematology |
| X3369 |
11963 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for males and females [cm] |
Drug response |
| X851 |
11964 |
Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for males and females [cm] |
Drug response |
| X4961 |
11965 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for males and females [cm] |
Drug response |
| X1692 |
11966 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for males and females [cm] |
Drug response |
| X1859 |
11967 |
Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for males and females [mg/dl XX min after injection] |
Drug response |
| X2169 |
11974 |
Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for males females [sec] |
Drug response |
| X1030 |
11975 |
Ethanol response (2.25 g/kg ip), duration on rotarod following injection for males and females [sec] |
Drug response |
| X4910 |
11976 |
Ethanol response (2.25 g/kg ip), time on rotarod after saline minus time on rotarod after ethanol for males and females [sec] |
Drug response |
| X1373 |
11977 |
Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for males and females [sec] |
Drug response |
| X2781 |
11978 |
Saline control response (dose ip), motor coordination effects, difference in time on rotarod between training session and saline for males and females [sec] |
Drug response |
| X2152 |
11983 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2136 |
11984 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2741 |
11985 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2529 |
11986 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1537 |
11987 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males and females [cm] |
Drug response |
| X2009 |
11988 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males and females [cm] |
Drug response |
| X3097 |
11989 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males and females [cm] |
Drug response |
| X2399 |
11990 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males and females [cm] |
Drug response |
| X429 |
11991 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for males and females [n beam breaks] |
Drug response |
| X719 |
11992 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for males and females [n beam breaks] |
Drug response |
| X2213 |
10823 |
Transferrin saturation of males and females [%] |
Hematology |
| X912 |
11993 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for males and females [n beam breaks] |
Drug response |
| X737 |
11994 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for males and females [n beam breaks] |
Drug response |
| X2368 |
11995 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1722 |
11996 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2081 |
11997 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 30-45 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X3651 |
11998 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1658 |
11999 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for males and females [cm] |
Drug response |
| X1628 |
12000 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for males and females [cm] |
Drug response |
| X2345 |
12001 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for males and females [cm] |
Drug response |
| X4172 |
12002 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for males and females [cm] |
Drug response |
| X715 |
12003 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X930 |
12004 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X504 |
12005 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2033 |
12006 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X4407 |
12007 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for males and females [sec] |
Drug response |
| X3083 |
12008 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for males and females [sec] |
Drug response |
| X4136 |
12009 |
Cocaine response (3 x 3.2 mg/kg ip, days 2,3, 4), conditioned place preference (CPP), time in drug-paired compartment on day 5 for males and females [sec] |
Drug response |
| X2620 |
12010 |
Cocaine response (3 x 3.2 mg/kg ip, days 2,3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on day 5 for males and females [sec] |
Drug response |
| X4928 |
10825 |
Hemoglobin in males [g/dL] |
Hematology |
| X4297 |
12011 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, percentage of time spent in conditioned side before conditioning for males and females [%] |
Drug response |
| X3997 |
12012 |
Cocaine response (3 x 3.2 mg/kg ip, days 2,3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (day 5 minus day 1) for males |
Drug response |
| X4145 |
12013 |
Cocaine response (3 x 3.2 mg/kg ip, days 2,3, and 4), conditioned place preference (CPP), change in percentage time in cocaine-paired compartment relative to baseline (day 5 minus day 1 |
Drug response |
| X2327 |
12017 |
Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2312 |
12018 |
Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for males and females [cm] |
Drug response |
| X1255 |
12019 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in the open field from 0-60 min after first cocaine injection for males and females [n beam breaks] |
Drug response |
| X1913 |
12048 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males and females [n beam breaks] |
Drug response |
| X1582 |
12049 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males and females [cm] |
Drug response |
| X512 |
12050 |
Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for males and females [n beam breaks/60 min] |
Drug response |
| X3914 |
12051 |
Cocaine response (2 x 10 mg/kg ip), sensitization, locomotion after the second injection minus locomotion after the first injection for males and females [difference in cm/1 hr test, positive values indicate |
Drug response |
| X1951 |
12052 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males and females [n beam breaks, positive values indicate sensitization] |
Drug response |
| X1998 |
12053 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males and females [cm, positive values indicate sensitization] |
Drug response |
| X642 |
12054 |
Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for males and females between first and second injections [difference in n/1 hr test, positive values indicate sensitiza |
Drug response |
| X2239 |
12055 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X1185 |
12056 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X2067 |
12057 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X2391 |
12058 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X1843 |
12059 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males and females [cm] |
Drug response |
| X1282 |
12060 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males and females [cm] |
Drug response |
| X1878 |
12061 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males and females [cm] |
Drug response |
| X2375 |
12062 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males and females [cm] |
Drug response |
| X413 |
12063 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X680 |
12064 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X649 |
12065 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X793 |
12066 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X5071 |
12393 |
Ethanol response (1.8 g/kg ip), anxiety assay in ethanol-treated (NOE) group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks/ |
Drug response |
| X4883 |
12565 |
Ethanol response (10% in tap water), average daily preference ratio, two-bottle choice in males and females [EtOH/water ratio] |
Drug response |
| X4263 |
12574 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 6th week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X4117 |
12575 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 5th week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X4697 |
12576 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 4th week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X3012 |
12577 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 3rd week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X2364 |
12578 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 2nd week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X4059 |
12579 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 1st week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X3920 |
12580 |
Ethanol response, consumption of 15% ethanol using a two-bottle choice systems (ethanol vs water), 2 h access, principal component 1 eigentrait (similar to residuals) based on weeks 1 through 6 data (Dec 200 |
Drug response |
| X2627 |
12586 |
Ethanol response (10% in tap water), average daily consumption, two-bottle choice, males and females [g/kg] |
Drug response |
| X4346 |
12623 |
Ethanol response (10% EtOH in tap water) average daily consumption, two bottle choice [g/kg], males |
Drug response |
| X2807 |
12624 |
Ethanol response (10% EtOH in tap water), average daily consumption using two-bottle choice method in females [g/kg] |
Drug response |
| X4043 |
12733 |
Ethanol response (10% v/v ethanol), average daily consumption at 2 hr, males and females combined [g/kg] |
Drug response |
| X2711 |
12741 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 4th cycle of eth |
Drug response |
| X775 |
12742 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 3rd cycle of eth |
Drug response |
| X2229 |
12743 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 2nd cycle of eth |
Drug response |
| X4091 |
12744 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 1st cycle of eth |
Drug response |
| X4703 |
12745 |
Ethanol response (chronic intermittent ethanol CIE cycles), baseline consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 before any ethano |
Drug response |
| X2903 |
12780 |
Ethanol response (chronic intermittent ethanol CIE cycles),3,4-dihydroxyphenylacetic acid (DOPAC) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old |
Drug response |
| X4898 |
12781 |
Ethanol response (chronic intermittent ethanol CIE cycles), norepinephrine (NE) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females ( |
Drug response |
| X4617 |
12782 |
Ethanol response (chronic intermittent ethanol CIE cycles), dopamine (DA) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 20 |
Drug response |
| X4174 |
12783 |
Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxyindoleacetic acid (5-HIAA) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old ma |
Drug response |
| X3606 |
12784 |
Ethanol response (chronic intermittent ethanol CIE cycles), homovanillic acid (HVA) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or femal |
Drug response |
| X3774 |
12785 |
Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxytryptamine (5-HT, serotonin) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old |
Drug response |
| X4510 |
12786 |
Control for ethanol response, norepinephrine (NE) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/ |
Drug response |
| X5050 |
12787 |
Control for ethanol response,3,4-dihydroxyphenylacetic acid (DOPAC) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec |
Drug response |
| X3026 |
10826 |
Hemoglobin in males and females [g/dL] |
Hematology |
| X4948 |
12788 |
Control for ethanol response, 5-hydroxyindoleacetic acid (5-HIAA) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 200 |
Drug response |
| X3207 |
12789 |
Control for ethanol response, homovanilic acid (HVA) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ |
Drug response |
| X4527 |
12790 |
Control for ethanol response, 5-hydroxytryptamine (5-HT, serotonin) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2 |
Drug response |
| X4534 |
12791 |
Ethanol response (chronic intermittent ethanol CIE cycles), norepinephrine levels (NE) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec |
Drug response |
| X2897 |
12792 |
Ethanol response (chronic intermittent ethanol CIE cycles),3,4-dihydroxyphenylacetic acid levels (DOPAC) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old mal |
Drug response |
| X3725 |
12793 |
Ethanol response (chronic intermittent ethanol CIE cycles), dopamine (DA) level in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Co |
Drug response |
| X2211 |
12794 |
Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxyindoleacetic acid levels (5-HIAA) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males |
Drug response |
| X1340 |
12795 |
Ethanol response (chronic intermittent ethanol CIE cycles), homovanillic acid (HVA) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 200 |
Drug response |
| X3713 |
12796 |
Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxytryptamine (5-HT, serotonin) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or f |
Drug response |
| X4292 |
12797 |
Control for ethanol response, norepinephrine (NE) level in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X2264 |
12798 |
Ethanol response,3,4-dihydroxyphenylacetic acid levels (DOPAC, a dopamine metabolite) in the medial septal nucleus 72 h after the 5th cycle of chronic intermittent ethanol (CIE) vapor chamber treatment, 15 to 17 week |
Drug response |
| X2204 |
12799 |
Control for ethanol response, dopamine (DA) level in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X4450 |
12800 |
Control for ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in the medial septal nucleus 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or fem |
Drug response |
| X2727 |
12801 |
Control for ethanol response, homovanillic acid (HVA) level in the medial septal nucleus 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X2705 |
10751 |
LDL cholesterol levels following 16-week chow diet (control group) [mg/dL] |
Hematology |
| X3967 |
12802 |
Control for ethanol response, 5-hydroxytryptamine (5-HT, serotonin) level in the medial septal nucleus 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Coho |
Drug response |
| X3399 |
12803 |
Ethanol response (chronic intermittent vapor exposure CIE), norepinephrine (NE) level in hindbrain tissue 72 h after the 5th cycle of treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X2845 |
12804 |
Control for ethanol response,3,4-dihydroxyphenylacetic acid (DOPAC) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [n |
Drug response |
| X3324 |
12805 |
Ethanol response (5 cycles of chronic intermittent vapor exposure CIE), dopamine level in hindbrain tissue 72h after the 5th cycle of treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X2382 |
12806 |
Ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in hindbrain tissue 72h after the 5th cycle of chronic intermittent ethanol (CIE) vapor chamber treatment, 16 to 18 weeks males or f |
Drug response |
| X1432 |
12807 |
Ethanol response (5 cycles of chronic intermittent vapor exposure CIE), homovanillic (HVA) level in hindbrain tissue 72 h after the 5th cycle of treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg |
Drug response |
| X805 |
12808 |
Ethanol response, 5-hydroxytrptamine levels (5-HT, serotonin) in hindbrain tissue 72h after the 5th cycle of chronic intermittent ethanol (CIE) vapor chamber treatment, 16 to 18 weeks males or females (Dec 2009 Cohort |
Drug response |
| X3990 |
12809 |
Control for ethanol response, norepinephrine (NE) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X4854 |
12810 |
Control for ethanol response,3,4-dihydroxyphenylacetic acid levels (DOPAC) in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ |
Drug response |
| X1872 |
12811 |
Control for ethanol response, dopamine levels (DA) in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X3294 |
12812 |
Control for ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in hindbrain tissue 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or females (Dec |
Drug response |
| X2105 |
12813 |
Control for ethanol response, homovanillic acid (HVA, a dopamine metabolite) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Coho |
Drug response |
| X3230 |
12814 |
Control for ethanol response, 5-hydroxytryptamine levels (5-HT, serotonin) in hindbrain tissue 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or females (Dec 2009 Cohort 1) [ng/mg |
Drug response |
| X4114 |
12815 |
Control for ethanol response, dopamine (DA) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X4701 |
10752 |
Cholesterol levels following 16-week high-fat diet [natural log of cholesterol levels] |
Hematology |
| X4452 |
12940 |
Mean corpuscular hemoglobin of 14-week old males [pg] |
Hematology |
| X3161 |
12816 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access, 3 days after 1st cycle of ethanol vapor chamber treatme |
Drug response |
| X229 |
12817 |
Ethanol response, ethanol consumption using a 2-bottle choice with 2 h access/day from day 3 to day 8 after the fourth cycle of treatment in a chronic intermittent ethanol vapor chamber (CIE) [g/kg/2h/day] |
Drug response |
| X1919 |
12961 |
Ethanol response, ethanol intake using a 2-bottle choice test, 2h access after cycle 4 of air exposure only (control for CIE) in vapor chambers (average of 5 days ethanol intake [g/kg/2h] |
Drug response |
| X661 |
12963 |
Ethanol response, ethanol intake using a 2-bottle choice test, 2 h access after the second cycle of air exposure (control for CIE) in vapor chamber (average of 5 days ethanol intake, young adult males or females [g/kg |
Drug response |
| X1000 |
12964 |
Ethanol response, ethanol intake using a 2-bottle choice test, 2 hr access after cycle 1 of air exposure only (control for CIE) in vapor chambers (average of 5 days ethanol intake, 16 to 18 weeks males or females [g/ |
Drug response |
| X4247 |
12965 |
Ethanol response (ethanol vapor inhalation chronic intermittent ethanol (CIE) inhalation chamber), two-bottle choice consumption, 2 hr access after first cycle of exposure, intake over 5 days [g/kg/2h] |
Drug response |
| X1759 |
12967 |
Ethanol response (ethanol vapor inhalation chronic intermittent ethanol (CIE) inhalation chamber), two-bottle choice consumption, 2 hr access after third cycle of exposure, intake over 5 days [g/kg/2h] |
Drug response |
| X3110 |
13018 |
Ethanol response (3 day exposure to 8-11 g/kg ethanol in vapor chamber with pyrazole 1 mM/kg/day),handling-induced convulsion (HIC) withdrawal severity score (15x 1 hour measurements) in 24-28 week-old males |
Drug response |
| X1309 |
13565 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, baseline in normally housed group, control for chronic mild stress (CMS) group (Phas |
Drug response |
| X1959 |
13566 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, baseline in chronic mild (CMS) stress group 1 week before start of 7 weeks of CMS (Ph |
Drug response |
| X2774 |
13567 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, first DID), difference between chronic mild stress (CMS) and control groups one week before the s |
Drug response |
| X623 |
13568 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID phase) in females, control group for chronic mild stress (CMS) group (Phase 2) [g/kg] |
Drug response |
| X3062 |
13569 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID) in females, chronic mild stress (CMS) group (Phase 2) [g/kg] |
Drug response |
| X1015 |
13570 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID) in females, difference between chronic mild stress (CMS) group and control group (Pha |
Drug response |
| X5015 |
13571 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, third DID)in females, in the control group for the chronic mild stress (CMS) group (Phase 3) [g/k |
Drug response |
| X2785 |
13572 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, third DID) in females, chronic mild stress (CMS) group following CMS (Phase 3) [g/kg] |
Drug response |
| X4300 |
13573 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, third DID) in females, difference between chronic mild stress (CMS) group and control group follo |
Drug response |
| X2509 |
13574 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 2) in the control group [g/kg] |
Drug response |
| X2494 |
13575 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 2) in the chronic mild stress (CMS) group [g |
Drug response |
| X701 |
13576 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 2 minus phase 1) in the control group for chronic mild str |
Drug response |
| X4637 |
13577 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 2 minus phase 1) for the chronic mild stress (CMS) group [ |
Drug response |
| X1048 |
13578 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 1) for the control group for chronic mild st |
Drug response |
| X3652 |
13579 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 1) for the chronic mild stress (CMS) group [ |
Drug response |
| X4536 |
14803 |
Nicotine response (0.5mg/kg, s.c., b.i.d., on days 2-4), conditioned place preference (CPP) on day 5 in 7-8-week old males (upper panel, Fig 1, dark bars) [sec] |
Drug response |
| X2975 |
14804 |
Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, conditioned place preference (CPP) on day 5 in 7-8-week old males (upper panel, Fig 1, light bars) [sec] |
Drug response |
| X2868 |
14805 |
Nicotine response (0.5mg/kg, sc, twice a day on days 2-4), post-conditioning scores on day 5 in 7-8-week old males (supplementary data) [sec] |
Drug response |
| X4211 |
14806 |
Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, post-conditioning score on day 5 of CPP in 7-8-week old males (supplementary data) [score] |
Drug response |
| X418 |
15572 |
Withdrawal anxiety assay, 7-day nicotine-treated (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2.0 mg/kg, s.c.), number of somatic signs observed in 8- to 12-week-old males during 20 min session [n] |
Drug response |
| X4150 |
15573 |
withdrawal anxiety assay (Nic_Sal_Som), 7-day nicotine-treated (24mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.), number of somatic signs observedin 8-12 week old males during 20 minute session [ |
Drug response |
| X1076 |
15574 |
Withdrawal anxiety assay, 7-day nicotine-treated (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2 mg/kg, s.c.), percent time spent in open arms of the elevated plus maze in 8-12 week old males during 5 |
Drug response |
| X4607 |
10753 |
LDL cholesterol levels following 16-week high-fat diet [natural log of cholesterol levels] |
Hematology |
| X1653 |
15575 |
Nicotine response (nicotine at 24 mg/kg/day for 7 days, s.c. by minipump followed by s.c. saline injection on day 8), withdrawal anxiety, percentage of time spent in open arms of an elevated plus maze in 8-1 |
Drug response |
| X662 |
16180 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 1 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Drug response |
| X707 |
16184 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) maximum after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Drug response |
| X4500 |
16197 |
Difference in nicotine response (0.5mg/kg, s.c., b.i.d., on days 2-4) and saline response (0.9%, s.c., b.i.d., on days 2-4), conditioned place preference (CPP) on day 5 in 7-8-week old males (lower panel, Fi |
Drug response |
| X625 |
16375 |
Ethanol response, blood ethanol concentration (BEC) during 4th cycle of ethanol exposure in vapor chamber (not associated with voluntary consumption) for male or female (Dec 2009 Cohort 1) [mg%] |
Drug response |
| X2907 |
17329 |
Saline control response (0.9%, s.c., b.i.d., on days 1) for nicotine experiment, basal movement on day 1 in CPP box in 7-8-week old males |
Drug response |
| X1934 |
17330 |
Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, locomotor activity on day 5 in CPP box in 7-8-week old males |
Drug response |
| X4882 |
17331 |
Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, change in movement (post - basal movement) on day 5 of CPP in 7-8-week old males |
Drug response |
| X4038 |
17332 |
Nicotine response (0.5 mg/kg, s.c., b.i.d., on day 1), locomotor activity prior to conditioning (pre-drug paired side) in CPP box in 7-8-week old males |
Drug response |
| X1823 |
17333 |
Nicotine response (0.5 mg/kg, s.c., b.i.d., on days 2-4), locomotor activity on test day (day 5) in CPP boxes in 7-8-week old males |
Drug response |
| X3668 |
17334 |
Nicotine response (0.5 mg/kg, s.c., b.i.d., on days 2-4), change in movement (pre - post-drug paired side) on day 5 of CPP in 7-8-week old males |
Drug response |
| X3744 |
17335 |
Withdrawal nociception assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2.0 mg/kg, s.c.), hot plate latency (sec) |
Drug response |
| X3445 |
17336 |
Withdrawal hyperlocomotion assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2.0 mg/kg, s.c.), hot plate activity (sec) |
Drug response |
| X2917 |
17337 |
Withdrawal nociception assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.), hot plate latency (sec) |
Drug response |
| X3403 |
17338 |
Withdrawal hyperlocomotion assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.), hot plate activity (sec) |
Drug response |
| X928 |
18103 |
Ethanol response (20% v/v) using the drinking in the dark (DID) method (4 hr access on day 4 of DID) to measure average baseline drinking under 5 weeks of normal housing [g/kg] |
Drug response |
| X1235 |
18104 |
Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 7 weeks (control for chronic mild stress (CMS) group) [g/k |
Drug response |
| X1500 |
18105 |
Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 4 weeks (control for chronic mild stress (CMS) group) [g/k |
Drug response |
| X3986 |
18106 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average baseline alcohol consumption for normally housed mice over |
Drug response |
| X2752 |
18107 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption during last 4 weeks and 7 weeks follow |
Drug response |
| X4151 |
18108 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption during first 5 weeks and last 4 weeks |
Drug response |
| X464 |
18114 |
Ethanol response (20% v/v) using the drinking in the dark (DID) method (4 hr access on day 4 of DID) to measure average baseline drinking under 5 weeks of normal housing [g/kg] |
Drug response |
| X2232 |
18115 |
Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 7 weeks of chronic mild stress (CMS) [g/kg] |
Drug response |
| X2084 |
18116 |
Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 4 weeks following 7 weeks of chronic mild stress (CMS) [g/ |
Drug response |
| X2403 |
18117 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average baseline alcohol consumption for normally housed mice over |
Drug response |
| X2528 |
18118 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption for normally housed mice 4 weeks after |
Drug response |
| X869 |
18119 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average baseline alcohol consumption for normally housed mice over |
Drug response |
| X81 |
10429 |
Serum amyloid P component level (APCS protein, endogenous SAP maps to Chr 1 at 174,8 Mb) [ug/ml] |
Hematology |
| X4139 |
10440 |
Red blood cell osmotic fragility, following treatment with 0.425% NaCl [% lysis] |
Hematology |
| X3707 |
10511 |
Blood glucose levels before 4 g/kg ip ethanol injection in females [mg/dl] |
Hematology |
| X4915 |
10512 |
Blood glucose levels before 4 g/kg ip ethanol injection in males [mg/dl] |
Hematology |
| X1551 |
10513 |
Ethanol response (4 g/kg ip), blood glucose levels 120 min after injection in females [mg/dl] |
Hematology |
| X4457 |
10514 |
Ethanol response (4 g/kg ip), blood glucose levels 120 min after injection in males [mg/dl] |
Hematology |
| X4632 |
10515 |
Blood glucose levels before saline ip control injection in females [mg/dl] |
Hematology |
| X4667 |
10516 |
Blood glucose levels before saline ip control injection in males [mg/dl] |
Hematology |
| X3348 |
10517 |
Blood glucose levels 120 min after saline control injection in females [mg/dl] |
Hematology |
| X4761 |
10518 |
Blood glucose levels 120 min after saline control injection in males [mg/dl] |
Hematology |
| X4451 |
10827 |
Iron binding capacity (systemic, total iron-binding capacity, TIBC, transferrin level) of males [ug/dL] |
Hematology |
| X3202 |
10828 |
Iron level in plasma of females [g/dL] |
Hematology |
| X1910 |
10829 |
Iron level in plasma of males and females [ug/dL] |
Hematology |
| X3601 |
10830 |
Transferrin saturation of females [%] |
Hematology |
| X4357 |
10831 |
Iron binding capacity (total iron-binding capacity, TIBC, transferrin level) of females [ug/dL] |
Hematology |
| X1790 |
10832 |
Hemoglobin in females [g/dL] |
Hematology |
| X4776 |
10833 |
Hematocrit (packed cell volume, erythrocyte volume fraction) in males [%] |
Hematology |
| X3750 |
10834 |
Hematocrit (packed cell volume, erythrocyte volume fraction) in females [%] |
Hematology |
| X3105 |
12073 |
Metabolism, Albumin-to-creatinine ratio (ABR) baseline control in males at 10-12 weeks of age [ratio of ug/mg] |
Hematology |
| X2530 |
12491 |
Hemoglobin of 120-day-old females fed 3 ppm iron (Fe) diet [ug/dl] |
Hematology |
| X2092 |
12492 |
Hematocrit of 120-day-old females fed 3 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X4540 |
12499 |
Hemoglobin of 120-day-old males fed 3 ppm Fe diet [ug/dl] |
Hematology |
| X4186 |
12500 |
Hematocrit of 120-day-old males fed 3 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X1319 |
12507 |
Hemoglobin of 120-day-old females fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X3620 |
12508 |
Hematocrit of 120-day-old females fed 270 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X78 |
12515 |
Hemoglobin of 120-day-old males fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X352 |
12516 |
Hematocrit of 120-day-old males fed 270 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X4166 |
12523 |
Transferrin saturation in plasma of 120-day-old males and females fed 3 ppm Fe diet [%] |
Hematology |
| X4175 |
12524 |
Iron binding capacity (total) in plasma of 120-day-old males and females fed 3 ppm Fe diet [ug/dl] |
Hematology |
| X1571 |
12525 |
Iron level of plasma of 120-day-old males and females fed 3 ppm Fe diet [ug/dl] |
Hematology |
| X1204 |
12526 |
Hemoglobin of 120-day-old males and females fed 3 ppm Fe diet [ug/dl] |
Hematology |
| X2024 |
12527 |
Hematocrit of 120-day-old males and females fed 3 ppm iron (Fe) diet [% packed red blood cells] |
Hematology |
| X2579 |
12534 |
Transferrin saturation in plasma of 120-day-old males and females fed 270 ppm Fe diet [%] |
Hematology |
| X4939 |
12535 |
Iron binding capacity (total) in plasma of 120-day-old males and females fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X4696 |
12536 |
Iron level of plasma of 120-day-old males and females fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X97 |
12537 |
Hemoglobin of 120-day-old males and females fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X654 |
12538 |
Hematocrit of 120-day-old males and females fed 270 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X2295 |
12540 |
Transferrin saturation of 120-day-old females fed 3 ppm iron diet [%] |
Hematology |
| X4547 |
12541 |
Iron binding capacity in plasma of 120-day-old females fed 3 ppm iron diet [ug/dL] |
Hematology |
| X4901 |
12547 |
Iron binding capacity in plasma of 120-day-old females fed 270 ppm iron diet [ug/dL] |
Hematology |
| X4585 |
12548 |
Plasma iron of 120-day-old females fed 270 ppm iron diet [ug/dL] |
Hematology |
| X2622 |
12549 |
Transferrin saturation of 120-day-old males fed 270 ppm iron diet [%] |
Hematology |
| X3853 |
12550 |
Iron binding capacity in plasma of 120-day-old males fed 270 ppm iron diet [ug/dL] |
Hematology |
| X5035 |
12551 |
Plasma iron of 120-day-old males fed 270 ppm iron diet [ug/dL] |
Hematology |
| X2324 |
12821 |
Alpha-amylase of 14-week old females [U/l] |
Hematology |
| X853 |
12822 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum of 14-week old females [U/L] |
Hematology |
| X979 |
12823 |
Albumin of 14-week old females [g/l] |
Hematology |
| X154 |
12824 |
Alkaline phosphatase of 14-week old females, (ALPL gene product) [U/l] |
Hematology |
| X3357 |
12825 |
Aspartate transaminase of 14-week old females [U/l] |
Hematology |
| X3551 |
12844 |
Calcium of 14-week old females [mM] |
Hematology |
| X4922 |
12845 |
Chloride of 14-week old females [mM] |
Hematology |
| X1272 |
12846 |
Creatinine of 14-week old females [uM] |
Hematology |
| X489 |
12855 |
Glucose after 4 hour fast of 14-week old females [mMl] |
Hematology |
| X3994 |
12861 |
Hematocrit of 14-week old females [%] |
Hematology |
| X3919 |
12862 |
Hemoglobin of 14-week old females [g/dl] |
Hematology |
| X3123 |
12864 |
Potassium of 14-week old females [mM] |
Hematology |
| X3746 |
12870 |
Mean corpuscular hemoglobin of 14-week old females [pg] |
Hematology |
| X628 |
12871 |
Mean cell hemoglobin concentration of 14-week old females [g/dl] |
Hematology |
| X198 |
12872 |
Mean red blood cell volume (MCV of standard complete blood count) of 14-week old females [fL] |
Hematology |
| X1936 |
12873 |
Sodium of 14-week old females [mM] |
Hematology |
| X992 |
12874 |
Phosphorus of 14-week old females [mM] |
Hematology |
| X692 |
12875 |
Platelet count of 14-week old females [x10^3/ul] |
Hematology |
| X4462 |
12877 |
Red blood cell count of 14-week old females [x10^6/ul] |
Hematology |
| X1675 |
12881 |
Cholesterol (total) of 14-week old females [mM] |
Hematology |
| X4049 |
12882 |
Triglyceride of 14-week old females [mM] |
Hematology |
| X3426 |
12883 |
Blood proteins (total) of 14-week old females [g/l] |
Hematology |
| X1988 |
12884 |
Urea of 14-week old females [mM] |
Hematology |
| X199 |
12888 |
White blood cell count of 14-week old females [x10^3/ul] |
Hematology |
| X4995 |
12891 |
Alpha-amylase of 14-week old males [U/l] |
Hematology |
| X1147 |
12892 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum of 14-week old males [U/L] |
Hematology |
| X1623 |
12893 |
Albumin of 14-week old males [g/l] |
Hematology |
| X122 |
12894 |
Alkaline phosphatase of 14-week old males (ALPL gene product) [U/l] |
Hematology |
| X3817 |
12895 |
Aspartate transaminase of 14-week old males [U/l] |
Hematology |
| X4695 |
12914 |
Calcium of 14-week old males [mM] |
Hematology |
| X4682 |
12915 |
Chloride of 14-week old males [mM] |
Hematology |
| X3865 |
12916 |
Creatinine of 14-week old males [uM] |
Hematology |
| X3598 |
12925 |
Glucose after 4 hour fast of 14-week old males [mMl] |
Hematology |
| X323 |
12931 |
Hematocrit of 14-week old males [%] |
Hematology |
| X248 |
12941 |
Mean cell hemoglobin concentration of 14-week old males [g/dl] |
Hematology |
| X151 |
12942 |
Mean cell volume of 14-week old males [fl] |
Hematology |
| X4494 |
12943 |
Sodium of 14-week old males [mM] |
Hematology |
| X633 |
12944 |
Phosphorus of 14-week old males [mM] |
Hematology |
| X2582 |
12945 |
Platelet count of 14-week old males [x10^3/ul] |
Hematology |
| X3730 |
12947 |
Red blood cell count of 14-week old males [x10^6/ul] |
Hematology |
| X2477 |
12951 |
Cholesterol (total) in serum of 14-week old males [mM] |
Hematology |
| X967 |
12952 |
Triglyceride of 14-week old males [mM] |
Hematology |
| X1933 |
12953 |
Blood proteins (total) of 14-week old males [g/l] |
Hematology |
| X2178 |
12954 |
Urea of 14-week old males [mM] |
Hematology |
| X569 |
12958 |
White blood cell count of 14-week old males [x10^3/ul] |
Hematology |
| X4275 |
12979 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum following alcohol (6 gm ethanol/kg via gastric gavage) at 24 hours after gavage in young adult males and females ( DBA/2J winsorized from 89.37 +/- 10.96 to 8 |
Hematology |
| X3721 |
12984 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum following alcohol (6 gm ethanol/kg via gastric gavage) at 24 hours after gavage in young adult females (associated with GenEx EtOH liver gene expression) [U/L |
Hematology |
| X3171 |
12985 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum following alcohol (6 gm ethanol/kg via gastric gavage) at 24 hours after gavage in young adult males (BXD16 winsorized from 158 +/- 32 to 92 and DBA/2J from 1 |
Hematology |
| X61 |
13034 |
Transthyretin protein serum band (prealbumin, Pre locus) detected by acylamide electrophoresis in adult males [a-genotype of DBA/2J with band is coded as 1, o-genotype without band is coded as -1] |
Hematology |
| X4803 |
15798 |
Bilirubin, fasted state, chow diet, males [umol/L] |
Hematology |
| X2552 |
15816 |
Bilirubin, fasted state, high fat diet, males [umol/L] |
Hematology |
| X46 |
15868 |
Nucleated red blood cells, chow diet, males [%] |
Hematology |
| X2444 |
15875 |
Nucleated red blood cells, chow diet, males [10^3/uL] |
Hematology |
| X47 |
15912 |
Nucleated red blood cells, high fat diet, males [%] |
Hematology |
| X48 |
15919 |
Nucleated red blood cells, high fat diet, males [10^3/uL] |
Hematology |
| X1553 |
16659 |
C16:1-carnitine_HFD for 20 weeks [nmol/ml] |
Hematology |
| X2158 |
16794 |
Ratio of C14:2-carnitine/C14:1-carnitine_HFD for 20 weeks |
Hematology |
| X4552 |
17799 |
Basal glucose in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X2472 |
17800 |
Basal glucose in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X3124 |
17801 |
Cholesterol in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X3636 |
17802 |
Cholesterol in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X1566 |
17803 |
HDL in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X1530 |
17804 |
HDL in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X4924 |
17805 |
HDL in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X1350 |
17806 |
HDL in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X3700 |
17807 |
LDL in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X4742 |
17808 |
LDL in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X4306 |
17809 |
Triglycerides in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X2719 |
17810 |
Triglycerides in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X3441 |
17811 |
Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X3145 |
17812 |
Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X3379 |
17813 |
Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X4980 |
17814 |
Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X2679 |
17815 |
Lactic acid in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X1239 |
17816 |
Lactic acid in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X4422 |
17817 |
Total protein in plasma, fasted state at 29 weeks of age_CD, males [g/L] |
Hematology |
| X2810 |
17818 |
Total protein in plasma, fasted state at 29 weeks of age_HFD, males [g/L] |
Hematology |
| X3702 |
17819 |
Alanine transaminase (ALAT) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X4565 |
17820 |
Alanine transaminase (ALAT) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X4286 |
17821 |
Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X4232 |
17822 |
Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X917 |
17823 |
Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X4278 |
17824 |
Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X1280 |
17825 |
Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X3621 |
17826 |
Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X2056 |
17827 |
Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X543 |
17828 |
Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X179 |
17829 |
Alkaline phosphatase (ALPL) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X181 |
17830 |
Alkaline phosphatase (ALPL) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X740 |
17831 |
Amylase in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X808 |
17832 |
Amylase in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X2342 |
17833 |
Creatine kinase (CPK) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X2614 |
17834 |
Creatine kinase (CPK) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X2884 |
17835 |
Creatinine in plasma, fasted state at 29 weeks of age_CD, males [umol/L] |
Hematology |
| X153 |
17836 |
Creatinine in plasma, fasted state at 29 weeks of age_HFD, males [umol/L] |
Hematology |
| X2675 |
17837 |
Creatinine in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X3501 |
17838 |
Creatinine in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X3935 |
17839 |
Iron (Fe) in plasma, fasted state at 29 weeks of age_CD, males [umol/L] |
Hematology |
| X4421 |
17840 |
Iron (Fe) in plasma, fasted state at 29 weeks of age_HFD, males [umol/L] |
Hematology |
| X1821 |
17841 |
Interferon-gamma (IFN-g) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X455 |
17842 |
Tumor necrosis factor-alpha (TNF, cachexin) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X1517 |
17843 |
Interleukin 15 (IL15) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X3151 |
17844 |
Monocyte chemotactic protein 1 (MCP1, CCL2) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X3491 |
17845 |
Interleukin 10 (IL10) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X2466 |
17846 |
Macrophage inflammatory protein 1-beta (MIP1B, CCL4) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X3777 |
17847 |
Macrophage inflammatory protein 1-alpha (MIP1A, CCL3) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X741 |
17848 |
Interleukin 6 (IL6) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X351 |
17849 |
Interleukin 18 (IL18) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X1781 |
17878 |
Mean corpuscular volume reticulocytes at 29 weeks of age_HFD, males [fL/RTC] |
Hematology |
| X404 |
17850 |
Regulated and normal T cell expressed and secreted (RANTES, CCL5) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X872 |
17851 |
Red blood cells at 29 weeks of age_CD, males [10^6/uL] |
Hematology |
| X4616 |
17852 |
Red blood cells at 29 weeks of age_HFD, males [10^6/uL] |
Hematology |
| X1128 |
17853 |
Mature red blood cells at 29 weeks of age_CD, males [%] |
Hematology |
| X3936 |
17854 |
Mature red blood cells at 29 weeks of age_HFD, males [%] |
Hematology |
| X1100 |
17855 |
Mature red blood cells at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X3925 |
17856 |
Mature red blood cells at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X3628 |
17857 |
Hemoglobin at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X3592 |
17858 |
Hemoglobin at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X3638 |
17859 |
Hematocrit at 29 weeks of age_CD, males [%] |
Hematology |
| X5058 |
17860 |
Hematocrit at 29 weeks of age_HFD, males [%] |
Hematology |
| X783 |
17861 |
Mean corpuscular volume (MCV) at 29 weeks of age_CD, males [fL/RBC] |
Hematology |
| X1402 |
17862 |
Mean corpuscular volume (MCV) at 29 weeks of age_HFD, males [fL/RBC] |
Hematology |
| X2366 |
17863 |
Mean corpuscular hemoglobin (MCH) at 29 weeks of age_CD, males [pg/RBC] |
Hematology |
| X4071 |
17864 |
Mean corpuscular hemoglobin (MCH) at 29 weeks of age_HFD, males [pg/RBC] |
Hematology |
| X2754 |
17865 |
Mean corpuscular hemoglobin concentration (MCHC) at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X2245 |
17866 |
Mean corpuscular hemoglobin concentration (MCHC) at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X3258 |
17867 |
Red blood cell hemoglobin content at 29 weeks of age_CD, males [pg/RBC] |
Hematology |
| X863 |
17868 |
Red blood cell hemoglobin content at 29 weeks of age_HFD, males [pg/RBC] |
Hematology |
| X3694 |
17869 |
Red blood cell distribution width at 29 weeks of age_CD, males [%] |
Hematology |
| X1921 |
17870 |
Red blood cell distribution width at 29 weeks of age_HFD, males [%] |
Hematology |
| X1808 |
17871 |
Hemoglobin concentration distribution width at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X4200 |
17872 |
Hemoglobin concentration distribution width at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X2246 |
17873 |
Reticulocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X3420 |
17874 |
Reticulocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X1256 |
17875 |
Reticulocytes at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X3755 |
17876 |
Reticulocytes at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X4415 |
17877 |
Mean corpuscular volume reticulocytes at 29 weeks of age_CD, males [fL/RTC] |
Hematology |
| X1399 |
17908 |
Mean platelet mass at 29 weeks of age_HFD, males [pg/PLT] |
Hematology |
| X2779 |
17879 |
Mean corpuscular hemoglobin concentration reticulocytes at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X4659 |
17880 |
Mean corpuscular hemoglobin concentration reticulocytes at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X1276 |
17881 |
Red cell hemoglobin content reticulocytes at 29 weeks of age_CD, males [pg/RTC] |
Hematology |
| X3879 |
17882 |
Red cell hemoglobin content reticulocytes at 29 weeks of age_HFD, males [pg/RTC] |
Hematology |
| X3789 |
17883 |
Mature reticulocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X1398 |
17884 |
Mature reticulocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X773 |
17885 |
Mature reticulocytes at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X4959 |
17886 |
Mature reticulocytes at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X1816 |
17887 |
Medium maturity reticulocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X3125 |
17888 |
Medium maturity reticulocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X2238 |
17889 |
Medium maturity reticulocytes at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X1220 |
17890 |
Medium maturity reticulocytes at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X2928 |
17891 |
Immature reticulocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X437 |
17892 |
Immature reticulocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X4578 |
17893 |
Immature reticulocytes at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X4231 |
17894 |
Immature reticulocytes at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X1464 |
17895 |
Platelets at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X2359 |
17896 |
Platelets at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4864 |
17897 |
Mean platelet volume at 29 weeks of age_CD, males [fL/PLT] |
Hematology |
| X3233 |
17898 |
Platelet volume at 29 weeks of age_HFD, males [fL/PLT] |
Hematology |
| X577 |
17899 |
Platelet distribution width at 29 weeks of age_CD, males [%] |
Hematology |
| X2454 |
17900 |
Platelet distribution width at 29 weeks of age_HFD, males [%] |
Hematology |
| X4165 |
17901 |
Plateletcrit at 29 weeks of age_CD, males [%] |
Hematology |
| X3604 |
17902 |
Plateletcrit at 29 weeks of age_HFD, males [%] |
Hematology |
| X4253 |
17903 |
Platelet component concentration at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X3433 |
17904 |
Platelet component concentration at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X4941 |
17905 |
Platelet component distribution width at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X4266 |
17906 |
Platelet component distribution width at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X4360 |
17907 |
Platelet mass at 29 weeks of age_CD, males [pg/PLT] |
Hematology |
| X4028 |
10186 |
Syngeneic breast cancer tumor growth, day 20 [mm3] |
Immune |
| X4743 |
17909 |
White blood cells at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X4432 |
17910 |
White blood cells at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4280 |
17911 |
Neutrophils at 29 weeks of age_CD, males [%] |
Hematology |
| X4242 |
17912 |
Neutrophils at 29 weeks of age_HFD, males [%] |
Hematology |
| X4954 |
17913 |
Lymphocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X4737 |
17914 |
Lymphocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X3679 |
17915 |
Monocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X4245 |
17916 |
Monocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X4839 |
17917 |
Eosinophils at 29 weeks of age_CD, males [%] |
Hematology |
| X5078 |
17918 |
Eosinophils at 29 weeks of age_HFD, males [%] |
Hematology |
| X2142 |
17919 |
Basophils at 29 weeks of age_CD, males [%] |
Hematology |
| X2849 |
17920 |
Basophils at 29 weeks of age_HFD, males [%] |
Hematology |
| X4909 |
17921 |
Large unknown cells at 29 weeks of age_CD, males [%] |
Hematology |
| X4317 |
17922 |
Large unknown cells at 29 weeks of age_HFD, males [%] |
Hematology |
| X3757 |
17923 |
Neutrophils at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X4734 |
17924 |
Neutrophils at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4921 |
17925 |
Lymphocytes at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X4322 |
17926 |
Lymphocytes at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X2841 |
17927 |
Monocytes at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X481 |
17928 |
Monocytes at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4694 |
17929 |
Eosinophils at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X5079 |
17930 |
Eosinophils at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4344 |
17931 |
Basophils at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X5055 |
17932 |
Basophils at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X3928 |
17933 |
Large unknown cells at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X3950 |
17934 |
Large unknown cells at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4257 |
17968 |
Blood 5-hydroxyindoleacetic acid (5-HIAA) level in adult males [pg/ul] |
Hematology |
| X2763 |
17970 |
Blood 5-hydroxytryptamine (5-HT, serotonin) level in adult females [pg/ul] |
Hematology |
| X2790 |
17972 |
Blood 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult females [units] |
Hematology |
| X4033 |
17973 |
Blood 5-hydroxytryptamine (5-HT, serotonin) level in adult males and females [pg/ul] |
Hematology |
| X2761 |
17974 |
Blood 5-hydroxyindoleacetic acid (5-HIAA) level in adult males and females [pg/ul] |
Hematology |
| X3579 |
17975 |
Blood 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult males and females [units] |
Hematology |
| X1273 |
10187 |
Growth of syngeneic breast cancer tumors day 25 [mm3] |
Immune |
| X1540 |
10034 |
Salmonella typhimurium bacterial strain LT2-Z growth from livers and spleens 6 days post inoculation with 10^2 CFU (figure 3, filled circles) [log10 CFU] |
Immune |
| X844 |
10035 |
Salmonella typhimurium bacterial strain WB500 from livers and spleens 6 days post inoculation with 10^2 CFU (figure 3 open circles) [log10 CFU] |
Immune |
| X79 |
10036 |
Salmonella typhimurium bacterial strain SR-11, net growth in livers and spleens 6 days after inoculation with 10^2 CFU (figure 5, triangles, Itk/Nramp1/Slc11a1-associated) [log10 CFU] |
Immune |
| X1298 |
10043 |
Ectromelia virus-induced mortality in males [3 = resistant, 2 = intermediate, 1 = susceptible, table 1 column 1, ordinal scale] |
Immune |
| X3912 |
10044 |
Ectromelia virus-induced mortality [3 = resistant, 1 = both intermediate and susceptible, ordinal scale] |
Immune |
| X321 |
10056 |
Hematopoietic stem cell pool size, cobblestone area-forming cells per 100,000 bone marrow cells [n] |
Immune |
| X746 |
10058 |
Peripheral blood lymphocytes, percentage of B cells [B220 %] |
Immune |
| X3210 |
10059 |
Peripheral blood lymphocytes, percentage of CD4+ T cells [%] |
Immune |
| X3868 |
10060 |
Peripheral blood lymphocytes, percentage of CD8+ T cells [%] |
Immune |
| X4584 |
10061 |
Polymorphonuclear leukocyte number (PMN) after aerosolized LPS exposure [PMN/ml (x103)] |
Immune |
| X1795 |
10062 |
Tumor necrosis factor (TNF)-alpha level in lung after aerosolized lipopolysaccharide (LPS) exposure [pg/ml] |
Immune |
| X4950 |
10113 |
Proliferative activity of hematopoietic stem cells, quiescent stem cells in aged mice, cobblestone area forming cells (CAFC) at day 35 in culture, frequency in bone marrow [CAFC per 10e5 bone marrow cells] |
Immune |
| X1762 |
10114 |
Proliferative activity of hematopoietic stem cells, quiescent HSCs in aged mice, cobblestone area forming cells (CAFC) on day 35, frequency in bone marrow [CAFC per 10e5 bone marrow cells] |
Immune |
| X4880 |
10115 |
Stem cell cycling, change in day 7 cobblestone area forming cell (CAFC) frequency during aging [%CAFC] |
Immune |
| X4430 |
10116 |
Proliferative activity of hematopoietic stem cells, day 21 cobblestone area forming cell (CAFC) frequency change [% CAFC] |
Immune |
| X3793 |
10117 |
Proliferative activity of hematopoietic stem cells, change in quiescent HSC percentage (cobblestone area-forming cells day 35 of culture) at 20 months [% CAFC] |
Immune |
| X4858 |
10118 |
Stem cell frequency, cobblestone area-forming cell assay count (CAFC) on day 35 [CAFC per 10e5 bone marrow cells] |
Immune |
| X2228 |
10119 |
Proliferative activity of hematopoietic stem cells on day 7 in culture [% CAFC] |
Immune |
| X312 |
10150 |
Thymic T-cell proliferative unresponsiveness (anergy) to anti-CD3-induced proliferation (chemokine-associated) [units] |
Immune |
| X3509 |
10179 |
Metastasis of implanted breast tumor in lymph node, cases with tumor metastasis [n] |
Immune |
| X3453 |
10180 |
Metastasis of implanted breast tumor in pancreas, cases with tumor metastasis [n] |
Immune |
| X3317 |
10181 |
Necrosis of implanted breast tumor [n] |
Immune |
| X2542 |
10182 |
Syngeneic breast tumor growth, number of cases with tumor metastasis [n] |
Immune |
| X2935 |
10183 |
Syngeneic breast cancer tumor growth, day 5 [mm3] |
Immune |
| X3791 |
10184 |
Growth of syngeneic breast cancer tumors day 10 [mm3] |
Immune |
| X3813 |
10185 |
Growth of syngeneic breast cancer tumors day 15 [mm3] |
Immune |
| X4364 |
10206 |
Granulocyte colony stimulating factor (G-CSF) induced progenitor cell mobilization from bone marrow to blood [PB-CFC/ul] |
Immune |
| X655 |
10207 |
Hematopoietic stem cell and progenitor cell proliferative capacity (Lin-Sca1++ cells from femur bone marrow), in vitro assay of cells from 2-3 month old females in response to KL, flt3L, and TPO (Figure 3A of paper) [n |
Immune |
| X790 |
10208 |
Hematopoietic stem cells and progenitor cells, numbers of Lin-Sca1++ cells at 2 months of age in females (Figure 3B of paper) [n] |
Immune |
| X2019 |
10209 |
Relative fraction of hematopoietic stem cells and progenitor cells (Lin-Sca1++) from bone marrow in 2-3 month old females (Figure 3C of paper) [%] |
Immune |
| X4558 |
10210 |
Hematopoietic stem cells and progenitor cells in femur bone marrow, percentage of c-kit-postiive cells to c-kit-ngative cells among Lin-Sca1++ cells in 2-month old femaies (Figure 3d of paper) [%] |
Immune |
| X4648 |
10211 |
Hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow (Fig 2A of paper) [n per well] |
Immune |
| X4896 |
10212 |
Percentage of hematopoietic stem cells and progenitor cells in femur bone marrow (lin-Sca1++ c-kit+) at 18 months of age (Figure 2B of paper) [%] |
Immune |
| X1887 |
10213 |
Proliferative capacity in vitro of bone marrow stem and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age in response to KL, flt3L and TPO (figure 2C of paper) [n cells] |
Immune |
| X1493 |
10214 |
Hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow (additional data not included in paper) [n cells total] |
Immune |
| X1644 |
10215 |
Hematopoietic stem cell and progenitor cell number (lin-Sca1++ c-kit+ cells) from femur bone marrow of females a 18 months (confirm) (unpublished additional data) [n cells] |
Immune |
| X4249 |
10216 |
Proliferative capacity, number of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) after treatment with transforming growth factor beta 2 (TGFB2, 0.01 ng/ml) at 18 months of age (confirm) (unpublished additiona |
Immune |
| X3015 |
10217 |
Proliferative capacity, effect of TGF-beta2 stimulation (0.1 ng/ml) on numbers of lin-Sca1++ c-kit+ cells (unpublished additional data) [% increase] |
Immune |
| X3046 |
10218 |
Proliferative capacity change, difference between old (18 months) and young (2 months) on number of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) after treatment with transforming growth factor beta 2 (TGFB2 |
Immune |
| X2592 |
10219 |
Percentage of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow [%] |
Immune |
| X145 |
10225 |
T-cell proliferative response (age-related decline), concavalin-A induced thymic T-cell response at 22-month-old in females (average of days 2 and 4)[unit] |
Immune |
| X4835 |
10226 |
Age-related T-cell decline, percentage of CD4-negative CD8-negative DN cells in thymus [%] |
Immune |
| X4876 |
10227 |
Age-related T-cell decline, percent of CD4-CD8 double positive cells in thymus [%] |
Immune |
| X3539 |
10228 |
T-cell decline during aging, percentage of CD25-negative/CD44-positive double negative (CD4(-)CD8(-)) cells in thymus at 22 months [%] |
Immune |
| X4788 |
10229 |
Age-related T-cell decline, percentage of CD25-positive CD44-negative DN cells in thymus [%] |
Immune |
| X1950 |
12907 |
Body weight at echocardiography of 17-week old males [g] |
Morphology |
| X4228 |
10230 |
Age-related T-cell decline, percentage of CD25-CD44 double negative thymocytes at 22 months in females [%] |
Immune |
| X4821 |
10231 |
Thymus involution, age-related rate of decline measured as involution slope (-beta 1x10^4) |
Immune |
| X2962 |
10232 |
Thymocyte count in young adult mice, initial [Beta 0] |
Immune |
| X3160 |
10233 |
Thymocyte count, projected at 60 days [units] |
Immune |
| X86 |
10235 |
Proliferation of T cell clone (JTL-G12 clone) without 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] |
Immune |
| X223 |
10236 |
Proliferation of T cell clone (JTL-G12 clone) with 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] |
Immune |
| X75 |
10237 |
Proliferation of T cell clone (JTL-G12.8 clone) without 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] |
Immune |
| X175 |
10238 |
Proliferation of T cell clone (JTL-G12.8 clone) with 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] |
Immune |
| X4042 |
10355 |
Airway inflammatory response to ozone (2 ppm for 3 h) measured as lavageable bronchoalveolar polymorphonuclear leukocytes 6 h after acute exposure [number of PMNs x10^3] |
Immune |
| X2028 |
10356 |
Airway inflammatory response to ozone (0.30 ppm for 48 h) measured as lavageable bronchoalveolar polymorphonuclear leukocytes 6 h after exposure [n PMNs x10^3] |
Immune |
| X1150 |
10361 |
Progenitor cell proliferation in young mice (2 months of age), effect of TGFB2 (0.1 ng/ml) on the proliferation of lin-Sca1++kit+ cells relative to control without TGFB2 [%] |
Immune |
| X4983 |
10370 |
Hepatocellular carcinoma tumor multiplicities induced by N,N-diethylnitrosamine (DEN 0.01 ml/g, ip at postnatal day 12), mean tumor multiplicity in liver at 32 weeks in male [n] |
Immune |
| X1897 |
10372 |
Tumor necrosis factor (TNF)-induced hypothermia [degree C] |
Immune |
| X339 |
10373 |
Tumor necrosis factor (TNF) lethal shock, induction of serum interleukin 6 (IL-6) cytokine after injection [ng/ml] |
Immune |
| X937 |
10374 |
Tumor necrosis factor (TNF) lethality after injection [%] |
Immune |
| X2851 |
10403 |
Theiler's murine encephalomyelitis virus (TMEV) spinal cored demyelination susceptibility (excludes strains with B allele at H2 locus) [% affected] |
Immune |
| X2352 |
10404 |
Theiler's murine encephalomyelitis virus (TMEV, dermal injection), delayed-type hypersensitivity (DTH) response measured as ear swelling [inch x 1E-3] |
Immune |
| X3980 |
10427 |
xenotropic MuLV envelope-related cell-surface antigens (XenCSA) levels on thymus cells measured as mean fluorescence value (sum of products of each channel number times n cells in that channel divided by n cells counted) |
Immune |
| X856 |
10428 |
lymphocyte major glycoprotein (gp70) xenotropic leukemia virus envelope-related cell-surface antigen (XenCSA) level measured as mean fluorescence value (sum of products of each channel number times the number of spleen cells in that channel |
Immune |
| X4925 |
10433 |
;Immune complex deposits in kidney immunized with the 16/6 Id [0=no immune complexes;; 1=1-5 immune complex deposits;; 2=5-20 immune complex deposits;; 3=20-50 immune complex deposits;; 4=50 immune complex deposits]; |
Immune |
| X2469 |
10439 |
Lung, Airway bronchial constrictor response after exposure to atracurium, airway pressure time index [cmH2O/s] |
Immune |
| X487 |
10463 |
Thymus to body size ratio [x10^3] |
Immune |
| X1868 |
13008 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 4 after infection in 9-14 week-old females [%] |
Immune |
| X212 |
10464 |
Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-1 positive, Vgamma-4 positive T cells) [%] |
Immune |
| X149 |
10465 |
Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-7 positive, Vgamma-4 positive T cells) [%] |
Immune |
| X109 |
10466 |
Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-7 positive, Vgamma-4 negative T cells) from Fig 4 y-axis [%] |
Immune |
| X3349 |
10467 |
Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-1 positive, Vgamma-4 negative T cells) from Fig 4 x-axis [%] |
Immune |
| X1539 |
10508 |
V beta 3+ T cells in lymph nodes [%] |
Immune |
| X94 |
10591 |
Murine cytomegalovirus (MCMV) titer in spleen 4 days after infection with 5X10^4 PFU (KLRA complex) [log10 burden] |
Immune |
| X2650 |
10592 |
Anergy measured by footpad thickness resulting from BCG injection [mm] |
Immune |
| X3710 |
10656 |
LacZ expression 7 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] |
Immune |
| X4993 |
10657 |
LacZ expression 21 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] |
Immune |
| X5037 |
10658 |
LacZ expression 30 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] |
Immune |
| X4994 |
10659 |
LacZ expression 50 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] |
Immune |
| X4857 |
10660 |
Cytotoxicity in spleen T cells 7 days after 5x109 PFU AdLacZ i.v injection [%] |
Immune |
| X5041 |
10661 |
Cytotoxicity in spleen T cells 21 days post 5x109 PFU AdLacZ i.v injection [%] |
Immune |
| X4726 |
10662 |
Cytotoxicity in spleen T cells 30 days post 5x109 PFU AdLacZ i.v injection [%] |
Immune |
| X2826 |
10663 |
Cytotoxicity in spleen T cells 50 days post 5x109 PFU AdLacZ i.v injection [%] |
Immune |
| X608 |
10664 |
Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as interferon gamma (IFNG) cytokine expression [ng/ml/] |
Immune |
| X3720 |
10665 |
Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as tumor necrosis factor alpha (TNFa) cytokine expression [pg/ml] |
Immune |
| X1543 |
10666 |
Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as interleukin 6 (IL-6) cytokine expression [pg/ml] |
Immune |
| X2216 |
10687 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU), fraction dead 21 days after infection [ratio] |
Immune |
| X4467 |
10688 |
Myoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection gross pulmonary lesions [burden] |
Immune |
| X3249 |
10689 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway exudate [units] |
Immune |
| X3388 |
10690 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway epithelial hyperplasia |
Immune |
| X3962 |
10691 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway lymphoid hyperplasia |
Immune |
| X1345 |
10692 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, alveolar exudate [units] |
Immune |
| X4618 |
10695 |
Lung inflammatory response, pulmonary granulomatous inflammation induced by Bacillus Calmette___Guê©rin tuberculosis vaccine (BCG) [units] |
Immune |
| X4144 |
10696 |
Spleen weight, splenomegaly induced by Bacillus Calmette___Guê©rin tuberculosis vaccine (iv injection in oil and saline) (BCG) [mg] |
Immune |
| X584 |
10697 |
Autoimmune disease, spontaneous development of immune response, anti-DNA antibodies sera titers, 13 month females (Fig 7 from Mountz et al., 2005) [natural log of the average sum of IgG1, IgG2a, IgG2b, IgM x10^4, ln of 0 |
Immune |
| X3558 |
10698 |
Autoimmune disease, rheumatoid factor sera titers, 13 month females (natural log of the average sum of IgG1, IgG2a, IgG2b, IgM x10^4) |
Immune |
| X442 |
10711 |
Phenyloxazolone hapten-induced Igh-Ox antibody marker level (public idiotype)[units] |
Immune |
| X4252 |
10712 |
Skin tumors after initiation with N-methyl-N'-nitro-N-nitrosoguanidine and promotion with phorbol ester, 12-o-tetradecanoylphorbol-13-acetate [n per case] |
Immune |
| X3436 |
10715 |
Sendai virus lethality with 1.0 TCID50 [% mortality] |
Immune |
| X3362 |
10716 |
Resistance to lymphoma tumors induced by ESb DBA/2 (H-2d) cell transplant [%] |
Immune |
| X3175 |
10736 |
Skin tumor incidence following initiation with N-Methyl-N'-nitro-N-nitrosoguanidine and promotion with phorbol ester, 12-o-tetradecanoylphorbol-13-acetate [% mice] |
Immune |
| X5072 |
10766 |
Autoimmune disease, spontaneous development of immune response, IgG1-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X5038 |
10767 |
Autoimmune disease, spontaneous development of immune response, IgG2a-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X5082 |
10768 |
Autoimmune disease, spontaneous development of immune response, IgG2b-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X3065 |
10769 |
Autoimmune disease, spontaneous development of IgM-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X4666 |
10770 |
Autoimmune disease, spontaneous development of immune response, IgG1-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X4481 |
10771 |
Autoimmune disease, spontaneous development of immune response, IgG2a-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X5070 |
10772 |
Autoimmune disease, spontaneous development of immune response, IgG2b-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X2010 |
10773 |
Autoimmune disease, spontaneous development of immune response, IgM-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X5076 |
10774 |
IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX, day 0 baseline [ELISA OD 450] |
Immune |
| X941 |
10775 |
IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX - Day 14 [ELISA OD 450] |
Immune |
| X891 |
10776 |
IgG2b anti-AAV2 (adeno-associated virus type 2) immune response following injection of 3xE11 vector genomes vg/mouse AAV2-(ApoE)4/hAAT-cF.IX, on day 42 [ELISA OD 450] |
Immune |
| X2804 |
12908 |
Body weight of 18-week old males [g] |
Morphology |
| X585 |
10777 |
IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX - Day 120 [ELISA OD 450] |
Immune |
| X412 |
10778 |
IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3xE11 vector genomes (vg) /mouse AAV2-(ApoE)4/hAAT-cF.IX on day 180 [ELISA OD 450] |
Immune |
| X1867 |
10779 |
IgG1 isotype-specific anti-cF.IX (coagulation Factor IX) response following injection of 3e11 vg/mouse AAV2-cF.IX [ELISA OD 450 (x 10^4)] |
Immune |
| X4140 |
10780 |
Antibody IgG1 response following iv injection of canine coagulation factor IX (cF.IX, 3E11 vg/mouse) [ng/ml] |
Immune |
| X2361 |
10784 |
Autoimmune disease, spontaneous development of generalized Ig to anti-DNA in 13-month-old mice [natural log of total Ig to anti-DNA (ELISA OD 450 x 10^4)] |
Immune |
| X3580 |
10785 |
Autoimmune disease, spontaneous development of generalized autoimmunity measured as ratio of Ig to rheumatoid factor (RF) in 13-month-old mice [ratio, natural log of total Ig to RF (ELISA OD 450 x 10^4)] |
Immune |
| X157 |
10801 |
Streptococcus pyogenes disease severity, corrected relative survival index (Fig 1A, residuals after correction for age, sex, body weight and log inoculum, with added strains BXD76 and BXD80) [-1 = high susceptible, +1 is |
Immune |
| X77 |
10806 |
Chlamydia psittaci (6BC) infection response (10^4 IFU ip), survival index at 11 days in 2-4 month males [mean score, 0=resistant, 1=weight loss and all survive, 2=weight loss some survive, 3=no survival] |
Immune |
| X2838 |
10811 |
Iron level in spleen of males and females [ug/g] |
Immune |
| X4606 |
10813 |
Iron level in spleen of females [ug/g] |
Immune |
| X4830 |
10818 |
Iron level in spleen of males [ug/g] |
Immune |
| X136 |
10836 |
Streptococcus pyogenes disease severity, corrected relative survival index (differs from Fig 1A slightly, residuals after correction for age, sex, body weight and log inoculum, with added strain BXD80) where -1 means hig |
Immune |
| X388 |
10855 |
Chlamydia psittaci (6BC) infection response (10^4 IFU ip), weight loss ratio at 11 days compared to baseline in 2-4 month males [ratio] |
Immune |
| X657 |
10865 |
H5N1 influenza A virus mortality rate 30 days after infection (10^4 EID-50 of HK213 virus in 30 microliters saline) [% death] |
Immune |
| X893 |
10866 |
H5N1 influenza A virus survival time (10^4 EID-50 of HK213 virus in 30 microliters saline) [days, max to 30] |
Immune |
| X2409 |
10890 |
Hematopoietic stem cell number (cobblestone-area-forming cells per femur at 35 days of age from 3 females, also previously published) [n] |
Immune |
| X4258 |
10954 |
Hepatocellular carcinoma tumor multiplicity in liver of males after infection with 0.01 ml/g body wt N,N-diethylnitrosamine [n] |
Immune |
| X4055 |
11001 |
Immune response to bacterial LPS, polymorphonuclear macrophage after 4 hr acute, bronchial lavage [1000/ml] |
Immune |
| X1980 |
11021 |
Streptococcus pyogenes (Group A streptococcal infection) dissemination to spleens, 24 h post-infection (Fig 1C) [CFU/ml] |
Immune |
| X236 |
11022 |
Streptococcus pyogenes (Group A streptococcal infection) sepsis bacteremia 24 h post-infection corrected for age, sex, body weight, log inoculum (Fig 1B) [corrected log CFU/ml] |
Immune |
| X107 |
11025 |
Chlamydia psittaci (6BC) infection response (10^4 IFU ip), pathogen load in peritoneal cavity at 30 days among surviving 3-5 month males (subset of cases) [log ng of DNA] |
Immune |
| X803 |
11026 |
Chlamydia psittaci (6BC) infection response (10^4 IFU ip), spleen weight at 30 days among surviving animals, 2-4 months males (subset of cases from Miyiari 2007) [gm] |
Immune |
| X2932 |
12488 |
Spleen weight of 120-day-old females fed 3 ppm Fe diet [g] |
Immune |
| X3943 |
12489 |
Iron level in spleen of 120-day-old females fed 3 ppm Fe diet [ug/g] |
Immune |
| X2947 |
12496 |
Spleen weight of 120-day-old males fed 3 ppm Fe diet [g] |
Immune |
| X5016 |
12497 |
Iron level in spleen of 120 day old males fed 3 ppm Fe diet [ug/g] |
Immune |
| X4371 |
12504 |
Spleen weight of 120-day-old females fed 270 ppm iron (Fe) diet [g] |
Immune |
| X5073 |
12505 |
Iron level in spleen of 120-day-old females fed 270 ppm Fe diet [ug/g] |
Immune |
| X1995 |
12512 |
Spleen weight of 120-day-old males fed 270 ppm Fe diet [g] |
Immune |
| X3520 |
12513 |
Iron level in spleen of 120 day old males fed 270 ppm Fe diet [ug/g] |
Immune |
| X3588 |
12520 |
Spleen weight of 120-day-old males and females fed 3 ppm Fe diet [g] |
Immune |
| X2896 |
12521 |
Iron level in spleen of 120 day old males and females fed 3 ppm Fe diet [ug/g] |
Immune |
| X2789 |
12531 |
Spleen weight of 120-day-old males and females fed 270 ppm Fe diet [g] |
Immune |
| X5065 |
12532 |
Iron level in spleen of 120 day old males and females fed 270 ppm Fe diet [ug/g] |
Immune |
| X4013 |
12603 |
Peripheral blood lymphocytes, CD4+/CD8+ T cell ratio, males at 3-5 month [ratio] |
Immune |
| X587 |
12667 |
Ectromelia virus survival over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age, and body weight [~2.7 days/unit] |
Immune |
| X884 |
12668 |
Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [presence |
Immune |
| X1274 |
12669 |
Ectromelia virus euthanasia scale over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [-1 is survival, +2 is rapid |
Immune |
| X693 |
12670 |
Ectromelia virus measure of disease onset, day of maximum clinical score over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age, and |
Immune |
| X378 |
12671 |
Ectromelia virus measure of severity of disease measured by the maximum clinical score over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for s |
Immune |
| X521 |
12672 |
Ectromelia virus survival over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, age, and body weight [~2.33 days/unit] |
Immune |
| X4331 |
12673 |
Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [presence of l |
Immune |
| X1139 |
12674 |
Ectromelia virus measure of severity of disease measured by the maximum clinical score over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, |
Immune |
| X2346 |
12675 |
Ectromelia virus measure of disease onset measured by the day of maximum clinical score over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, |
Immune |
| X2730 |
12676 |
Cowpox virus survival over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight [~2.67/unit] |
Immune |
| X1307 |
12677 |
Cowpox virus severity of disease measured by the maximum clinical score over two weeks after a 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age, and body |
Immune |
| X3687 |
12678 |
Cowpox virus measure of disease onset measured by the day of maximum clinical score over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age |
Immune |
| X4349 |
12679 |
Cowpox virus maximum body temperature over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight [scaled deg C where -0.5 is > |
Immune |
| X3431 |
12680 |
Cowpox virus measure of disease onset measured by the day of maximum body temperature over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, a |
Immune |
| X2133 |
12681 |
Cowpox virus maximum weight loss over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight at time of inoculation [scaled % l |
Immune |
| X4991 |
12682 |
Cowpox virus measure of disease onset measured by the day of maximum weight loss over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age an |
Immune |
| X387 |
12683 |
Ectromelia virus mortality score (combined data from Brownstein 1999 and Rice et al. 2010) [3 = resistant, 2 = intermediate, 1 = susceptible, table 1 column 1, ordinal scale] |
Immune |
| X2505 |
12702 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) footpad swelling, 3 weeks post infection in females (BXD80 winsorized from 196 to 120) [% of C57BL/6 control] |
Immune |
| X477 |
12703 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), parasite burden in feet 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2739 |
12704 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) Interferon-gamma from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X1375 |
12705 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), granulocyte colony-stimulating factor (G-CSF, CSF3, Chr 11 at 98.6 Mb) from draining lymph node 3 weeks post infection in females [%of C57BL/6 con |
Immune |
| X2087 |
12706 |
Leishmania major (footpad injection of 5 million promastigotes at 7 weeks) granulocyte macrophage colony-stimulating factor (GM-CSF) level from draining lymph node, 3 weeks after infection in females (Luminex assay) [% |
Immune |
| X3112 |
12707 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-1 alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X593 |
13009 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 5 after infection in 9-14 week-old females [%] |
Immune |
| X894 |
12708 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), interleukin-1 beta level (IL1B, Chr 2 at 129 Mb) from draining lymph node 3 weeks post infection in females [%of C57BL/6 control] |
Immune |
| X5027 |
12709 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-2 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X3459 |
12710 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-3 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2946 |
12711 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-4 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X4926 |
12712 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-5 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2887 |
12713 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-6 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X3496 |
12714 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-10 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X3507 |
12715 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-13 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X1631 |
12716 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-17 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X1917 |
12717 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) IP-10 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2532 |
12718 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) macrophage inflammatory protein-2 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X927 |
12719 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), chemokine (C-X-C motif) ligand 1 level (CXCL1, KC, Chr 5 at 91 Mb) from draining lymph node 3 weeks post infection in females [% of C57BL/6 contro |
Immune |
| X2339 |
12720 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) LIF from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X4118 |
12721 |
Leishmania major response (footpad injection, 5 million promastigotes at 7 weeks), monocyte chemoattractant protein-1 (MCP1) level from draining lymph nodes 3 weeks after infection in females [% of C57BL/6 control] |
Immune |
| X1819 |
12723 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) macrophage inflammatory protein-1 alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X4260 |
12724 |
Leishmania major response (footpad injection, 5 million promastigotes at 7 weeks), macrophage inflammatory protein-1 beta (MIP1B) from draining lymph nodes 3 weeks after infection in females [% of C57BL/6 control] |
Immune |
| X544 |
13010 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 6 after infection in 9-14 week-old females [%] |
Immune |
| X1770 |
12725 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) MIG alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2431 |
12726 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) RANTES from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X815 |
12727 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), tumor necrosis factor alpha level (TNFA, Chr 17 at 35 Mb) from draining lymph node 3 weeks post infection in females using Luminex assay |
Immune |
| X1045 |
12728 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), vascular endothelial growth factor (VEGF) level from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X3733 |
12968 |
Malaria lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC) in 7-12 week-old males (1 = 100% susceptible and 0 = 100% resistant) [fraction of cohort that survives] |
Immune |
| X670 |
12969 |
Malaria lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC i.p.) in 7-12 week-old females (1 = 100% susceptible and 0 = 100% resistant) [fraction of cohort that survives] |
Immune |
| X216 |
12971 |
TNFa cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL] |
Immune |
| X1144 |
12972 |
MCP1 cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL] |
Immune |
| X194 |
12973 |
Interferon alpha (IFNa) cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL] |
Immune |
| X4722 |
12994 |
Malaria lethality, Plasmodium yoelii (PY17XL subclone, 10^6 PRBC i.p.) in 7-10 week old males (1=resistant and 0= susceptible)[survival fraction] |
Immune |
| X2266 |
12995 |
Malaria lethality, Plasmodium yoelii (PY17XL subclone, 10^6 PRBC i.p.) in 7-10 week old females (1=resistant and 0= susceptible)[survival fraction] |
Immune |
| X419 |
12996 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), mean time to death after infection in 9-14 week-old females [days] |
Immune |
| X1797 |
13000 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 11 after infection in 9-14 week-old females [%] |
Immune |
| X217 |
13001 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 7 after infection in 9-14 week-old females [%] |
Immune |
| X511 |
13002 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 8 after infection in 9-14 week-old females [%] |
Immune |
| X1071 |
13003 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 9 after infection in 9-14 week-old females [%] |
Immune |
| X1618 |
13004 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 10 after infection in 9-14 week-old females [%] |
Immune |
| X1832 |
13005 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 1 after infection in 9-14 week-old females [%] |
Immune |
| X2637 |
13006 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 2 after infection in 9-14 week-old females [%] |
Immune |
| X2468 |
13007 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 3 after infection in 9-14 week-old females [%] |
Immune |
| X1481 |
13011 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 7 after infection in 9-14 week-old females [%] |
Immune |
| X2558 |
13012 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 8 after infection in 9-14 week-old females [%] |
Immune |
| X2275 |
13013 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 9 after infection in 9-14 week-old females [%] |
Immune |
| X1586 |
13014 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 10 after infection in 9-14 week-old females [%] |
Immune |
| X2030 |
13015 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 11 after infection in 9-14 week-old females [%] |
Immune |
| X1288 |
13016 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 12 after infection in 9-14 week-old females [%] |
Immune |
| X1573 |
13017 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 13 after infection in 9-14 week-old females [%] |
Immune |
| X999 |
13043 |
Coccidioides immitis (Valley fever, San Joaquin California disease fungus, Coccidioidomycosis) susceptibility after an IP injection (500 - 800 CFU of the RS strain) in 7 to 12-week-old females, 10 per |
Immune |
| X674 |
13507 |
Burkholderia pseudomallei (126b) infection response (50 CFU intranasal), survival in males, [1=resistant, 0=sensitive] |
Immune |
| X600 |
14309 |
Serum glucose (unfasted) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [mg/dL serum) |
Immune |
| X4075 |
14310 |
Candida albicans titer in brain at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue] |
Immune |
| X706 |
14312 |
Candida albicans titer in kidney (log) at 72 h after inoculation with 1 x 10^6 cfu (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue] |
Immune |
| X4057 |
14316 |
lipocalin-2 (LCN-2) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X4281 |
14317 |
Interleukin-6 (IL-6) protein level in kidney 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein] |
Immune |
| X1717 |
14318 |
G-CSF (granulocyte colony stimulating factor) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X2668 |
14319 |
IP-10 (Interferon gamma-induced protein 10 or CXLC10) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [pg/mg protein, kidney] |
Immune |
| X4965 |
14320 |
MIP-2 (macrophage inflammatory protein 2-alpha or CXCL2) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X1829 |
14321 |
;\KC (CXCL1;; keratinocyte-derived chemokine at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X1769 |
10175 |
Ethanol response (2 g/kg ip), rate of ethanol clearance [mg/ml/hr] |
Metabolism |
| X3772 |
14322 |
MCP-1 (CCL2 or monocyte chemotactic protein-1) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X2894 |
14323 |
TNF-a at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X2654 |
14324 |
temperature during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset (difference from baseline, C) |
Immune |
| X3321 |
14326 |
Temperature during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C] |
Immune |
| X4463 |
14328 |
Temperature during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C] |
Immune |
| X4428 |
14330 |
locomotor activity during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline] |
Immune |
| X3848 |
14331 |
locomotor activity during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline] |
Immune |
| X4793 |
14332 |
locomotor activity during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] |
Immune |
| X2806 |
14333 |
locomotor activity during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] |
Immune |
| X1353 |
14334 |
locomotor activity during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] |
Immune |
| X1094 |
14335 |
Locomotor activity 60-72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] |
Immune |
| X2674 |
14338 |
G-CSF (granulocyte colony stimulating factor) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] |
Immune |
| X2035 |
14339 |
IL-6 (interleukin-6) protein level in kidney 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [log pg/mg protein] |
Immune |
| X2179 |
14340 |
;\KC (CXCL1;; keratinocyte-derived chemokine) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney]\ |
Immune |
| X3406 |
14341 |
IP-10 (Interferon gamma-induced protein 10 or CXLC10) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [pg/mg protein, log, kidney] |
Immune |
| X491 |
14342 |
Lipocalin-2 (LCN-2) level in kidney 72 h after inoculation with 1 x 10^6 CFU Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [log pg/mg protein] |
Immune |
| X2951 |
10176 |
Ethanol response (3 g/kg ip), rate of clearance, beta [mg/ml/hr] |
Metabolism |
| X1422 |
14343 |
MCP-1 (CCL2 or monocyte chemotactic protein-1) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] |
Immune |
| X2308 |
14344 |
MIP-2 (macrophage inflammatory protein 2-alpha or CXCL2) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidn |
Immune |
| X634 |
14345 |
TNF-a (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] |
Immune |
| X4984 |
14349 |
locomotor activity (log) during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline. log] |
Immune |
| X4711 |
14350 |
locomotor activity (log) during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] |
Immune |
| X4816 |
14351 |
locomotor activity (log) during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] |
Immune |
| X2284 |
14352 |
locomotor activity (log) during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] |
Immune |
| X1588 |
14353 |
Locomotor activity (log) during h 60-72 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] |
Immune |
| X2920 |
14401 |
Acinetobacter baumannii infection, bronchoalveolar lavage (BAL) lung lymphocyte cell number following (BXD65 winsorized from 47.5 to 26.0) [units/ul] |
Immune |
| X1639 |
14402 |
Bronchoalveolar lavage (BAL) lung lymphocyte cell number following infection with Acinetobacter baumannii [units/ul] |
Immune |
| X264 |
14783 |
Chlamydia muridarum upper genital tract disease severity (endometrium, uterine horn) after primary and secondary intravaginal infection by with 5x10^3 C. muridarum [ordinal scale 0 = no disease, 4 = severe] |
Immune |
| X414 |
14785 |
Chlamydia muridarum upper genital tract disease severity (oviduct) after primary and secondary intravaginal infection by with 5x10^3 C. muridarum [ordinal scale 0 = no disease, 4 = severe disease] |
Immune |
| X3266 |
14807 |
Susceptibility to Staphylococcus aureus, colony forming units (CFU) in blood 48h after infection of 10E5 CFU per mouse in 10-14 old females [CFU (log10)] |
Immune |
| X2350 |
14808 |
Susceptibility to Staphylococcus aureus, colony forming units (CFU) in kidney 48 h after infection of 10E5 CFU in 10-14 old females [CFU (log10)] |
Immune |
| X4506 |
14809 |
Susceptibility to Staphylococcus aureus, colony forming units (CFU) in liver 48 h after infection of 10E5 CFU in 10-14 old females [CFU (log10)] |
Immune |
| X1663 |
14810 |
Susceptibility to Staphylococcus aureus, colony forming units (CFU) in heart 48h after infection of 10E5 CFU per mouse in 10-14 old females [CFU (log10)] |
Immune |
| X3981 |
14811 |
Susceptibility to Staphylococcus aureus, mean time of death in days of mice infected with 10E5 colony forming units (CFU) per mouse in 10-14 old females [days] |
Immune |
| X1194 |
14812 |
Susceptibility to Staphylococcus aureus, survival 10 days after infection with 10E5 colony forming units (CFU) in 10 to 14 day-old females [%] |
Immune |
| X1970 |
14813 |
Susceptibility to Staphylococcus aureus, % survival after 4 days of mice infected with 10E5 colony forming units (CFU) per mouse in 10-14 old females [%] |
Immune |
| X1891 |
14814 |
Mycobacterium tuberculosis (H37Rv, 100 colony forming units (CFU)) response, bacterial load in lung 21 days after aerosol infection in 12-23 week-old females [linear CFU/lung/1000] |
Immune |
| X575 |
14815 |
Linear bacterial load in lung 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / lung / 10000] |
Immune |
| X4934 |
14816 |
Linear bacterial load in spleen 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [linear CFU / spleen / 100] |
Immune |
| X3526 |
14817 |
Linear bacterial load in spleen 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / spleen / 1000] |
Immune |
| X1834 |
14818 |
Linear bacterial load in liver 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [linear CFU / liver / 10] |
Immune |
| X5053 |
14819 |
Linear bacterial load in liver 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / liver / 100] |
Immune |
| X3128 |
14820 |
Quantity of lung pathology 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [quantitative score (10 lowest - 70 highest)] |
Immune |
| X3989 |
14821 |
Quantity of lung pathology 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [quantitative score (10 lowest - 70 highest)] |
Immune |
| X1642 |
14822 |
Lung weight/body weight 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [lung weight/body weight * 10000] |
Immune |
| X4891 |
14823 |
Lung weight/body weight 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [lung weight/body weight * 10000] |
Immune |
| X2495 |
14824 |
Linear median survival time after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [days] |
Immune |
| X3416 |
14825 |
Bacterial load in lungs 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [log10 CFU / lung * 100] |
Immune |
| X2967 |
14826 |
Bacterial load in lungs 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [log10 CFU / lung * 100] |
Immune |
| X4933 |
14827 |
Normalized bacterial load in lungs 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [ratio CFU BXD / CFU C57BL/6J * 100] |
Immune |
| X2343 |
15120 |
CD44+ Ly6C+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4086 |
14828 |
Quality of lung pathology 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [ordinal scale (10 = normal, 20 = intermediate, 30 = severe)] |
Immune |
| X4997 |
14829 |
Body weight 13 weeks after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 13-30 week-old females [g] |
Immune |
| X2402 |
14830 |
Mean moribund body weight after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [g * 10] |
Immune |
| X4427 |
14831 |
Mean temperature 13 weeks after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 13-30 week-old females [deg C * 10] |
Immune |
| X4923 |
14832 |
Mean moribund temperature after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [deg C * 10] |
Immune |
| X3195 |
14833 |
Normalized median survival time after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [ratio survival time BXD / survival time C57BL/6J * 100] |
Immune |
| X4194 |
14834 |
Median survival time in log10 after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [days in log10 * 100] |
Immune |
| X1198 |
15107 |
CD3+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1041 |
15108 |
CD3+CD4+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2992 |
15109 |
CD3+CD8a+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2508 |
15110 |
CD25+ cells as a percentage of CD3+ CD4+ in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2020 |
15111 |
CD3+ gamma/delta TCR+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2325 |
15112 |
Ly6C+ cells as a percentage of CD3+ CD4+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1895 |
15113 |
CD62L+ cells as a percentage of CD3+ CD4+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X126 |
15114 |
CD44+ effector-memory T cells as a percentage of CD3+ CD4+ T cells in peripheral blood measured by fluorescence activated cell sorting (this trait maps to CD44 locus) (FACS) [%] |
Immune |
| X1945 |
15115 |
CD44+ cells as a percentage of CD3+ CD4+ without CD62L cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X991 |
15116 |
CD62L+ T cells without CD44 cells as a percentage of CD3+ CD4+ T cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2891 |
15117 |
Ly6C+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2986 |
15118 |
CD62L+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4376 |
15119 |
CD44+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1997 |
15121 |
CD44+ cells excluding CD62L cells as a percentage of CD8+ CD3+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X660 |
15122 |
CD62L+ cells excluding CD44 cells as a percentage of CD3+CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X3451 |
15123 |
GR-1+ CD11b+ cells as a percentage of CD45 cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X3969 |
15124 |
Gr-1-NKp46- CD11b+ as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4986 |
15125 |
Nkp46+ cells as a percentage of CD45 cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4000 |
15126 |
B cells (CD19 or B220 and IgD) as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4459 |
15127 |
CD5+ cells as a percentage of B cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4680 |
15128 |
IgD+ cells as a percentage of B cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1043 |
15129 |
B cells as a percentage of MHC class II (I/A-E) cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1909 |
15130 |
Immune system, CD11b+ NKp46+ cells as a percentage of CD5-cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X3655 |
15133 |
Malaria infection lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC i.p.) in 7-12 week-old males and females (0 = 100% resistant, 1 = 100% susceptible) [fraction of cohort that survives] |
Immune |
| X1550 |
15167 |
Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, females between 40 and 150 days of age, residuals corrected for age and body weight [presence of lesions wh |
Immune |
| X3149 |
15168 |
Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, males only between 40 and 150 days of age, residuals corrected for age and body weight [presence of lesions |
Immune |
| X475 |
15555 |
Kramer RM, Lamkin T, and colleagues TAFI1 |
Immune |
| X823 |
15556 |
Kramer RM, Lamkin T, and colleagues TAFI3 |
Immune |
| X278 |
15557 |
Kramer RM, Lamkin T, and colleagues TAFI2 |
Immune |
| X347 |
15558 |
Kramer RM, Lamkin T, and colleagues TAFI4 |
Immune |
| X552 |
15559 |
Kramer RM, Lamkin T, and colleagues TAFI5 |
Immune |
| X525 |
15560 |
Kramer RM, Lamkin T, and colleagues TAFI6 |
Immune |
| X406 |
15561 |
Kramer RM, Lamkin T, and colleagues TAFI7 |
Immune |
| X1572 |
15562 |
Kramer RM, Lamkin T, and colleagues TAFI8 |
Immune |
| X1650 |
15563 |
Kramer RM, Lamkin T, and colleagues TAFI9 |
Immune |
| X782 |
15564 |
Kramer RM, Lamkin T, and colleagues TAFI10 |
Immune |
| X2684 |
15565 |
Kramer RM, Lamkin T, and colleagues TAFI11 |
Immune |
| X4530 |
15566 |
Kramer RM, Lamkin T, and colleagues TAFI12 |
Immune |
| X3561 |
15568 |
Kramer RM, Lamkin T, and colleagues, TAFI13 |
Immune |
| X2166 |
15569 |
Kramer RM, Lamkin T, and colleagues TAFI14 |
Immune |
| X331 |
15963 |
Tuberculosis, bacterial load in lung (BXD71 winsorized from 4.18 to 4.98) [log CFU] |
Immune |
| X4135 |
15964 |
Malaria susceptibility, murine Plasmodium yoelli 17 (PY17X-L) [0=resistant, 1= susceptible] |
Immune |
| X531 |
16185 |
Herpes simplex virus type 1, virulence following corneal infection, young adult male and female (combined) [percent mortality] |
Immune |
| X1506 |
16186 |
Herpes simplex virus type 1, stromal keratitis severity following corneal infection, young adult male and female (combined) [ordinal 1 t0 5 scale, 0=none, 5 = penetrating lesions] |
Immune |
| X4083 |
16191 |
Herpes simplex virus type 1, spleen weight following corneal infection, young adult female [g] |
Immune |
| X4851 |
16192 |
Herpes simplex virus type 1, spleen weight following corneal infection, young adult male [g] |
Immune |
| X5018 |
16193 |
Herpes simplex virus type 1, spleen weight following corneal infection, young adult male and female (combined) [g] |
Immune |
| X310 |
16194 |
Herpes simplex virus type 1, percent maximum weight loss following corneal infection, young adult female (combined) [max weight loss %] |
Immune |
| X203 |
16195 |
Herpes simplex virus type 1, percent weight loss following corneal infection, young adult male [max weight loss %] |
Immune |
| X133 |
16196 |
Herpes simplex virus type 1, percent weight loss following corneal infection, young adult female and male [max weight loss %] |
Immune |
| X2001 |
16228 |
Herpes simplex virus 1 (HSV-1) ocular pathogenesis, please add details on sex, innoculum, age, etc here [units] |
Immune |
| X2370 |
16242 |
Cowpox virus disease onset measured by day of max clinical score over three weeks after 10^5pfu intranasal infection, males and females between XX and XXX days of age, residuals corrected for age, sex and body weight [ |
Immune |
| X3884 |
16304 |
Herpes simplex virus type 1, serum neutralizing antibody titer in young adult males [unit] |
Immune |
| X749 |
16305 |
Herpes simplex virus type 1, serum neutralizing antibody titer in young adult females [unit] |
Immune |
| X3828 |
16314 |
serum inhibition of TSH binding to the TSHR before immunization [% inhibition] |
Immune |
| X98 |
16315 |
TBI-2x, serum inhibition of TSH binding to the TSHR 1 week after 2 immunizations with TSHR A-subunit adenovirus [% inhibition] |
Immune |
| X74 |
16316 |
Serum inhibition of TSH binding to the TSHR 4 weeks after 3 immunizations with TSHR A-subunit adenovirus in young adult females [% inhibition] |
Immune |
| X2102 |
16320 |
ELISA-2x, IgG class antibody binding to TSHR A-subunit protein in ELISA 1 week after 2 immunizations of female mice with TSHR A-subunit adenovirus [OD 490 nm] |
Immune |
| X1687 |
16321 |
ELISA-3x, IgG class antibody binding to TSHR A-subunit protein in ELISA 4 weeks after 3 immunizations with TSHR A-subunit adenovirus [OD490 nm] |
Immune |
| X215 |
16330 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, [1=resistant, 0=sensitive] |
Immune |
| X254 |
16331 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, day of death [days] |
Immune |
| X1317 |
16332 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 1 [% change in body weight] |
Immune |
| X1963 |
15733 |
Body temperature after 6 hours in 4 deg C chamber, high fat diet / chow diet, males [ratio] |
Metabolism |
| X1778 |
16333 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 2 [% change in body weight] |
Immune |
| X1308 |
16334 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 3 [% change in body weight] |
Immune |
| X745 |
16335 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 4 [% change in body weight] |
Immune |
| X1427 |
16343 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), body weight loss day 3 after infection in 9-14 week-old females [%] - individual mice from RNAseq experiment (HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) |
Immune |
| X1489 |
16346 |
Herpes simplex virus type 1, serum neutralization titer following corneal infection, young adult male and female (combined) [unit] |
Immune |
| X1010 |
16350 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss, first principal component, days 1-4 [% change in body weight] |
Immune |
| X798 |
16376 |
Please enter the full trait description here even BEFORE publication. Only you will see these descriptions. |
Immune |
| X3506 |
16377 |
EOMES coefficient (Malak Kotb and colleagues 2014) Please provide a full description of the trait now here with information on sex, age range, innoculum, route of infection etc. [units] |
Immune |
| X2731 |
16607 |
Please put in a full description of the phenotype here with sex, age, innoculum, dose, route and at the end in square brackets the [units] 3_colo_Russo |
Immune |
| X3143 |
16608 |
Please put in a full description of the phenotype here with sex, age, innoculum, dose, route and at the end in square brackets the [units]deltaD2-D1_colo_Russo |
Immune |
| X743 |
17081 |
Staphloccocus pyogenes (sq injection of 1.0x10x8 CFU) survival index in males and females injected at 10___16 weeks of age (scored as follows: death before day 3 = 1, death from 3 to 7 = 2, death after day 7 =3) [index] |
Immune |
| X4894 |
17319 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral HA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X4802 |
17320 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral M gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X3699 |
17321 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X3830 |
17322 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NP gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X3263 |
17323 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NS gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X1939 |
17324 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PB1 gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM |
Immune |
| X3584 |
17325 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PB2 gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM |
Immune |
| X4315 |
17326 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X59 |
17439 |
Rickettsiu tsutsugamushi susceptibility (strain Gilliam, ip 100 50% mouse infectious doses, two treatments) of both sexes at 6-12 weeks-of-age (ordinal scale 0 = resistant, 1=susceptible, also see BXH RI set), maps to Gb |
Immune |
| X443 |
17467 |
Log Day 1 of counts of E coli colonization in BXD strains colon after infection with 109 cfu of E. coli strain O157:H7, isolate Tuv 86-2 (Stx2-), intra-gastric gavage, female mice, 5___7 weeks old [CFU/g feces] |
Immune |
| X958 |
17520 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 4 [%] |
Immune |
| X449 |
17521 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 3 [%] |
Immune |
| X989 |
17522 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 2 [%] |
Immune |
| X871 |
17523 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 1 [%] |
Immune |
| X106 |
17524 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections survival after infection corrected for strain, sex, age and body weight given as corrected relative survival index [-1.5 = high |
Immune |
| X1541 |
17525 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections lesion size after infection corrected for strain, sex, age and body weight given as maximum lesion area [Sq.mm] |
Immune |
| X284 |
17527 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight given as principal component 1 of day 1 to da |
Immune |
| X4233 |
18440 |
Malaria susceptibility, murine Plasmodium yoelli 17X-lethal (PY17X-L) [0=100% resistant, 1= 100% susceptible] |
Immune |
| X1700 |
10019 |
Body temperature following saline injection, control for morphine response [degree C] |
Metabolism |
| X3400 |
10045 |
Body temperature (baseline control for quinpirole study) [degrees C] |
Metabolism |
| X687 |
10112 |
Life span, longevity of females (RWW winsorized outliers BXD2, BXD14, and DBA2J from 400,500, and 175 days, respectively, data originally from Gelman et al. 1988, except parental strains) [days] |
Metabolism |
| X536 |
10148 |
Life span, longevity of females (mean age) at the Dana-Faber Cancer Institute (Redstone Animal Facility, Boston MA) from Jackson Laboratory between Nov 1982 and Mar 1983 on Purina chow (all data reinstated, authors initially excluded BXD13 due to s |
Metabolism |
| X3076 |
10149 |
Hepatic lipid peroxidation (LPO) levels in 2-month-old males [malondialdehyde (MDA)/mg] |
Metabolism |
| X261 |
17731 |
Body weight in home cage_CD, males [g] |
Morphology |
| X4553 |
10177 |
Pharmacology. Ethanol response (2 g/kg ip), blood ethanol concentration (BEC) 60 min after injection [mg/ml] |
Metabolism |
| X3138 |
10178 |
Ethanol response (3 g/kg ip), blood ethanol concentration (BEC) 60 min after injection [mg/ml] |
Metabolism |
| X3824 |
10247 |
Iron level in liver of males [ug/g] |
Metabolism |
| X2462 |
10248 |
Iron level in liver of females [ug/g] |
Metabolism |
| X90 |
10371 |
Cytosolic aryl-hydrocarbon receptor (AHR) protein levels in liver (fmol/mg cytosolic protein) |
Metabolism |
| X1214 |
10380 |
B-mannosidase activity in liver of females, p-nitrophenl liberated per tissue wet weight per hour at 37 deg C (Manba gene on Chr 3 at 135 Mb) [mg/gm/hr] |
Metabolism |
| X3132 |
10510 |
Ethanol response (4 g/kg ip), body temperature 120 min after injection in males [degrees C] |
Metabolism |
| X3177 |
10519 |
Body temperature baseline control before injection with ethanol (4 g/kg ip) in females [degrees C] |
Metabolism |
| X4040 |
10520 |
Body temperature baseline control before injection with ethanol (4 g/kg ip) in males [degrees C] |
Metabolism |
| X1649 |
10521 |
Ethanol response (4 g/kg ip), body temperature 120 min after injection in females [degrees C] |
Metabolism |
| X1875 |
10522 |
Body temperature baseline control before saline injection in females [degrees C] |
Metabolism |
| X4372 |
10812 |
Iron level in liver of males [ug/g] |
Metabolism |
| X4392 |
10821 |
Iron level in liver of males and females [ug/g] |
Metabolism |
| X4763 |
10835 |
Iron level in liver of females [ug/g] |
Metabolism |
| X4167 |
11710 |
Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for females [mg/dl XX min after injection] |
Metabolism |
| X5045 |
12490 |
Iron level of liver of 120-day-old females fed 3 ppm Fe diet [ug/g] |
Metabolism |
| X4310 |
12498 |
Iron level of liver of 120-day-old males fed 3 ppm Fe diet [ug/g] |
Metabolism |
| X2319 |
12506 |
Iron level in liver of 120-day-old females fed 270 ppm Fe diet [ug/g] |
Metabolism |
| X1854 |
12514 |
Iron level of liver of 120-day-old males fed 270 ppm Fe diet [ug/g] |
Metabolism |
| X5034 |
12522 |
Iron level of liver of 120-day-old males and females fed 3 ppm Fe diet [ug/g] |
Metabolism |
| X2127 |
12533 |
Iron level of liver of 120-day-old males and females fed 270 ppm Fe diet [ug/g] |
Metabolism |
| X3332 |
12563 |
Life span, longevity of males on ad libitum diet, 12 hr light cycle [median of 12 animals in days] (BXD13=116 days and BXD31=434 days are deleted outliers) |
Metabolism |
| X3309 |
12564 |
Life span, longevity of females on ad libitum diet, 12 hr light cycle [median of 12 animals in days] (BXD13=158 days and BXD31=264 days are deleted outliers) |
Metabolism |
| X4495 |
12684 |
High-dose total body gamma-irradiation survival for 12-week-old females, mean survival time (MST) after a 137-Cesium 6 Gy single exposure (LD80/30) evaluated over a 30 day post-exposure, no supportive care [resid |
Metabolism |
| X1518 |
12826 |
Blood glucose level (intraperitoneal glucose tolerance test), area under curve (AUC) of 18-week old females [mg/dl] |
Metabolism |
| X1731 |
12852 |
Food intake of 13-week old females [g/mouse] |
Metabolism |
| X3365 |
12856 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=0 min of 18-week old females [mg/dl] |
Metabolism |
| X3340 |
12857 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=120 min of 18-week old females [mg/dl] |
Metabolism |
| X3528 |
12858 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=15 min of 18-week old females [mg/dl] |
Metabolism |
| X3358 |
12859 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=30 min of 18-week old females [mg/dl] |
Metabolism |
| X2713 |
12860 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=60 min of 18-week old females [mg/dl] |
Metabolism |
| X4264 |
12867 |
Liver mass of 20-week old females [g] |
Metabolism |
| X508 |
12878 |
Respiratory exchange ratio (RER) of 13-week old females [ratio] |
Metabolism |
| X3446 |
12879 |
Body temperature (rectal) of 13-week old females [deg C] |
Metabolism |
| X2846 |
12885 |
Volume of CO2 production of 13-week old females [ml/kg/h] |
Metabolism |
| X3053 |
12886 |
Volume oxygen consumption of 13-week old females [ml/kg/h] |
Metabolism |
| X1210 |
12889 |
Water intake of 13-week old females [ml/mouse/unit time] |
Metabolism |
| X913 |
12896 |
Blood glucose level (intraperitoneal glucose tolerance test), area under curve (AUC) of 18-week old males [mg/dl] |
Metabolism |
| X4872 |
12922 |
Food intake of 13-week old males [g/mouse] |
Metabolism |
| X1475 |
12926 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=0 min of 18-week old males [mg/dl] |
Metabolism |
| X1863 |
12927 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=120 min of 18-week old males [mg/dl] |
Metabolism |
| X2159 |
12928 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=15 min of 18-week old males [mg/dl] |
Metabolism |
| X1078 |
12929 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=30 min of 18-week old males [mg/dl] |
Metabolism |
| X2941 |
12930 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=60 min of 18-week old males [mg/dl] |
Metabolism |
| X4956 |
12937 |
Liver mass of 20-week old males [g] |
Metabolism |
| X993 |
12948 |
Respiratory exchange ratio (RER) of 13-week old males [ratio] |
Metabolism |
| X4758 |
12949 |
Body temperature (rectal) of 13-week old males [deg C] |
Metabolism |
| X309 |
12955 |
Volume of CO2 production of 13-week old males [ml/kg/h] |
Metabolism |
| X966 |
12956 |
Volume oxygen consumption of 13-week old males [ml/kg/h] |
Metabolism |
| X3600 |
12959 |
Water intake of 13-week old males [ml/mouse/unit time] |
Metabolism |
| X4023 |
12977 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 1-3 hr after gavage of young adult males and females (strain average associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X3630 |
12978 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 24 hr after gavage of young adult males and females (strain average associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X3764 |
12980 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 1-3 hr after gavage of young adult males (associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X2338 |
12981 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 1-3 hr after gavage of young adult females (associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X3008 |
12983 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 24 hr after gavage of young adult females (associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X3645 |
16924 |
Ratio of acid beta-glucosidase/hexosaminidase A activity in liver _CD |
Metabolism |
| X2619 |
13030 |
Vials of hepatocyte obtained per strain from first run of spring 2011 by Piedmont and Varigenix, one vial of approximately 1 million cells (the error term is 2 times the percentage of non-viable cells) [n] |
Metabolism |
| X2749 |
13037 |
Hepatocyte phase I (CYP1A) metabolic activity measured by 7-ethoxycoumarin-o-deethylase (ECOD, 7EC) consumption at 0 and 30 minutes (25 uM/sample) using cryorederived hepatocytes from young adult male liver (BXD31 winsorize |
Metabolism |
| X1694 |
13038 |
Hepatocyte phase II metabolic activity (7HC, glucuronidation and sulfation) measured by production of 7-hydroxycoumarin glucouronide at 30 minutes (100 uM 7-EC/sample) using cryorederived hepatocytes from young adult male li |
Metabolism |
| X3854 |
13040 |
Hepatocyte viability, fraction of viable cells after rederivation relative to viable cells immediately after isolation in suspension (data from first run of spring 2011 by Piedmont and Varigenix) [ratio] |
Metabolism |
| X3780 |
13042 |
Hepatocyte phase II metabolic activity measured by 7-HCS sulfation assay at 30 minutes (100 uM 7-EC/sample) using cryorederived hepatocytes from young adult male liver [7-HCS pmol/million cells/min] |
Metabolism |
| X3663 |
13542 |
Hepatocyte general viability at 0 hr post-thaw in suspension, young adult male pool, Promega CellTiter-Blue fluorometric assay (5 replicates) [RFU/20000 cells/well] |
Metabolism |
| X1682 |
13543 |
Hepatocyte general viability at 4 hr post-thaw on plates, young adult male pool, Promega CellTiter-Blue fluorometric assay (5 replicates) [RFU/20000 cells/well] |
Metabolism |
| X3610 |
13552 |
Hepatocyte injury assay, lactate dehydrogenase (LDH) release in culture medium from control wells corrected for DNA content 31.5 hr after seeding with 20,000 cells, young adult male liver (BXD15 winsorized from 223 to 160) [ |
Metabolism |
| X1513 |
13553 |
Hepatocyte plating efficiency, cells per control wells (DNA assay) 31.5 hr after seeding with 20,000 cells/well, young adult male liver [ng/ml] |
Metabolism |
| X714 |
13554 |
Hepatocyte injury assay, lactate dehydrogenase (LDH) release in culture medium from control wells (uncorrected for viable cell number) 33 hours after seeding with 20,000 cells, young adult male liver (BXD29 and BXD15 winsori |
Metabolism |
| X366 |
13555 |
Acetaminophen hepatocyte viability response 9 hr after treatment (0.5 mM in vehicle), lactate dehydrogenase (LDH) release assay adjusted for DNA content, young adult male liver (BXD31 winsorized from 243 to 200) [LDH/DNA rat |
Metabolism |
| X4516 |
13556 |
Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), lactate dehydrogenase (LDH) release assay adjusted for DNA content, young adult male liver (BXD15 deleted due to bad LDH control, BXD21 winsorized from 1 |
Metabolism |
| X3408 |
13557 |
Maximal hepatocyte cytotoxicity response 9 hr after treatment with lysis buffer, lactate dehydrogenase (LDH) release assay, young adult male liver [LDH] |
Metabolism |
| X903 |
13558 |
Acetaminophen hepatocyte viability response 9 hr after treatment (0.5 mM in vehicle), lactate dehydrogenase (LDH) assay adjusted for DNA content minus Control LDH/DNA background ratio, young adult male liver (BXD15 deleted d |
Metabolism |
| X4443 |
13559 |
Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), lactate dehydrogenase (LDH) assay adjusted for DNA content minus Control LDH/DNA background ratio, young adult male liver (BXD15 deleted due to bad LDH c |
Metabolism |
| X3045 |
16925 |
Sphingomyelin (d16:1) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X2564 |
13560 |
Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), lactate dehydrogenase (LDH) release assay (relative fluorescent units), young adult male liver [RFU] |
Metabolism |
| X4845 |
13561 |
Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), ratio of ethanol-induced release to maximal (lysis) lactate dehydrogenase (LDH) release, young adult male liver (BXD15 deleted due to bad LDH control, BX |
Metabolism |
| X4238 |
14355 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean hepatic collagen, data trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X4512 |
14356 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median hepatic collagen, data trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X1807 |
14357 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean hepatic collagen, trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X2734 |
14358 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median hepatic collagen, data trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X3033 |
14359 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean hepatic collagen, data, trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X3795 |
14360 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median hepatic collagen data, trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X2064 |
14361 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean liver to body weight ratio, trimmed [g] |
Metabolism |
| X2737 |
14362 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4829 |
14363 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4602 |
14364 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, Days 1 and 4), median liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4045 |
14365 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4234 |
14366 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4132 |
14367 |
Liver injury day 0 in adult males before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X3544 |
14368 |
Liver injury day 0 in adult males before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median of alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X2496 |
14369 |
Liver injury day 0 in adult females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X2511 |
14370 |
Liver injury day 0 in adult females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median of alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X4759 |
14371 |
Liver injury day 0 in adult males and females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X4853 |
14372 |
Liver injury day 0 in adult males and females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median of alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X3684 |
14373 |
Liver injury in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X3581 |
14374 |
Liver injury in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X2026 |
14375 |
Liver injury in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) activity, trimmed [U/l] |
Metabolism |
| X2057 |
14376 |
Liver injury in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median alanine aminotransferase (ALT) activity, trimmed [U/l] |
Metabolism |
| X3807 |
14377 |
Liver injury in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X4475 |
14378 |
Liver injury in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X4108 |
14379 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X1211 |
14380 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X3612 |
14381 |
Fibrosis susceptibility in males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X3515 |
14382 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X3916 |
14383 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X4391 |
14384 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severety] |
Metabolism |
| X3649 |
14385 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X3298 |
14386 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X3968 |
14387 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X4801 |
14388 |
Fibrosis susceptibility in females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X4982 |
14389 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X4769 |
14390 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X2237 |
14391 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, laboratory at Homburg), data trimmed [%] |
Metabolism |
| X2215 |
14392 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, Homburg Laboratory), trimmed [%] |
Metabolism |
| X4161 |
14393 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] |
Metabolism |
| X3696 |
14394 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] |
Metabolism |
| X4840 |
14395 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] |
Metabolism |
| X4137 |
14396 |
fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] |
Metabolism |
| X335 |
14796 |
Acetaminophen (APAP) hepatocyte viability response 9 hr after treatment (0.5 mM in vehicle), lactate dehydrogenase (LDH) release assay adjusted for DNA content, young adult male liver [log2 LDH/DNA ratio treated/control] |
Metabolism |
| X4343 |
14975 |
Lung, morphology, Lung weight at 20 weeks in females and males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Metabolism |
| X2696 |
15048 |
Food intake between 17 and 20 weeks in males on a high fat diet (45% energy from fat, Ssniff(R) diet S8074-E010, Germany) initiated at 4 weeks [g/day] |
Metabolism |
| X1969 |
15091 |
Saturated fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Metabolism |
| X990 |
15092 |
Total fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Metabolism |
| X530 |
15094 |
Ratio of lipid to protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Metabolism |
| X532 |
15095 |
Ratio of total lipid to total protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [ratio] |
Metabolism |
| X4403 |
16181 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 2 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Metabolism |
| X3374 |
16182 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 3 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Metabolism |
| X2991 |
16183 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 7 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Metabolism |
| X4704 |
16229 |
Hepatocyte damage in vitro measured as lactate dehydrogenase (LDH) release after 24 hrs attachment (no treatment) median in males and females [% LDH supernatant of total LDH] |
Metabolism |
| X4162 |
16230 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 0.6% alcohol, median in males and females [% LDH increase] |
Metabolism |
| X1510 |
16231 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta median in males and females [% LDH increase] |
Metabolism |
| X3215 |
16232 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol, median in males and females [% LDH increase] |
Metabolism |
| X4725 |
16233 |
Hepatocyte damage in vitro measured as lactate dehydrogenase (LDH) release after 24 hrs attachment (no treatment) median in males [% LDH supernatant of total LDH] |
Metabolism |
| X2575 |
16234 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 0.6% alcohol median in males [% LDH increase] |
Metabolism |
| X1635 |
16235 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta, median in males [% LDH increase] |
Metabolism |
| X3662 |
16236 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol, median in males [% LDH increase] |
Metabolism |
| X3841 |
16237 |
Hepatocyte damage in vitro measured as lactate dehydrogenase (LDH) release after 24 hrs attachment (no treatment), median in females [% LDH supernatant of total LDH] |
Metabolism |
| X4149 |
16238 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 0.6% alcohol, median in females [% LDH increase] |
Metabolism |
| X2297 |
16239 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta, median in females [% LDH increase] |
Metabolism |
| X444 |
16240 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol median in females [% LDH increase vs. untreated cells] |
Metabolism |
| X96 |
16604 |
Induction of CYP1B1 mRNA after treatment with beta-Naphthoflavone (BNF, 15 uM for 24 h), measured by rtPCR in cryorederived primary hepatocytes (Varigenix CRL Panel, three technical replicates/strain/treatment) [fold-incre |
Metabolism |
| X4449 |
10108 |
Striatum cholinergic neurons in section 17 [n/section] |
Nervous system |
| X635 |
16605 |
Basal CYP1B1 mRNA expression measured by rtPCR in cryorederived primary hepatocytes in DMSO (Varigenix CRL Panel, three technical replicates/strain/treatment, higher numbers = lower endogenous expression, the Cyp1b1 gene i |
Metabolism |
| X3118 |
16874 |
Total sphingomyelin_CDHFD [nmol/ml] |
Metabolism |
| X1961 |
16875 |
Total sphingomyelin_HFD for 20 weeks [nmol/ml] |
Metabolism |
| X2089 |
16876 |
Total sphingomyelin_CD [nmol/ml] |
Metabolism |
| X4647 |
16905 |
Sphingomyelin (d16:1) _CD [nmol/mg] |
Metabolism |
| X1604 |
16906 |
Sphingomyelin (d18:2) _CD [nmol/mg] |
Metabolism |
| X4834 |
16907 |
Sphingomyelin (d16:0) _CD [nmol/mg] |
Metabolism |
| X1463 |
16908 |
Sphingomyelin (d18:1) _CD [nmol/mg] |
Metabolism |
| X1439 |
16909 |
Total sphingomyelin _CD [nmol/mg] |
Metabolism |
| X4930 |
16910 |
Gluco(galacto)sylsphingosine levels measured by LC-MS/MS in liver _CD [pmol/mg] |
Metabolism |
| X1352 |
16911 |
Globotriaosylsphingosine levels measured by LC-MS/MS in liver _CD [AU/mg] |
Metabolism |
| X1755 |
16912 |
N-glycolyl GM2 (ganglioside) _CD [nmol/mg] |
Metabolism |
| X1599 |
16913 |
Gluco(galacto)sylceramide _CD [nmol/mg] |
Metabolism |
| X1824 |
16914 |
Ceramide (d18:1) _CD [nmol/mg] |
Metabolism |
| X3658 |
16915 |
Acid beta-glucosidase activity _CD [nmol/(hour*mg)] |
Metabolism |
| X4903 |
16916 |
Hexosaminidase activity _CD [nmol/(hour*mg)] |
Metabolism |
| X4062 |
16917 |
Ratio of Gluco(galacto)sylceramide/Ceramide levels in liver _CD |
Metabolism |
| X4350 |
16918 |
Ratio of Total sphingomyelin/Ceramide levels in liver _CD |
Metabolism |
| X836 |
16919 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide levels in liver _CD |
Metabolism |
| X2768 |
16920 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide levels in liver _CD |
Metabolism |
| X2628 |
16921 |
Ratio of Globotriaosylsphingosine/Ceramide levels in liver _CD |
Metabolism |
| X1018 |
16922 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide levels in liver _CD |
Metabolism |
| X5001 |
16923 |
Ratio of Gluco(galacto)sylsphingosine/Gluco(galacto)sylceramide levels in liver _CD |
Metabolism |
| X1894 |
10363 |
Hippocampus mossy fiber pathway volume, CA4 (dentate gyrus) component [volume units] |
Morphology |
| X2243 |
16926 |
Sphingomyelin (d18:2) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X1986 |
16927 |
Sphingomyelin (d16:0) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X4384 |
16928 |
Sphingomyelin (d18:1) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X4050 |
16929 |
Total sphingomyelin _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X2872 |
16930 |
Gluco(galacto)sylsphingosine levels measured by LC-MS/MS in liver _HFD for 20 weeks [pmol/mg] |
Metabolism |
| X3709 |
16931 |
Globotriaosylsphingosine levels measured by LC-MS/MS in liver _HFD for 20 weeks [AU/mg] |
Metabolism |
| X3328 |
16932 |
N-glycolyl GM2 (ganglioside) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X1227 |
16933 |
Gluco(galacto)sylceramide _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X1826 |
16934 |
Ceramide (d18:1) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X3982 |
16935 |
Acid beta-glucosidase activity _HFD for 20 weeks [nmol/(min*mg)] |
Metabolism |
| X2796 |
16936 |
Hexosaminidase activity _HFD for 20 weeks [nmol/(min*mg)] |
Metabolism |
| X2569 |
16937 |
Ratio of Gluco(galacto)sylceramide/Ceramide levels in liver after overnight fasting in males at 29 weeks of age_HFD for 20 weeks |
Metabolism |
| X2054 |
16938 |
Ratio of Total sphingomyelin/Ceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X2079 |
16939 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X2965 |
16940 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X2770 |
16941 |
Ratio of Globotriaosylsphingosine/Ceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X3646 |
16942 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X2760 |
16943 |
Ratio of Gluco(galacto)sylsphingosine/Gluco(galacto)sylceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X1842 |
16944 |
Ratio of acid beta-glucosidase/hexosaminidase A activity in liver _HFD for 20 weeks |
Metabolism |
| X2570 |
16945 |
Sphingomyelin (d16:1) _CDHFD [nmol/mg] |
Metabolism |
| X2631 |
16946 |
Sphingomyelin (d18:2) _CDHFD [nmol/mg] |
Metabolism |
| X4104 |
16947 |
Sphingomyelin (d16:0) _CDHFD [nmol/mg] |
Metabolism |
| X1621 |
16948 |
Sphingomyelin (d18:1) _CDHFD [nmol/mg] |
Metabolism |
| X1725 |
16949 |
Total sphingomyelin _CDHFD [nmol/mg] |
Metabolism |
| X1360 |
16950 |
Gluco(galacto)sylsphingosine levels measured by LC-MS/MS in liver _CDHFD [pmol/mg] |
Metabolism |
| X1145 |
16951 |
Globotriaosylsphingosine levels measured by LC-MS/MS in liver _CDHFD [AU/mg] |
Metabolism |
| X702 |
16952 |
N-glycolyl GM2 (ganglioside) _CDHFD [nmol/mg] |
Metabolism |
| X3201 |
16953 |
Gluco(galacto)sylceramide _CDHFD [nmol/mg] |
Metabolism |
| X2571 |
16954 |
Ceramide (d18:1) _CDHFD [nmol/mg] |
Metabolism |
| X932 |
16955 |
Acid beta-glucosidase activity _CDHFD [nmol/(min*mg)] |
Metabolism |
| X4290 |
16956 |
Hexosaminidase activity _CDHFD [nmol/(min*mg)] |
Metabolism |
| X2963 |
16957 |
Ratio of Gluco(galacto)sylceramide/Ceramide levels in liverafter overnight fasting in males at 29 weeks of age_CDHFD [units] |
Metabolism |
| X2792 |
16958 |
Ratio of Total sphingomyelin/Ceramide levels in liver _CDHFD [units] |
Metabolism |
| X166 |
16959 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide levels in liver _CDHFD [units] |
Metabolism |
| X1648 |
16960 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide levels in liver _CDHFD [units] |
Metabolism |
| X607 |
16961 |
Ratio of Globotriaosylsphingosine/Ceramide levels in liver _CDHFD [units] |
Metabolism |
| X826 |
16962 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide levels in liver _CDHFD [units] |
Metabolism |
| X2793 |
16963 |
Ratio of Gluco(galacto)sylsphingosine/Gluco(galacto)sylceramide levels in liver _CDHFD [units] |
Metabolism |
| X2036 |
16964 |
Ratio of acid beta-glucosidase/hexosaminidase A activity in liver _CDHFD [units] |
Metabolism |
| X5074 |
17020 |
Diabetes model, response to alloxan (80 mg/kg iv to induce diabetes by killing pancretic beta cells), kidney weight 7 days after treatment as a percentage of body weight in adult males and females without statistical adjust |
Metabolism |
| X975 |
17023 |
Diabetes model, alloxan response (80 mg/kg iv to induce diabetes by killing pancretic beta cells), eye weight 7 days after treatment as a percentage of body weight in adult males and females without statistical |
Metabolism |
| X4353 |
17466 |
Life span, longevity of females (mean age) at UTHSC, Memphis TN, on standard low fat diet (Harlan Teklad 2018 chow diet, 18.6% protein, 6.2% fat, 3.1 kcal/g of which 18% are from fat), 12 hr light cycle in polypropylene cages (145 sq-in with up to |
Metabolism |
| X1318 |
17468 |
Life span, longevity of females (mean age) at UTHSC, Memphis TN, on high fat diet (Harlan Teklad 06414, 18.4% protein, 60.3% calories from fat, 5.1 kcal/g), 12 hr light cycle in polypropylene cages (145 sq-in with up to 10 animals/cage, Harlan Tekl |
Metabolism |
| X3229 |
12589 |
Hippocampus mossy fiber pathway volume, suprapyramidal (SMF) [mm^3] |
Morphology |
| X4321 |
17469 |
Life span, longevity difference of females at UTHSC on either a normal low fat chow diet or a high fat diet (60% calories from fat), 12 hr light cycle (only computed if more than 4 cases per diet) [days] |
Metabolism |
| X173 |
17475 |
Life span, longevity of females (median age) at the Dana-Faber Cancer Institute (Redstone Animal Facility, Boston MA) from Jackson Laboratory between Nov 1982 and Mar 1983 on Purina chow (all data reinstated, authors initially excluded BXD13 due to |
Metabolism |
| X373 |
17548 |
Lrp6 mRNA expression in liver after carbon tetrachloride treatment, first principal component generated using SNP-free exon probe sets (exons 14, 17 and 18) and SUH_Liv_RMAEx_0611 data [relative residual concentration] |
Metabolism |
| X1332 |
17549 |
Lrp6 mRNA expression in untreated rederived hepatocytes, first principal component eigengene (loads heavily on almost all central exons, from exon 4 to exon 21, 40% of variance) with correct polarity generated using 18 SNP-free exo |
Metabolism |
| X4395 |
17550 |
Lrp6 mRNA expression in untreated rederived hepatocytes, second principal component eigengene (loads mainly on most proximal and most distal exons, exon 1, 22 and 23, 17% of total variance) with correct polarity generated using 18 |
Metabolism |
| X2656 |
17551 |
Metabolism, Diabetes model, Streptozotocin-induced albumin-to-creatinine ratio (ABR, Streptozocin, STZ, Zanosar), in males at 10-12 weeks of age (BXD32 winsorised from 5047 to 1100) [ratio of ug/mg] |
Metabolism |
| X3740 |
17552 |
Metabolism, Diabetes model, Streptozotocin-induced albumin-to-creatinine log ratio (ABR, Streptozocin, STZ, Zanosar), in males at 10-12 weeks of age (BXD32 winsorised from 5047 to 1100) [log ratio of ug/mg] |
Metabolism |
| X4783 |
17611 |
Respiratory exchange ratio (RER) light phase (day) _CD, males [ratio] |
Metabolism |
| X5014 |
17612 |
Respiratory exchange ratio (RER) light phase (day) _HFD, males [ratio] |
Metabolism |
| X4962 |
17613 |
Respiratory exchange ratio (RER) dark phase (night) _CD, males [ratio] |
Metabolism |
| X4992 |
17614 |
Respiratory exchange ratio (RER) dark phase (night) _HFD, males [ratio] |
Metabolism |
| X4945 |
17615 |
Respiratory exchange ratio (RER) over 24 hours _CD, males [ratio] |
Metabolism |
| X5003 |
17616 |
Respiratory exchange ratio (RER) over 24 hours _HFD, males [ratio] |
Metabolism |
| X4320 |
17617 |
VO2 light phase (day) average _CD, males [mL/kg/h] |
Metabolism |
| X1563 |
17618 |
VO2 light phase (day) average _HFD, males [mL/kg/h] |
Metabolism |
| X4318 |
17619 |
VO2 dark phase (night) average _CD, males [mL/kg/h] |
Metabolism |
| X1443 |
17620 |
VO2 dark phase (night) average _HFD, males [mL/kg/h] |
Metabolism |
| X4468 |
17621 |
VO2 over 24 hours _CD, males [mL/kg/h] |
Metabolism |
| X1558 |
17622 |
VO2 over 24 hours _HFD, males [mL/kg/h] |
Metabolism |
| X3623 |
17623 |
VCO2 light phase (day) average _CD, males [mL/kg/h] |
Metabolism |
| X1672 |
17624 |
VCO2 light phase (day) average _HFD, males [mL/kg/h] |
Metabolism |
| X3897 |
17625 |
VCO2 dark phase (night) average _CD, males [mL/kg/h] |
Metabolism |
| X1321 |
17626 |
VCO2 dark phase (night) average _HFD, males [mL/kg/h] |
Metabolism |
| X4022 |
17627 |
VCO2 over 24 hours _CD, males [mL/kg/h] |
Metabolism |
| X1470 |
17628 |
VCO2 over 24 hours _HFD, males [mL/kg/h] |
Metabolism |
| X1365 |
17633 |
Food intake in 24 h _CD, males [g] |
Metabolism |
| X3078 |
17634 |
Food intake in 24 h _HFD, males [g] |
Metabolism |
| X1364 |
17635 |
Food intake in 24 h _CD, males [kCal] |
Metabolism |
| X3079 |
17636 |
Food intake in 24 h _HFD, males [kCal] |
Metabolism |
| X4487 |
17637 |
Water intake in 24 h _CD, males [mL] |
Metabolism |
| X2987 |
17638 |
Water intake in 24 h _HFD, males [mL] |
Metabolism |
| X1148 |
17639 |
VO2 light phase (day) average, lean mass corrected _CD, males [mL/kg/h] |
Metabolism |
| X2207 |
17640 |
VO2 light phase (day) average, lean mass corrected _HFD, males [mL/kg/h] |
Metabolism |
| X1411 |
17641 |
VO2 dark phase (night) average, lean mass corrected _CD, males [mL/kg/h] |
Metabolism |
| X821 |
17642 |
VO2 dark phase (night) average, lean mass corrected _HFD, males [mL/kg/h] |
Metabolism |
| X2958 |
17643 |
Glycemia after overnight fast_CD, males [mg/mL] |
Metabolism |
| X1983 |
17644 |
Glycemia after overnight fast_HFD, males [mg/mL] |
Metabolism |
| X2585 |
17645 |
OGTT_ 15min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X1718 |
17646 |
OGTT_ 15min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X1271 |
17647 |
OGTT_ 30 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X2893 |
17648 |
OGTT_ 30 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X931 |
17649 |
OGTT_ 45min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X3597 |
17650 |
OGTT_ 45min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X858 |
17651 |
OGTT_ 60 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X3220 |
17652 |
OGTT_ 60 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X1419 |
17653 |
OGTT_ 90 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X599 |
17654 |
OGTT_ 90 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X3164 |
17655 |
OGTT_ 120 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X3312 |
17656 |
OGTT_ 120 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X4608 |
17657 |
OGTT_ 150 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X4588 |
17658 |
OGTT_ 150 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X4791 |
17659 |
OGTT_ 180 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X4046 |
17660 |
OGTT_ 180 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X1259 |
17661 |
OGTT_ overall_CD, males [AUC] |
Metabolism |
| X2751 |
17662 |
OGTT_ overall_HFD, males [AUC] |
Metabolism |
| X2075 |
17663 |
Insulin response from oral glucose tolerance test (OGTT), at 17 weeks of age_CD, males [AUC] |
Metabolism |
| X1862 |
17664 |
Insulin response from oral glucose tolerance test (OGTT), at 17 weeks of age_HFD, males [AUC] |
Metabolism |
| X3518 |
17665 |
Insulin during oral glucose tolerance test (OGTT), 0min, at 17 weeks of age, (after overnight fast)_CD, males [ug/mL] |
Metabolism |
| X4609 |
17666 |
Insulin during oral glucose tolerance test (OGTT), 0min, at 17 weeks of age, (after overnight fast)_HFD, males [ug/mL] |
Metabolism |
| X2203 |
17667 |
Insulin during oral glucose tolerance test (OGTT), 15min, at 17 weeks of age_CD, males [ug/mL] |
Metabolism |
| X1106 |
17668 |
Insulin during oral glucose tolerance test (OGTT), 15min, at 17 weeks of age_HFD, males [ug/mL] |
Metabolism |
| X837 |
17669 |
Insulin during oral glucose tolerance test (OGTT), 30min, at 17 weeks of age_CD, males [ug/mL] |
Metabolism |
| X1536 |
17670 |
Insulin during oral glucose tolerance test (OGTT), 30min, at 17 weeks of age_HFD, males [ug/mL] |
Metabolism |
| X1971 |
17671 |
Glucose / insulin ratio in plasma after overnight fast, at 17 weeks of age_CD, males [ratio] |
Metabolism |
| X5043 |
17672 |
Glucose / insulin ratio in plasma after overnight fast, at 17 weeks of age_HFD, males [ratio] |
Metabolism |
| X5011 |
17673 |
Glucose / insulin ratio in plasma 15 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_CD, males [ratio] |
Metabolism |
| X1773 |
17674 |
Glucose / insulin ratio in plasma 15 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_HFD, males [ratio] |
Metabolism |
| X4437 |
17675 |
Glucose / insulin ratio in plasma 30 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_CD, males [ratio] |
Metabolism |
| X2104 |
17676 |
Glucose / insulin ratio in plasma 30 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_HFD, males [ratio] |
Metabolism |
| X4182 |
17677 |
Glucose * insulin in plasma after overnight fast, at 17 weeks of age_CD, males [(ug*mg)/(mL*mL)] |
Metabolism |
| X4164 |
17678 |
Glucose * insulin in plasma after overnight fast, at 17 weeks of age_HFD, males [(ug*mg)/(mL*mL)] |
Metabolism |
| X3432 |
17679 |
McAuley fasted insulin ratio in plasma after overnight fast, at 17 weeks of age_CD, males. This phenotype is part of the EPFL LISP3 Study. |
Metabolism |
| X4574 |
17680 |
McAuley fasted insulin ratio in plasma after overnight fast, at 17 weeks of age_HFD, males. This phenotype is part of the EPFL LISP3 Study. |
Metabolism |
| X3424 |
17681 |
HOMA-IR after overnight fast, at 17 weeks of age_CD, males [index] |
Metabolism |
| X3676 |
17682 |
HOMA-IR after overnight fast, at 17 weeks of age_HFD, males [index] |
Metabolism |
| X4656 |
17683 |
HOMA-B after overnight fast, at 17 weeks of age_CD, males [index] |
Metabolism |
| X4225 |
17684 |
HOMA-B after overnight fast, at 17 weeks of age_HFD, males [index] |
Metabolism |
| X374 |
17685 |
Diastolic blood pressure measured using a tail cuff system at 19 weeks of age_CD, males [mmHg] |
Metabolism |
| X2426 |
17686 |
Diastolic blood pressure measured using a tail cuff system at 19 weeks of age_HFD, males [mmHg] |
Metabolism |
| X1787 |
17687 |
Systolic blood pressure measured using a tail cuff system at 19 weeks of age_CD, males [mmHg] |
Metabolism |
| X3593 |
17688 |
Systolic blood pressure measured using a tail cuff system at 19 weeks of age_HFD, males [mmHg] |
Metabolism |
| X1833 |
17689 |
Heart rate measured using a tail cuff system at 19 weeks of age_CD, males [bpm] |
Metabolism |
| X1384 |
17690 |
Heart rate measured using a tail cuff system at 19 weeks of age_HFD, males [bpm] |
Metabolism |
| X860 |
17691 |
Body temperature, basal, at 21 weeks of age_CD, males [Celsius] |
Metabolism |
| X2428 |
17692 |
Body temperature, basal, at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X1109 |
17693 |
Body temperature after 1 hour in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X4785 |
17694 |
Body temperature after 1 hour in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X1299 |
17695 |
Body temperature after 2 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X3688 |
17696 |
Body temperature after 2 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X2567 |
17697 |
Body temperature after 3 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X2413 |
17698 |
Body temperature after 3 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X3310 |
17699 |
Body temperature after 4 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X1458 |
17700 |
Body temperature after 4 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X865 |
17701 |
Body temperature after 5 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X648 |
17702 |
Body temperature after 5 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X2874 |
17703 |
Body temperature after 6 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X756 |
17704 |
Body temperature after 6 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X1595 |
17705 |
Body temperature loss after 3 hours in 4 deg C chamber at 21 weeks of age_CD, males [%] |
Metabolism |
| X1881 |
17706 |
Body temperature loss after 3 hours in 4 deg C chamber at 21 weeks of age_HFD, males [%] |
Metabolism |
| X3677 |
17707 |
Body temperature loss after 6 hours in 4 deg C chamber at 21 weeks of age_CD, males [%] |
Metabolism |
| X1749 |
17708 |
Body temperature loss after 6 hours in 4 deg C chamber at 21 weeks of age_HFD, males [%] |
Metabolism |
| X4179 |
17709 |
Body temperature loss between 3 to 6 hours after being placed in 4 deg C chamber at 21 weeks of age_CD, males [%] |
Metabolism |
| X1665 |
17710 |
Body temperature loss between 3 to 6 hours after being placed in 4 deg C chamber at 21 weeks of age_HFD, males [%] |
Metabolism |
| X3209 |
17711 |
Body temperature, basal, diet ratio, at 21 weeks of age_HFD / chow diet (6% kCal/fat Harlan.2918), males [ratio] |
Metabolism |
| X1973 |
17712 |
Body temperature, after 6 hours in 4 deg C chamber at 21 weeks of age, diet ratio_HFD / chow diet (6% kCal/fat Harlan.2918), males [ratio] |
Metabolism |
| X4197 |
17725 |
Food intake in 24 h, standard housing cage at 23 weeks of age_CD, males [g] |
Metabolism |
| X732 |
17726 |
Food intake in 24 h, standard housing cage at 23 weeks of age_HFD, males [g] |
Metabolism |
| X3690 |
17727 |
Food intake in 24 h, standard housing cage at 23 weeks of age_CD, males [kCal] |
Metabolism |
| X907 |
17728 |
Food intake in 24 h, standard housing cage at 23 weeks of age_HFD, males [kCal] |
Metabolism |
| X275 |
17729 |
Food intake/body weight g, standard housing cage at 23 weeks of age_CD, males [g/g] |
Metabolism |
| X4886 |
17730 |
Food intake/body weight g, standard housing cage at 23 weeks of age_HFD, males [g/g] |
Metabolism |
| X1208 |
17739 |
VO2 basal untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [mL/kg/min] |
Metabolism |
| X2052 |
17740 |
VO2 basal untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [mL/kg/min] |
Metabolism |
| X595 |
17741 |
VO2 max untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [mL/kg/min] |
Metabolism |
| X2141 |
17742 |
VO2 max untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [mL/kg/min] |
Metabolism |
| X4461 |
17743 |
Respiratory exchange ratio (RER) basal untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [ratio] |
Metabolism |
| X4957 |
17744 |
Respiratory exchange ratio (RER) basal untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [ratio] |
Metabolism |
| X3698 |
10364 |
Hippocampus mossy fiber pathway volume, suprapyramidal component (SPMF) [units] |
Morphology |
| X5085 |
17745 |
Respiratory exchange ratio (RER) max untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [ratio] |
Metabolism |
| X2489 |
17746 |
Respiratory exchange ratio (RER) max untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [ratio] |
Metabolism |
| X2262 |
17747 |
VO2 basal trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [mL/kg/min] |
Metabolism |
| X2252 |
17748 |
VO2 basal trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [mL/kg/min] |
Metabolism |
| X3825 |
17749 |
VO2 max trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [mL/kg/min] |
Metabolism |
| X1730 |
17750 |
VO2 max trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [mL/kg/min] |
Metabolism |
| X4465 |
17751 |
Respiratory exchange ratio (RER) basal trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [ratio] |
Metabolism |
| X2755 |
17752 |
Respiratory exchange ratio (RER) basal trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [ratio] |
Metabolism |
| X1886 |
17753 |
Respiratory exchange ratio (RER) max trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [ratio] |
Metabolism |
| X883 |
17754 |
Respiratory exchange ratio (RER) max trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [ratio] |
Metabolism |
| X3084 |
17755 |
VO2 basal improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [mL/kg/min] |
Metabolism |
| X4312 |
17756 |
VO2 basal improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [mL/kg/min] |
Metabolism |
| X1196 |
17757 |
VO2 max improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [mL/kg/min] |
Metabolism |
| X3624 |
17758 |
VO2 max improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [mL/kg/min] |
Metabolism |
| X4122 |
17759 |
Respiratory exchange ratio (RER) improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [ratio] |
Metabolism |
| X3627 |
17760 |
Respiratory exchange ratio (RER) improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [ratio] |
Metabolism |
| X5047 |
18404 |
Urinary albumin/creatinin ratio (ACR microgram/milligram) in following longterm diabetes induced by streptozotocin (STZ) treatment [ug/mg] |
Metabolism |
| X3098 |
18430 |
Ejection fraction by echocardiography of 17-week old females and males [%] |
Metabolism |
| X1830 |
18431 |
Shortening fraction by echocardiography of 17-week old females and males [%] |
Metabolism |
| X4222 |
18432 |
Ejection fraction by echocardiography of 17-week old paired females and males [%] |
Metabolism |
| X1390 |
18433 |
Shortening fraction by echocardiography of 17-week old paired females and males [%] |
Metabolism |
| X2379 |
16641 |
C12-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2478 |
18435 |
Life span, longevity of females at UTHSC on high fat diet (Harlan Teklad 06414, 60.3% calories from fat), 12 hr light cycle with up to 10 animals/cage, updated March 2016 (n=382) [days] |
Metabolism |
| X4730 |
18441 |
Life span, longevity of females at UTHSC on standard chow diet (Harlan Teklad 2018 chow diet, 6.2% fat), 12 hr light cycle with up to 10 animals/cage, updated March 2016 (n=357) [days] |
Metabolism |
| X4007 |
14308 |
Blood chemistry, infectious disease, Blood [serum] urea nitrogen (BUN) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [mg/dl serum] |
Metabolites |
| X1641 |
14337 |
Blood chemistry, infectious disease, Blood [serum] urea nitrogen (BUN) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [mg/dl serum, log] |
Metabolites |
| X2658 |
16622 |
Alanine levels_CDHFD [nmol/ml] |
Metabolites |
| X4328 |
16623 |
Alanine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2006 |
16624 |
Alanine levels_CD [nmol/ml] |
Metabolites |
| X170 |
16625 |
Alpha-aminoadipate levels_CDHFD [nmol/ml] |
Metabolites |
| X319 |
16626 |
Alpha-aminoadipate levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X164 |
16627 |
Alpha-aminoadipate levels_CD [nmol/ml] |
Metabolites |
| X4356 |
16628 |
Asparagine levels_CDHFD [nmol/ml] |
Metabolites |
| X3179 |
16629 |
Asparagine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1879 |
16630 |
Asparagine levels_CD [nmol/ml] |
Metabolites |
| X1195 |
16631 |
C0-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3715 |
16632 |
C0-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1578 |
16633 |
C0-carnitine_CD [nmol/ml] |
Metabolites |
| X3670 |
16634 |
C10-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2692 |
16635 |
C10-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4669 |
16636 |
C10-carnitine_CD [nmol/ml] |
Metabolites |
| X1262 |
16637 |
C12:1-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3378 |
16638 |
C12:1-carnitine_CD [nmol/ml] |
Metabolites |
| X2395 |
16639 |
C12:1-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3767 |
16640 |
C12-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4274 |
16642 |
C12-carnitine_CD [nmol/ml] |
Metabolites |
| X3074 |
16643 |
C12-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2113 |
16644 |
C12-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4842 |
16645 |
C12-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4605 |
16646 |
C14:1-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3339 |
16647 |
C14:1-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3372 |
16648 |
C14:1-carnitine_CD [nmol/ml] |
Metabolites |
| X3508 |
16649 |
C14:1-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3959 |
16650 |
C14:1-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2873 |
16651 |
C14:1-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4370 |
16652 |
C14:2-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3181 |
16653 |
C14:2-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4205 |
16654 |
C14:2-carnitine_CD [nmol/ml] |
Metabolites |
| X4750 |
16655 |
C14-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2740 |
16656 |
C14-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4817 |
16657 |
C14-carnitine_CD [nmol/ml] |
Metabolites |
| X4670 |
16658 |
C16:1-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3297 |
16660 |
C16:1-carnitine_CD [nmol/ml] |
Metabolites |
| X1453 |
16661 |
C16:1-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X1199 |
16662 |
C16:1-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3038 |
16663 |
C16:1-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4865 |
16664 |
C16:2-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4561 |
16665 |
C16:2-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4813 |
16666 |
C16:2-carnitine_CD [nmol/ml] |
Metabolites |
| X4503 |
12590 |
Hippocampus mossy fiber pathway volume, hilus [mm^3] |
Morphology |
| X4488 |
16667 |
C16-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X1924 |
16668 |
C16-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4906 |
16669 |
C16-carnitine_CD [nmol/ml] |
Metabolites |
| X484 |
16670 |
C16-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3944 |
16671 |
C16-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4302 |
16672 |
C16-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4056 |
16673 |
C18:1-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2072 |
16674 |
C18:1-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3781 |
16675 |
C18:1-carnitine_CD [nmol/ml] |
Metabolites |
| X1544 |
16676 |
C18:1-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3664 |
16677 |
C18:1-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4309 |
16678 |
C18:1-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4195 |
16679 |
C18:2-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3675 |
16680 |
C18:2-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3761 |
16681 |
C18:2-carnitine_CD [nmol/ml] |
Metabolites |
| X2094 |
16682 |
C18-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2121 |
16683 |
C18-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4955 |
16684 |
C18-carnitine_CD [nmol/ml] |
Metabolites |
| X4764 |
16685 |
C2-carnitine-acetylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X4146 |
16686 |
C2-carnitine-acetylcarnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4550 |
16687 |
C2-carnitine-acetylcarnitine_CD [nmol/ml] |
Metabolites |
| X3271 |
16688 |
C4-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4720 |
16689 |
C4-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2860 |
16690 |
C4-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4987 |
12906 |
Body weight of 17-week old males [g] |
Morphology |
| X286 |
16691 |
C5 dicarboxylylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X2827 |
16692 |
C5 dicarboxylylcarnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1914 |
16693 |
C5 dicarboxylylcarnitine_CD [nmol/ml] |
Metabolites |
| X2780 |
16694 |
C6-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4643 |
16695 |
C6-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2221 |
16696 |
C6-carnitine_CD [nmol/ml] |
Metabolites |
| X4261 |
16697 |
C8-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X1482 |
16698 |
C8-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4843 |
16699 |
C8-carnitine_CD [nmol/ml] |
Metabolites |
| X2733 |
16700 |
Ceramide (d18:1)_CDHFD [nmol/ml] |
Metabolites |
| X2703 |
16701 |
Ceramide (d18:1)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X322 |
16702 |
Ceramide (d18:1)_CD [nmol/ml] |
Metabolites |
| X3718 |
16703 |
Citrulline levels_CDHFD [nmol/ml] |
Metabolites |
| X2801 |
16704 |
Citrulline levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4027 |
16705 |
Citrulline levels_CD [nmol/ml] |
Metabolites |
| X758 |
16706 |
Globotriaosylsphingosine levels (without sphingomyelinase)_CDHFD [nmol/ml] |
Metabolites |
| X855 |
16707 |
Globotriaosylsphingosine levels (without sphingomyelinase)_HFD for 20 weeks [nmol/ml |
Metabolites |
| X2802 |
16708 |
Globotriaosylsphingosine levels (without sphingomyelinase)_CD [nmol/ml] |
Metabolites |
| X1124 |
16709 |
Gluco(galacto)sylceramide_CDHFD [nmol/ml] |
Metabolites |
| X3926 |
16710 |
Gluco(galacto)sylceramide_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2398 |
16711 |
Gluco(galacto)sylceramide_CD [nmol/ml] |
Metabolites |
| X4408 |
16712 |
Glutamate levels_CDHFD [nmol/ml] |
Metabolites |
| X1339 |
16713 |
Glutamate levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3163 |
16714 |
Glutamate levels_CD [nmol/ml] |
Metabolites |
| X3475 |
16715 |
Glutamine levels_CDHFD [nmol/ml] |
Metabolites |
| X2833 |
16716 |
Glutamine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3674 |
16717 |
Glutamine levels_CD [nmol/ml] |
Metabolites |
| X241 |
16718 |
Glycine levels_CDHFD [nmol/ml] |
Metabolites |
| X308 |
16719 |
Glycine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X540 |
16720 |
Glycine levels_CD [nmol/ml] |
Metabolites |
| X3364 |
16721 |
Isoleucine levels_CDHFD [nmol/ml] |
Metabolites |
| X4971 |
16722 |
Isoleucine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1269 |
16723 |
Isoleucine levels_CD [nmol/ml] |
Metabolites |
| X2294 |
16724 |
Kynurenine levels_CDHFD [nmol/ml] |
Metabolites |
| X2693 |
16725 |
Kynurenine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1568 |
16726 |
Kynurenine levels_CD [nmol/ml] |
Metabolites |
| X2555 |
16727 |
Leucine levels_CDHFD [nmol/ml] |
Metabolites |
| X2423 |
16728 |
Leucine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2602 |
16729 |
Leucine levels_CD [nmol/ml] |
Metabolites |
| X3191 |
16730 |
Lysine levels_CDHFD [nmol/ml] |
Metabolites |
| X4810 |
16731 |
Lysine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1794 |
16732 |
Lysine levels_CD [nmol/ml] |
Metabolites |
| X2981 |
16733 |
Methionine levels_CDHFD [nmol/ml] |
Metabolites |
| X4784 |
16734 |
Methionine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1113 |
16735 |
Methionine levels_CD [nmol/ml] |
Metabolites |
| X2892 |
16736 |
Natural logarithm of Arginine levels_CDHFD [nmol/ml] |
Metabolites |
| X2151 |
16737 |
Arginine levels (LogN)_HFD for 20 weeks [logN nmol/ml] |
Metabolites |
| X4438 |
16738 |
Natural logarithm of Arginine levels_CD [nmol/ml] |
Metabolites |
| X516 |
16831 |
Ratio of ornithine/citrulline_CD |
Metabolites |
| X1112 |
16739 |
Natural logarithm of Aspartate levels_CDHFD [nmol/ml] |
Metabolites |
| X1758 |
16740 |
Natural logarithm of Aspartate levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2349 |
16741 |
Natural logarithm of Aspartate levels_CD [nmol/ml] |
Metabolites |
| X104 |
16742 |
Natural logarithm of C3 dicarboxylylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X103 |
16743 |
C3 dicarboxylylcarnitine_HFD for 20 weeks [logN nmol/ml] |
Metabolites |
| X119 |
16744 |
Natural logarithm of C3 dicarboxylylcarnitine_CD [nmol/ml] |
Metabolites |
| X1247 |
16745 |
Natural logarithm of C3-carnitine_propionylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X774 |
16746 |
Natural logarithm of C3-carnitine_propionylcarnitine_HFD for 20 weeks [nmol/ |
Metabolites |
| X1542 |
16747 |
Natural logarithm of C3-carnitine_propionylcarnitine_CD [nmol/ml] |
Metabolites |
| X3560 |
16748 |
Natural logarithm of C4-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4100 |
16749 |
Natural logarithm of C4-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3061 |
16750 |
Natural logarithm of C4-carnitine_CD [nmol/ml] |
Metabolites |
| X675 |
16751 |
Natural logarithm of C5-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3281 |
16752 |
Natural logarithm of C5-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X346 |
16753 |
Natural logarithm of C5-carnitine_CD [nmol/ml] |
Metabolites |
| X590 |
16754 |
Natural logarithm of Fasting glucose_CDHFD [mg/ml] |
Metabolites |
| X1714 |
16755 |
Natural logarithm of Fasting glucose_HFD for 20 weeks [mg/ml] |
Metabolites |
| X1589 |
16756 |
Natural logarithm of Fasting glucose_CD [mg/ml] |
Metabolites |
| X4641 |
16757 |
Natural logarithm of N-glycolyl GM2 (ganglioside)_CDHFD [nmol/ml] |
Metabolites |
| X3169 |
16758 |
Natural logarithm of N-glycolyl GM2 (ganglioside)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3466 |
16759 |
Natural logarithm of N-glycolyl GM2 (ganglioside)_CD [nmol/ml] |
Metabolites |
| X304 |
16760 |
Natural logarithm of Phenylalanine levels_CDHFD [nmol/ml] |
Metabolites |
| X583 |
16761 |
Natural logarithm of Phenylalanine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X637 |
16762 |
Natural logarithm of Phenylalanine levels_CD [nmol/ml] |
Metabolites |
| X3701 |
16763 |
Natural logarithm of Proline levels_CDHFD [nmol/ml] |
Metabolites |
| X4324 |
16764 |
Natural logarithm of Proline levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3882 |
16765 |
Natural logarithm of Proline levels_CD [nmol/ml] |
Metabolites |
| X252 |
16766 |
Ornithine levels_CDHFD [nmol/ml] |
Metabolites |
| X1691 |
16767 |
Ornithine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X178 |
16768 |
Ornithine levels_CD [nmol/ml] |
Metabolites |
| X265 |
16769 |
Alpha-aminoadipate to lysine ratio_CDHFD [ratio] |
Metabolites |
| X700 |
16770 |
Alpha-aminoadipate to lysine ratio_HFD for 20 weeks [ratio] |
Metabolites |
| X222 |
16771 |
Alpha-aminoadipate to lysine ratio_CD [ratio] |
Metabolites |
| X728 |
16772 |
Ratio of total branched-chain amino acid/Alanine_CDHFD [units] |
Metabolites |
| X1609 |
16773 |
Ratio of total branched-chain amino acid/Alanine_HFD for 20 weeks |
Metabolites |
| X1328 |
16774 |
Ratio of total branched-chain amino acid/Alanine_CD |
Metabolites |
| X1598 |
16775 |
Ratio of total branched-chain amino acid/C3-carnitine_CDHFD [units] |
Metabolites |
| X3121 |
16776 |
Ratio of total branched-chain amino acid/C3-carnitine_HFD for 20 weeks |
Metabolites |
| X2949 |
16777 |
Ratio of total branched-chain amino acid/C3-carnitine_CD |
Metabolites |
| X3051 |
16778 |
Ratio of total branched-chain amino acid/Glutamine_CDHFD [units] |
Metabolites |
| X2128 |
16779 |
Ratio of total branched-chain amino acid/Glutamine_HFD for 20 weeks |
Metabolites |
| X4823 |
16780 |
Ratio of total branched-chain amino acid/Glutamine_CD |
Metabolites |
| X2315 |
16781 |
Ratio of total branched-chain amino acid/total amino acid_HFD for 20 weeks |
Metabolites |
| X1388 |
16782 |
Ratio of total branched-chain amino acid/total amino acid_CDHFD [units] |
Metabolites |
| X4005 |
16832 |
Ratio of phenylalanine/tyrosine_CDHFD [units] |
Metabolites |
| X1224 |
16783 |
Ratio of total branched-chain amino acid/total amino acid_CD |
Metabolites |
| X1707 |
16784 |
Ratio of C0-carnitine/C2-carnitine_CDHFD [units] |
Metabolites |
| X4163 |
16785 |
Ratio of C0-carnitine/C2-carnitine_HFD for 20 weeks |
Metabolites |
| X3661 |
16786 |
Ratio of C0-carnitine/C2-carnitine_CD |
Metabolites |
| X2329 |
16787 |
Ratio of C14:1-carnitine/C14-carnitine_CDHFD [units] |
Metabolites |
| X2017 |
16788 |
Ratio of C14:1-carnitine/C14-carnitine_HFD for 20 weeks |
Metabolites |
| X2476 |
16789 |
Ratio of C14:1-carnitine/C14-carnitine_CD |
Metabolites |
| X3286 |
16790 |
Ratio of C14:1-carnitine/C2-carnitine_CDHFD [units] |
Metabolites |
| X4289 |
16791 |
Ratio of C14:1-carnitine/C2-carnitine_HFD for 20 weeks |
Metabolites |
| X3320 |
16792 |
Ratio of C14:1-carnitine/C2-carnitine_CD |
Metabolites |
| X1565 |
16793 |
Ratio of C14:2-carnitine/C14:1-carnitine_CDHFD [units] |
Metabolites |
| X3422 |
16795 |
Ratio of C14:2-carnitine/C14:1-carnitine_CD |
Metabolites |
| X1294 |
16796 |
Ratio of C16:1-carnitine/C16-carnitine_CDHFD [units] |
Metabolites |
| X2424 |
16797 |
Ratio of C16:1-carnitine/C16-carnitine_HFD for 20 weeks |
Metabolites |
| X1397 |
16798 |
Ratio of C16:1-carnitine/C16-carnitine_CD |
Metabolites |
| X1825 |
16799 |
Ratio of C16:2-carnitine/C16:1-carnitine_CDHFD [units] |
Metabolites |
| X3734 |
16800 |
Ratio of C16:2-carnitine/C16:1-carnitine_HFD for 20 weeks |
Metabolites |
| X2306 |
16801 |
Ratio of C16:2-carnitine/C16:1-carnitine_CD |
Metabolites |
| X3042 |
16802 |
Ratio of C18:1-carnitine/C18-carnitine_CDHFD [units] |
Metabolites |
| X4595 |
16803 |
Ratio of C18:1-carnitine/C18-carnitine_HFD for 20 weeks |
Metabolites |
| X4638 |
16804 |
Ratio of C18:1-carnitine/C18-carnitine_CD |
Metabolites |
| X1164 |
16805 |
Ratio of C18:2-carnitine/C18:1-carnitine_CDHFD [units] |
Metabolites |
| X771 |
16806 |
Ratio of C18:2-carnitine/C18:1-carnitine_HFD for 20 weeks |
Metabolites |
| X629 |
16807 |
Ratio of C18:2-carnitine/C18:1-carnitine_CD |
Metabolites |
| X4509 |
16808 |
Ratio of Gluco(galacto)sylceramide/Ceramide_CDHFD [units] |
Metabolites |
| X761 |
16809 |
Ratio of Gluco(galacto)sylceramide/Ceramide_HFD for 20 weeks |
Metabolites |
| X2464 |
16810 |
Ratio of Gluco(galacto)sylceramide/Ceramide_CD |
Metabolites |
| X1395 |
16811 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide_CDHFD [units] |
Metabolites |
| X1297 |
16812 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide_HFD for 20 weeks |
Metabolites |
| X852 |
16813 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide_CD |
Metabolites |
| X3394 |
16814 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide_CDHFD [units] |
Metabolites |
| X4070 |
16815 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide_HFD for 20 weeks |
Metabolites |
| X3810 |
16816 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide_CD |
Metabolites |
| X3421 |
16817 |
Ratio of Isoleucine/C3-carnitine_CDHFD [units] |
Metabolites |
| X1705 |
16818 |
Ratio of Isoleucine/C3-carnitine_HFD for 20 weeks |
Metabolites |
| X2797 |
16819 |
Ratio of Isoleucine/C3-carnitine_CD |
Metabolites |
| X1219 |
16820 |
Ratio of Kynurenine/Tryptophan_CDHFD [units] |
Metabolites |
| X1420 |
16821 |
Ratio of Kynurenine/Tryptophan_HFD for 20 weeks |
Metabolites |
| X1004 |
16822 |
Ratio of Kynurenine/Tryptophan_CD |
Metabolites |
| X2463 |
16823 |
Ratio of Globotriaosylsphingosine/Ceramide_CDHFD [units] |
Metabolites |
| X2565 |
16824 |
Ratio of Globotriaosylsphingosine/Ceramide_HFD for 20 weeks |
Metabolites |
| X2282 |
16825 |
Ratio of Globotriaosylsphingosine/Ceramide_CD |
Metabolites |
| X2817 |
16826 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide_CDHFD [units] |
Metabolites |
| X1456 |
16827 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide_HFD for 20 weeks |
Metabolites |
| X3681 |
16828 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide_CD |
Metabolites |
| X533 |
16829 |
Ratio of ornithine/citrulline_CDHFD [units] |
Metabolites |
| X1974 |
16830 |
Ratio of ornithine/citrulline_HFD for 20 weeks |
Metabolites |
| X4818 |
16833 |
Ratio of phenylalanine/tyrosine_HFD for 20 weeks |
Metabolites |
| X4053 |
16834 |
Ratio of phenylalanine/tyrosine_CD |
Metabolites |
| X2977 |
16835 |
Ratio of total long chain acylcarnitine/C0-carnitine_CDHFD [units] |
Metabolites |
| X3683 |
16836 |
Ratio of total long chain acylcarnitine/C0-carnitine_HFD for 20 weeks |
Metabolites |
| X4998 |
16837 |
Ratio of total long chain acylcarnitine/C0-carnitine_CD |
Metabolites |
| X2219 |
16838 |
Ratio of total long chain acylcarnitine/C2-carnitine_CDHFD [units] |
Metabolites |
| X2296 |
16839 |
Ratio of total long chain acylcarnitine/C2-carnitine_HFD for 20 weeks |
Metabolites |
| X2924 |
16840 |
Ratio of total long chain acylcarnitine/C2-carnitine_CD |
Metabolites |
| X1416 |
16841 |
Ratio of total sphingomyelin/ceramide_CDHFD [units] |
Metabolites |
| X1848 |
16842 |
Ratio of total sphingomyelin/ceramide_HFD for 20 weeks |
Metabolites |
| X1698 |
16843 |
Ratio of total sphingomyelin/ceramide_CD |
Metabolites |
| X1445 |
16844 |
Ratio of Valine/C3-carnitine_CDHFD [units] |
Metabolites |
| X3319 |
16845 |
Ratio of Valine/C3-carnitine_HFD for 20 weeks |
Metabolites |
| X1907 |
16846 |
Ratio of Valine/C3-carnitine_CD |
Metabolites |
| X3521 |
16847 |
Serine levels_CDHFD [nmol/ml] |
Metabolites |
| X3691 |
16848 |
Serine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4058 |
16849 |
Serine levels_CD [nmol/ml] |
Metabolites |
| X4786 |
16850 |
Sphingomyelin (d16:0)_CDHFD [nmol/ml] |
Metabolites |
| X3454 |
16851 |
Sphingomyelin (d16:0)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4474 |
16852 |
Sphingomyelin (d16:0)_CD [nmol/ml] |
Metabolites |
| X2710 |
16853 |
Sphingomyelin (d16:1)_CDHFD [nmol/ml] |
Metabolites |
| X2456 |
16854 |
Sphingomyelin (d16:1)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4237 |
16855 |
Sphingomyelin (d16:1)_CD [nmol/ml] |
Metabolites |
| X2853 |
16856 |
Sphingomyelin (d18:1)_CDHFD [nmol/ml] |
Metabolites |
| X1557 |
16857 |
Sphingomyelin (d18:1)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1673 |
16858 |
Sphingomyelin (d18:1)_CD [nmol/ml] |
Metabolites |
| X2812 |
16859 |
Sphingomyelin (d18:2)_CDHFD [nmol/ml] |
Metabolites |
| X2085 |
16860 |
Sphingomyelin (d18:2)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4479 |
16861 |
Sphingomyelin (d18:2)_CD [nmol/ml] |
Metabolites |
| X2112 |
16862 |
Spingosine-1-phosphate levels_CDHFD [pmol/ml] |
Metabolites |
| X3954 |
16863 |
Spingosine-1-phosphate levels_HFD for 20 weeks [pmol/ml] |
Metabolites |
| X300 |
16864 |
Spingosine-1-phosphate levels_CD [pmol/ml] |
Metabolites |
| X2701 |
16865 |
Total amino acid levels_CDHFD [nmol/ml] |
Metabolites |
| X4741 |
16866 |
Total amino acid levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1603 |
16867 |
Total amino acid levels_CD [nmol/ml] |
Metabolites |
| X2175 |
16868 |
Total branched-chain amino acid levels_CDHFD [nmol/ml] |
Metabolites |
| X3489 |
16869 |
Total branched-chain amino acid levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2513 |
16870 |
Total branched-chain amino acid levels_CD [nmol/ml] |
Metabolites |
| X4424 |
16871 |
Total long-chain acylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X1801 |
16872 |
Total long-chain acylcarnitine_HFD for 20 weeks |
Metabolites |
| X4047 |
16873 |
Total long-chain acylcarnitine_CD [nmol/ml] |
Metabolites |
| X3006 |
16877 |
Tryptophan levels_CDHFD [nmol/ml] |
Metabolites |
| X4999 |
16878 |
Tryptophan levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1293 |
16879 |
Tryptophan levels_CD [nmol/ml] |
Metabolites |
| X3695 |
16880 |
Tyrosine levels_CDHFD [nmol/ml] |
Metabolites |
| X4492 |
16881 |
Tyrosine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3556 |
16882 |
Tyrosine levels_CD [nmol/ml] |
Metabolites |
| X4273 |
10358 |
Body weight [g] |
Morphology |
| X3154 |
16883 |
Unknown lipid (16minRT)_CDHFD [nmol/ml] |
Metabolites |
| X3457 |
16884 |
Unknown lipid (16minRT)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2587 |
16885 |
Unknown lipid (16minRT)_CD [nmol/ml] |
Metabolites |
| X3669 |
16886 |
Valine levels_CDHFD [nmol/ml] |
Metabolites |
| X4942 |
16887 |
Valine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X962 |
16888 |
Valine levels_CD [nmol/ml] |
Metabolites |
| X3786 |
16889 |
Free fatty acid (FFA)_CDHFD [z scores of umol/ml] |
Metabolites |
| X3705 |
16890 |
Free fatty acid (FFA)_HFD for 20 weeks [z scores of umol/ml] |
Metabolites |
| X4850 |
16891 |
Free fatty acid (FFA)_CD for 20 weeks [z scores of umol/ml] |
Metabolites |
| X2184 |
16892 |
Z score normalized HDL_CDHFD [umol/ml] |
Metabolites |
| X1300 |
16893 |
Z score normalized HDL_HFD for 20 weeks [umol/ml] |
Metabolites |
| X4869 |
16894 |
Z score normalized HDL_CD [umol/ml] |
Metabolites |
| X2479 |
16895 |
Weighted metabolite coexpression network, Blue module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X1835 |
16896 |
Weighted metabolite coexpression network, Brown module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X2086 |
16897 |
Weighted metabolite coexpression network, Green module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X4878 |
16898 |
Weighted metabolite coexpression network, Turquoise module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X515 |
16899 |
Weighted metabolite coexpression network, Yellow module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X1023 |
16900 |
Weighted metabolite coexpression network, Blue module eigengene_HFD for 20 weeks |
Metabolites |
| X3609 |
16901 |
Weighted metabolite coexpression network, Brown module eigengene_HFD for 20 weeks |
Metabolites |
| X3439 |
16902 |
Weighted metabolite coexpression network, Green module eigengene_HFD for 20 weeks |
Metabolites |
| X4119 |
16903 |
Weighted metabolite coexpression network, Turquoise module eigengene_HFD for 20 weeks |
Metabolites |
| X2808 |
16904 |
Weighted metabolite coexpression network, Yellow module eigengene_HFD for 20 weeks |
Metabolites |
| X2786 |
16247 |
Microbiome, Actinobacteria (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2787 |
16248 |
Microbiome, Actinobacteria (phylum) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1877 |
16249 |
Microbiome, Actinobacteridae (subclass) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1989 |
16250 |
Microbiome, Actinomycetales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4920 |
16251 |
Microbiome, Aerococcaceae (family) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4919 |
16252 |
Microbiome, Aerococcus (genus) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1966 |
16253 |
Microbiome, Alistipes (genus) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2794 |
16254 |
Microbiome, Bacilli (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1495 |
16255 |
Microbiome, Bacteroidales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1496 |
16256 |
Microbiome, Bacteroidetes (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2591 |
16257 |
Microbiome, Bacteroidetes (phylum) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3314 |
16258 |
Microbiome, Clostridia (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3334 |
16259 |
Microbiome, Clostridiales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4860 |
16260 |
Microbiome, Coriobacteriaceae (family) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4861 |
16261 |
Microbiome, Coriobacteriales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4862 |
16262 |
Microbiome, Coriobacteridaesub (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4863 |
16263 |
Microbiome, Coriobacterineae (suborder) proportionassessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3273 |
16264 |
Microbiome, Corynebacteriaceae (family) proportionassessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4613 |
10362 |
Hippocampus mossy fiber pathway volume, total [units] |
Morphology |
| X2814 |
16265 |
Microbiome, Corynebacterineae (suborder) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3274 |
16266 |
Microbiome, Corynebacterium (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3448 |
16267 |
Microbiome, Erysipelotrichaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3449 |
16268 |
Microbiome, Erysipelotrichales (order) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3450 |
16269 |
Microbiome, Erysipelotrichi (class) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2108 |
16270 |
Microbiome, Firmicutes (phylum) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1661 |
16271 |
Microbiome, Lachnospiraceae Incertae Sedis (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2902 |
16272 |
Microbiome, Lachnospiraceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4217 |
16273 |
Microbiome, Lactobacillaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3946 |
16274 |
Microbiome, Lactobacillales (order) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4208 |
16275 |
Microbiome, Lactobacillus (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1096 |
16276 |
Microbiome, Marinilabilia (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X213 |
16277 |
Microbiome, Prevotellaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X555 |
16278 |
Microbiome, Rikenellaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3657 |
16279 |
Microbiome, Ruminococcaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X251 |
16280 |
Microbiome, TM7 genera incertae sedis (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X250 |
16281 |
Microbiome, TM7 (phylum) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2300 |
16282 |
Microbiome, Turicibacter (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X509 |
16283 |
Microbiome, Bacillales (order) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X574 |
16284 |
Microbiome, Staphylococcaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X554 |
16285 |
Microbiome, Staphylococcus (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4756 |
16286 |
Microbiome, Jeotgalicoccus (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X723 |
16287 |
Microbiome, Bacteroidaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X722 |
16288 |
Microbiome, Bacteroides (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4171 |
16289 |
Microbiome, Proteobacteria (phylum) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2442 |
16290 |
Microbiome, Lactobacillus johnsonii (OTU) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1417 |
16291 |
Microbiome, Lactobacillus murinus (OTU) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4380 |
16292 |
Microbiome, Lactobacillus intestinalis (OTU) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3999 |
16293 |
Microbiome, Staphylococcus xylosus (OTU) |
